The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed P. Mahoney

Dated 12 February 2004

PRIORITY DOCUMENT
SUBMITTED OR TRANSMITTED IN COMPLIANCE WITH RULE 17.1(a) OR (b)

27FEB03 E788130-1 001030
P01/7700 0.00-0304424.5

Patents Form 1/77

Patents Act 1977
(Rule 16)

THE PATENT OFFICE
G
26 FEB 2003
LONDON

The Patent Office

1/77

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office
Cardiff Road
Newport
Gwent NP9 1RH

1. Your reference — VJR/KMM/VB60107

2. Patent application number *(The Patent Office will fill in his part)* — 0304424.5 — 26 FEB 2003

3. Full name, address and postcode of the or of each applicant *(underline all surnames)*

   GlaxoSmithKline Biologicals s.a.
   Rue de l'Institut 89, B-1330 Rixensart, , Belgium

   Patents ADP number *(if you know it)* 8101271000

   If the applicant is a corporate body, give the country/state of its incorporation — Belgian

4. Title of the invention — Novel Compounds

5. Name of your agent *(If you have one)*

   "Address for service" in the United Kingdom to which all correspondence should be sent *(including the postcode)*

   Corporate Intellectual Property

   GlaxoSmithKline
   Corporate Intellectual Property (CN9 25.1)
   980 Great West Road
   BRENTFORD
   Middlesex TW8 9GS

   Patents ADP number *(if you know it)* 8002555 8072555006

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or each of these earlier applications and *(if you know it)* the or each application number

Country	Priority application number *(If you know it)*	Date of filing *(day / month / year)*

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application	Date of filing *(day / month / year)*

8. Is a statement of inventorship and of right

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form	/
Description	79
Claim(s)	3
Abstract	1
Drawing(s)	9 only

10. If you are also filing any of the following, state how many against each item.

Priority documents	
Translations of priority documents	
Statement of inventorship and right to grant of a patent *(Patents Form 7/77)*	
Request for preliminary examination and search *(Patents Form 9/77)*	
Request for substantive examination *(Patents Form 10/77)*	
Any other documents *(please specify)*	SEQUENCE LISTING 33 PAGES

11. I/We request the grant of a patent on the basis of this application.

Signature [signature] Date Michael Lubiecki 26.2.2003

12. Name and daytime telephone number of person to contact in the United Kingdom

VICTORIA J. RILEY
020 8047 4470

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

a) *If you need help to fill in this form or you have any questions, please contact the Patent Office on 08459 500505.*

b) *Write your answers in capital letters using black ink or you may type them.*

c) *If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.*

d) *If you have answered 'Yes' Patents Form 7/77 will need to be filed.*

e) *Once you have filled in the form you must remember to sign and date it.*

f) *For details of the fee and ways to pay please contact the Patent Office.*

to grant of a patent required in support of this request? *(Answer yes if:*

a) any applicant named in part 3 is not an inventor, or

b) there is an inventor who is named as an applicant, or

c) any named applicant is a corporate body

See note (d)

Novel compounds

The present invention relates to novel prophylactic and therapeutic formulations, said formulations being effective in the prevention and/or the reduction of allergic responses to specific allergens. Further this invention relates to hypoallergenic recombinant derivatives of the major protein allergen from *Dermatophagoides pteronyssinus,* allergen DerP1 and its precursor form ProDerP1. In particular the derivatives of the invention include physically modified DerP1 or ProDerP1 such as the thermally treated protein; or genetically modified recombinant DerP1 or ProDerP1 wherein one or more cysteine residues involved in disulphide bond formation have been mutated. Methods are also described for expressing and purifying the DerP1 and ProDerP1 derivatives and for formulating immunogenic compositions and vaccines.

Further this invention relates to hypoallergenic recombinant derivatives of a further protein allergen from *Dermatophagoides pteronyssinus,* allergen DerP3 and its precursor form ProDerP3. In particular the derivatives of the invention include physically modified DerP3 or ProDerP3 such as the thermally treated protein; or genetically modified recombinant DerP3 or ProDerP3 wherein one or more cysteine residues involved in disulphide bond formation have been mutated. Methods are also described for expressing and purifying the DerP3 and ProDerP3 derivatives and for formulating immunogenic compositions and vaccines.

Allergic responses in humans are common, and may be triggered by a variety of allergens. Allergic individuals are sensitised to allergens, and are characterised by the presence of high levels of allergen specific IgE in the serum, and possess allergen specific T-cell populations which produce Th2-type cytokines (IL-4, IL-5, and IL-13). Binding of IgE, in the presence of allergen, to FcεRI receptors present on the surface of mastocytes and basophils, leads to the rapid degranulation of the cells and the subsequent release of histamine, and other preformed and neoformed mediators of the inflammatory reaction. In addition to this, the stimulation of the T-cell recall response results in the production of IL-4 and IL-13, together cooperating to switch B-cell responses further towards allergen specific IgE production. For details of the generation of early and late phase allergic responses see Joost Van Neeven *et al.*, 1996, Immunology Today, 17, 526. In non-allergic individuals, the immune response to the same antigens may additionally include

Th1-type cytokines such as IFN-γ. These cytokines may prevent the onset of allergic responses by the inhibition of high levels of Th2-type immune responses, including high levels of allergen specific IgE. Importantly in this respect, is the fact that IgE synthesis may be controlled by an inhibitory feedback mechanism mediated by the binding of IgE/allergen complexes to the CD23 (FcεRII) receptor on B-cells (Luo et al., J.Immunol., 1991, 146(7), 2122-9; Yu et al., 1994, Nature, 369(6483):753-6). In systems that lack cellular bound CD23, this inhibition of IgE synthesis does not occur.

Type I allergic diseases mediated by IgE against allergens such as bronchial asthma, atopic dermatitis and perrenial rhinitis affect more than 20% of the world's population. Current strategies in the treatment of such allergic responses include means to prevent the symptomatic effects of histamine release by anti-histamine treatments and/or local administration of anti-inflammatory corticosteroids. Other strategies which are under development include those which use the hosts immune system to prevent the degranulation of the mast cells, Stanworth *et al.*, EP 0 477 231 B1. Other forms of immunotherapy have been described (Hoyne *et al.*, J.Exp.Med., 1993, 178, 1783-1788; Holt *et al.*, Lancet, 1994, 344, 456-458).

While immediate as well as late symptoms can be ameliorated by pharmalogical treatment, allergen-specific immunotherapy is the only curative approach to type I allergy. However, some problems related to this method remain to be solved. First, immunotherapy is currently performed with total allergen extracts which can be heterogeneous from batch to batch. Moreover, these allergen mixtures are not designed for an individual patient's profile and may contain unwanted toxic proteins. Second, the administration of native allergens at high doses can cause severe anaphylactic reactions and therefore the optimally efficient high dose of allergen for successful immunotherapy can often not be reached. The first problem has been addressed through alternative vaccination with better characterised and more reproducible recombinant allergens as compared to allergen extracts. The second problem, namely the risk of anaphylactic reactions induced by repeated injections of allergen extracts, can be minimised through the use of recombinant "hypoallergens", whose the IgE reactivity was altered by deletions or mutagenesis (Akdis, CA and Blaser, K, Regulation of specific immune responses by chemical and structural modifications of allergens, Int. Arch. Allergy Immunol., 2000, 121, 261-269).

Formulations have been described for the treatment and prophylaxis of allergy, which provide means to down-regulate the production of IgE, as well as modifying the cell mediated response to the allergen, through a shift from a Th2 type to a Th1 type of response (as measured by the reduction of ratio of IL-4 : IFN-γ producing DerP1 specific T-cells, or alternatively a reduction of the IL-5:IFN-γ ratio). This may for example be achieved through the use of recombinant allergens such as recDerP1 with reduced enzymatic activity as described in WO 99/25823. However the immunogenicity of these recombinant allergens is thought to be similar to that of wild-type ProDerP1 in terms of IgE synthesis induction.

Non-anaphylactic forms of allergens with reduced IgE-binding activity have been reported. Allergen engineering has allowed a reduction of IgE-binding capacities of the allergen proteins by site-directed mutagenesis of amino acid residues or deletions of certain amino acid sequences. In the same time, T-cell activating capacity is still conserved as T cell epitopes are maintained. This has been shown using several approaches for different allergens although with variable results. Examples have been published for the timothy grass pollen allergen Phl p 5b (Schramm G et al., 1999, J Immunol.,162, 2406-14), for the major house dust mite allergens Derf2 (Takai et al.. 2000, Eur. J. Biochem., 267, 6650-6656), DerP2 (Smith & Chapman 1996, Mol. Immunol. 33, 399-405) and Derf1 (Takahashi K et al. 2001, Int Arch Allergy Immunol.124, 454-60). One study has reported the generation of Derf1 hypoallergens by introductions of point mutations at the level of cysteine residues involved in disulfides bridges (Takahashi K Int Arch Allergy Immunol. 2001;124(4):454-60., Takai T, Yasuhara T, Yokota T, Okumura Y). However, if wild-type ProDerf1 was successfully secreted by *P. pastoris*, cysteine mutants concerning intramolecular disulfide bonds were, by contrast, not secreted.

The allergens from the house dust mite *Dermatophagoides pteronyssinus* are one of the major causative factors associated with allergic hypersensitivity reactions. Amongst these molecules, DerP1 is a an immunodominant allergen which elicits the strongest IgE-mediated immune response (Topham *et al.*, 1994, Protein Engineering, 7, 7, 869-894; Simpson *et al.*, 1989, Protein Sequences and Data Analyses, 2, 17-21) and with more than 75% of allergic patients to dust mites who develop IgE directed to this allergen.

Hypoallergen derived from house dust mite DerP1, and effective prophylactic as well as therapeutic vaccine against this allergen have never been described.

DerP3 is a further allergen of the house dust mite *Dermatophagoides pteronyssinus*.

The present invention relates to the provision and use of recombinant derivatives of *Dermatophagoides pteronyssinus* DerP1 allergen or of its precursor form ProDerP1 thereafter referred to as "DerP1/ProDerP1", with reduced allergenic activity compared to the wild-type allergen. The recombinant forms of DerP1 derivatives according to the invention, either adjuvanted recombinant proteins or plasmid encoding DerP1/ProDerP1 suitable for NAVAC, are used as prophylactic or therapeutic vaccines to induce strong preventive Th1 or to shift Th2 to Th1 immune responses. The hypoallergenic derivatives can be successfully produced in recombinant expression systems and this is also an aspect of the present invention.

The present invention further relates to the provision and use of recombinant derivatives of *Dermatophagoides pteronyssinus* DerP3 allergen or of its precursor form ProDerP3 thereafter referred to as "DerP3/ProDerP3", with reduced allergenic activity compared to the wild-type allergen. The recombinant forms of DerP3 derivatives according to the invention, either adjuvanted recombinant proteins or plasmid encoding DerP3/ProDerP3 suitable for NAVAC, are used as prophylactic or therapeutic vaccines to induce strong preventive Th1 or to shift Th2 to Th1 immune responses. The hypoallergenic derivatives can be successfully produced in recombinant expression systems and this is also an aspect of the present invention.

DerP1 is a 30 KDa protein and has been cloned and sequenced (Chua *et al.*, 1988, J.Exp.Med., 167, 175-182). It is known to contain 222 amino acid residues in the mature protein. The sequence of DerP1 shares 31% homology to papain, and shares more particularly homology in the enzymatically active regions, most notably the Cys34-His170 ion pair (*Topham et al., supra*). DerP1 is produced in the mid-gut of the mite, where its role is probably related to the digestion of food. Up to 0.2 ng or proteolytically active DerP1 is incorporated into each fecal pellet, each around 10-40 μm in diameter and, therefore, easily inspired into the human respiratory tract. Overnight storage of purified DerP1 preparations at room temperature results in almost complete loss of enzymatic activity due to autoproteolytic degradation (Machado *et al.*, 1996, Eur.J.Immunol. 26, 2972-2980). The DerP1 encoding cDNA sequence reveals that, like

many mammalian and plant proteinases, DerP1 is synthetised as an inactive preproenzyme of 320 amino acid residues which is subsequently processed into a 222-amino acid mature form (Chua *et al.*, 1988, J.Exp.Med., 167, 175-182; Chua et al., 1993, Int. Arch Allergy Immunol 101, 364-368). The maturation of ProDerP1 is not known to date but it is thought that the allergen is processed by the cleavage of the 80-residues proregion.

The present invention provides a recombinant *Dermatophagoides pteronyssinus* DerP1/ProDerP1 protein allergen derivative wherein said allergen derivative has a significantly reduced allergenic activity compared to that the wild-type allergen. The allergenic activity can be impaired by several means which aim at disrupting the 3D-conformational shape of the protein forms by disrupting its intramolecular disulphide bridges thereby destabilising its 3-dimensional structure or by deleting a region of the protein, such as the amino acids 227-240 of ProDerP1 (147-160 of the DerP1 sequence). Said allergen derivatives having the following advantages over the unaltered wild-type allergen: 1) increases the Th1-type aspect of the immune responses (higher IgG2a for example) in comparison to those stimulated by the wild type allergen, thereby leading to the suppression of allergic potential of the vaccinated host, 2) having reduced allergenicity while still retaining T cell reactivity, thus being more suitable for systemic administration of high doses of the immunogen, 3) will induce DerP1 specific IgG which compete with IgE for the binding of native DerP1, 4) efficiently protects against airway eosinophilia even after exposure to aerosolised allergen extract. Such derivatives are suitable for use in therapeutic and prophylactic vaccine formulations which are suitable for use in medecine and more particularly for the treatment or prevention of allergic reactions.

According to a first aspect, the present invention provides a recombinant DerP1/ProDerP1 (i.e. DerP1 or ProDerP1) allergen derivative wherein the allergenic activity has been significantly reduced, e.g. almost or completely abolished, by a physical means such as by thermally treating the protein, preferably in the presence of a reducing agent. Typically, the DerP1/ProDerP1 protein is treated during a few minutes at about 100°C in the presence of a reducing agent. Preferably the reducing agent is beta-mercaptoethanol or DTT. Still more preferably the protein is treated during 5 minutes at

about 100°C in the presence of 50 mM beta-mercaptoethanol. This treatment has a detrimental effect on the stability of the protein conformational IgE-binding epitopes.

In a second aspect the present invention provides a recombinant DerP1/ProDerP1 protein derivative wherein the allergenic activity has been genetically impaired such as by introducing specific mutations into the encoding cDNA or the genomic DNA. Accordingly an aspect of the invention provides the genetically mutated recombinant DerP1/ProDerP1 *per se*. The reduction of the allergenicity of DerP1/ProDerP1 may be performed by introducing mutations into the native sequence before recombinantly producing the hypoallergenic mutants. This may be achieved by: introducing substitutions, deletions, or additions in or by altering the three dimensional structure of the protein such that the tridimensional conformation of the protein is lost. This may be achieved, amongst others, by expressing the protein in fragments, or by deleting cysteine residues involved in disulphide bridge formation, or by deleting or adding residues such that the tertiary structure of the protein is substantially altered. Preferably, mutations may be generated with the effect of altering the interaction between two cysteine residues, typically one mutation at positions 4, 31, 65, 71, 103 and 117 of the native – mature - DerP1 (which corresponds to positions 84, 111, 145, 151, 183 and 197 of ProDerP1, respectively). A mutated protein according to the invention may comprise two or more (3, 4, 5 or all 6) cysteine mutations, thereby affecting different disulphide bridges, such as mutations at positions 4 & 31, 4 & 65, 4 & 71, 4 & 103, 31 & 65, or 4 & 31 & 65, or at positions 71 & 103, 71 & 117, 103 & 117, 31 & 117, 65 & 117, or 71 & 103 & 117. Preferably the derivatives comprise one single mutation at any of the above positions. The most preferred mutation involves Cys4 (or alternatively, or in addition, Cys117 which is thought to be the disulphide bond partner of Cys4). The Cys mutations can be deletions, but are preferably substitutions for any of the other natural 19 amino acids. Preferred substitutions introduce positively charged amino acid residues to further destabilise the 3D-structure of the resulting protein. For example, preferred substitutions involve cysteine→arginine (or lysine) substitution.

In one aspect of the present invention, the derivatives comprise a triple mutation in which the cysteine residues 71, 103 and 117 are all mutated into alanine.

In a further aspect the present invention provides a form of proDerP1 in which the amino acids 227-240 of the ProDerP1 sequence are deleted. These amino acids correspond to 147-160 of the DerP1 sequence.

Accordingly, the invention is illustrated herein by, but is not limited to, six specific mutations which are given as examples of hypoallergenic DerP1/ProDerP1 derivatives and a further mutation in which amino acids 227-240 of ProDerP1 (147-160 of DerP1) are deleted First the allergenic activity of ProDerP1 is substantially reduced, preferably completely abrogated by substituting a cysteine residue for an arginine residue at position Cys4 of DerP1 protein sequence, and is set out in SEQ ID NO:3. Second, the allergenic activity of ProDerP1 is substantially abrogated by substituting a cysteine residue for an arginine residue at any of the following positions (calculated by reference to the sequence in mature DerP1): Cys31 of DerP1 protein sequence (SEQ ID NO:5), Cys65 (SEQ ID NO:7), Cys71 (SEQ ID NO:9), Cys103 (SEQ ID NO:11), Cys117 (SEQ ID NO:13).

Further, the allergenic activity of ProDerP1 is substantially reduced, preferably completely abrogated, by deletion of the amino acids 227-240 of ProDerP1 (147-160 of DerP1) (SEQ ID NO:15).

Mutated versions of DerP1/ProDerP1 may be prepared by site-directed mutagenesis of the cDNA which codes for the DerP1/ProDerP1 protein by conventional methods such as those described by G. Winter *et al* in Nature 1982, 299, 756-758 or by Zoller and Smith 1982; Nucl. Acids Res., 10, 6487-6500, or deletion mutagenesis such as described by Chan and Smith in Nucl. Acids Res., 1984, 12, 2407-2419 or by G. Winter et al in Biochem. Soc. Trans., 1984, 12, 224-225.

Hypoallergenic ProDerP1 is also provided by the present invention, together with mutated versions of DerP3/ProDerP3.

The invention is not limited to the specifically disclosed sequence, but includes any hypoallergenic allergen which has been mutated to decrease or abolish its IgE-binding reactivity and/or histamine release activity, whilst retaining its T cell reactivity and/or the ability to stimulate an immune response against the wild-type allergen. The allergenic activity, and consequently the reduction in the allergenic activity, of the mutant allergens may be compared to the wild type by any of the following methods: histamine release activity or by IgE-binding reactivity, according to the method detailed in the Example section.

"Substantially reduced allergenic activity" means that the allergenic activity as measured by residual IgE-binding activity is reduced to a maximum of 50% of the activity of the native – unmodified or unmutated - protein, preferably to a maximum of 20%, more preferably to a maximum of 10%, still more preferably to a maximum of 5%, still more preferably to less than 5%. Alternatively, "substantially reduced allergenic activity" can also be assessed by measuring the histamine release activity of the mutant. A substantial reduction in activity is when there is a reduction of at least a 100-fold factor as compared to the native protein, preferably by a factor of 1000-fold, still more preferably by a factor of 10000-fold.

The immunogenicity of the mutant allergen may be compared to that of the wild-type allergen by various immunologicals assays. The cross-reactivity of the mutant and wild-type allergens may be assayed by *in vitro* T-cell assays after vaccination with either mutant or wild-type allergens. Briefly, splenic T-cells isolated from vaccinated animals may be restimulated *in vitro* with either mutant or wild-type allergen followed by measurement of cytokine production with commercially available ELISA assays, or proliferation of allergen specific T cells may be assayed over time by incorporation of tritiated thymidine. Also the immunogenicity may be determined by ELISA assay, the details of which may be easily determined by the man skilled in the art. Briefly, two types of ELISA assay are envisaged. First, to assess the recognition of the mutant DerP1 by sera of mice immunized with the wild type DerP1; and secondly by recognition of wild type DerP1 allergen by the sera of animals immunised with the mutant allergen. Briefly, each wells will be coated with 100 ng of purified wild type or mutated DerP1 overnight at 4°C. After incubating with a blocking solution (TBS-Tween 0.1% with 1% BSA) successive dilutions of sera will be incubated at 37°C for 1 hour. The wells are washed 5 times, and total IgG revealed by incubating with an anti-IgG antibody conjugated with Alkaline phosphatase. The immunogenicity of mutant DerP3 may be compared to wild-type DerP3 as described for DerP1, above.

A further aspect of the present invention provides an isolated nucleic acid encoding a mutated version of the DerP1/ProDerP1 allergen as disclosed herein. Preferably the nucleotide sequence is a DNA sequence and can be synthesized by standard DNA synthesis techniques, such as by enzymatic ligation as described by D.M. Roberts *et al* in Biochemistry 1985, 24, 5090-5098, by chemical synthesis, by *in vitro* enzymatic

polymerization, or by a combination of these techniques. Preferably the nucleic acid sequence has a codon usage pattern that has been optimised so as to mimic the one used in the intended expression host, more preferably resembling that of highly expressed mammalian e.g. human genes. Preferred DNA sequences are codon-optimised sequences and are set out in SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:15 and SEQ ID NO:17.

A further aspect of the present invention provides an isolated nucleic acid encoding a mutated version of the DerP3/ProDerP3 allergen as disclosed herein. Preferably the nucleotide sequence is a DNA sequence and can be synthesized by standard DNA synthesis techniques, such as by enzymatic ligation as described by D.M. Roberts *et al* in Biochemistry 1985, 24, 5090-5098, by chemical synthesis, by *in vitro* enzymatic polymerization, or by a combination of these techniques. Preferably the nucleic acid sequence has a codon usage pattern that has been optimised so as to mimic the one used in the intended expression host, more preferably resembling that of highly expressed mammalian e.g. human genes. A preferred DNA sequence is set out in SEQ ID NOs:20 and 21.

Enzymatic polymerisation of DNA may be carried out *in vitro* using a DNA polymerase such as DNA polymerase I (Klenow fragment) in an appropriate buffer containing the nucleoside triphosphates dATP, dCTP, dGTP and dTTP as required at a temperature of 10°-37°C, generally in a volume of 50ml or less. Enzymatic ligation of DNA fragments may be carried out using a DNA ligase such as T4 DNA ligase in an appropriate buffer, such as 0.05M Tris (pH 7.4), 0.01M $MgCl_2$, 0.01M dithiothreitol, 1mM spermidine, 1mM ATP and 0.1mg/ml bovine serum albumin, at a temperature of 4°C to ambient, generally in a volume of 50ml or less. The chemical synthesis of the DNA polymer or fragments may be carried out by conventional phosphotriester, phosphite or phosphoramidite chemistry, using solid phase techniques such as those described in 'Chemical and Enzymatic Synthesis of Gene Fragments - A Laboratory Manual' (ed. H.G. Gassen and A. Lang), Verlag Chemie, Weinheim (1982),or in other scientific publications, for example M.J. Gait, H.W.D. Matthes, M. Singh, B.S. Sproat, and R.C. Titmas, Nucleic Acids Research, 1982, 10, 6243; B.S. Sproat and W. Bannwarth, Tetrahedron Letters, 1983, 24, 5771; M.D. Matteucci and M.H Caruthers, Tetrahedron Letters, 1980, 21, 719; M.D. Matteucci and M.H. Caruthers, Journal of the

American Chemical Society, 1981, 103, 3185; S.P. Adams et al., Journal of the American Chemical Society,1983, 105, 661; N.D. Sinha, J. Biernat, J. McMannus, and H. Koester, Nucleic Acids Research, 1984, 12, 4539; and H.W.D. Matthes et al., EMBO Journal, 1984, 3, 801.

Alternatively, the coding sequence can be derived from DerP1/ProDerP1 mRNA, using known techniques (e.g. reverse transcription of mRNA to generate a complementary cDNA strand), and commercially available cDNA kits. The coding sequence of DerP3/ProDerP3 may be derived as described above; the codon usage pattern of the PreProDer p 3 nucleotide sequence is typical of highly expressed bacterial genes.

Surprisingly, it has been found that ProDerP3 is highly hypoallergenic compared to DerP3.

Desirably the codon usage pattern of the nucleotide sequence is typical of highly expressed human genes. Accordingly there is provided in a particular aspect of the invention a nucleotide sequence comprising a plurality of codons together encoding the mutated DerP1/ProDerP1 protein, wherein the selection of the possible codons used for encoding the recombinant mite protein amino acid sequence has been changed to closely mimic the optimised mammalian codon usage, such that the frequency of codon usage in the resulting gene sequence is substantially the same as a mammalian gene which would encode the same protein. Codon usage patterns for mammals, including humans, can be found in the literature (see e.g. Nakamura et al. 1996, Nucleic Acids Res. 24, 214-215.

The DNA code has 4 letters (A, T, C and G) and uses these to spell three letter "codons" which represent the amino acids the proteins encoded in an organism's genes. The linear sequence of codons along the DNA molecule is translated into the linear sequence of amino acids in the protein(s) encoded by those genes. The code is highly degenerate, with 61 codons coding for the 20 natural amino acids and 3 codons representing "stop" signals. Thus, most amino acids are coded for by more than one codon - in fact several are coded for by four or more different codons.

Where more than one codon is available to code for a given amino acid, it has been observed that the codon usage patterns of organisms are highly non-random. Different species show a different bias in their codon selection and, furthermore, utilization of codons may be markedly different in a single species between genes which are expressed at high and low levels. This bias is different in viruses, plants, bacteria, insect and

mammalian cells, and some species show a stronger bias away from a random codon selection than others. For example, humans and other mammals are less strongly biased than certain bacteria or viruses. For these reasons, there is a significant probability that a mammalian gene expressed in *E.coli* or a viral gene expressed in mammalian cells will have an inappropriate distribution of codons for efficient expression. However, a gene with a codon usage pattern suitable for *E.coli* expression may also be efficiently expressed in humans. It is believed that the presence in a heterologous DNA sequence of clusters of codons which are rarely observed in the host in which expression is to occur, is predictive of low heterologous expression levels in that host.

There are several examples where changing codons from those which are rare in the host to those which are host-preferred ("codon optimisation") has enhanced heterologous expression levels, for example the BPV (bovine papilloma virus) late genes L1 and L2 have been codon optimised for mammalian codon usage patterns and this has been shown to give increased expression levels over the wild-type HPV sequences in mammalian (Cos-1) cell culture (Zhou et. al. J. Virol 1999. **73**, 4972-4982). In this work, every BPV codon which occurred more than twice as frequently in BPV than in mammals (ratio of usage >2), and most codons with a usage ratio of >1.5 were conservatively replaced by the preferentially used mammalian codon. In WO97/31115, WO97/48370 and WO98/34640 (Merck & Co., Inc.) codon optimisation of HIV genes or segments thereof has been shown to result in increased protein expression and improved immunogenicity when the codon optimised sequences are used as DNA vaccines in the host mammal for which the optimisation was tailored.

In this work, the sequences preferably consist entirely of optimised codons (except where this would introduce an undesired restriction site, intron splice site etc.) because each *D. pteronyssinus* codon is conservatively replaced with the optimal codon for a mammalian host. Surprisingly such optimised ProDerP1/DerP1 sequences also express very well in yeast despite the different codon usage of yeast.

A still further aspect of the invention provides a process for the preparation of a mutated DerP1/ProDerP1 protein which process comprises expressing DNA, either codon optimised or not, encoding the said protein in a recombinant host cell and recovering the product; the above process also applies for DerP3/ProDerP3.

Although DerP1 is well characterized in terms of its enzymatic activity, allergenicity and gene cloning, heterologous expression of DerP1 has been reported to be problematic (Chapman and Platts-Mills, J Immunol 1980;125:587-592), probably because this cysteine proteinase is synthesized as a PreProDerP1 precursor. Even more problematic is the expression of DerP1/ProDerP1 sequences wherein cysteine residues involved in the protein conformation have been mutated. Accordingly the present invention further provides a process overcoming all these drawbacks therefore allowing the production of the mutated proteins and the industrial development of therapeutic and prophylactic vaccines to mite allergy.

A process for production of DerP3/ProDerP3 mutated proteins is also provided.

A substantial amelioration of protein expression has been achieved in *E. coli* when DerP1/ProDerP1 either mutated or not was expressed as a Maltose Binding Protein (MBP) fusion protein. Accordingly there is provided a process for expressing the mutated ProDerP/DerP1 protein as a MBP fusion protein in *E. coli*. Furthermore, a substantial amelioration of protein expression in yeast has been surprisingly achieved for the mutated protein even though disulphide bonds are said to be essential for secretion in *Pichia pastoris* (Takai et al. 2001, Int. Arch. Allergy Immunol. 124, 454-460). This was achieved by re-engineering the polynucleotide sequence which encodes the *Dermaphagoides* mutated ProDerP/DerP1 protein to fit the codon usage found in highly expressed human genes, thereby also allowing the recombinant antigen to have the same conformation and immunological properties as native ProDerP/DerP1 *Dermaphagoides* allergens. Surprisingly, the cloning and expression of mutated ProDerP1, codon-optimised for mammalian cell expression, could be achieved in *Pichia pastoris,* with a certain proportion being secreted, although expression in *P. pastoris* has been formerly reported to be unsuccessful (Takai et al. 2001, Int. Arch. Allergy Immunol. 124, 454-460).

The process of the invention may be performed by conventional recombinant techniques such as described in Maniatis et. al., Molecular Cloning - A Laboratory Manual; Cold Spring Harbor, 1982-1989.

In particular, the process may comprise the steps of:

1. Preparing a replicable or integrating expression vector capable, in a host cell, of expressing a DNA polymer comprising a nucleotide sequence that encodes the said DerP1/ProDerP1 protein;
2. Altering the IgE-binding activity of the resultant protein by replacing the cysteine residues involved in disuphide bonds with another residue, preferably an arginine residue, using site directed mutagenesis;
3. Transforming a host cell with the said vector
4. Culturing the transformed host cell under conditions permitting expression of the DNA polymer to produce the protein; and
5. Recovering the protein.

The above process may also apply for DerP3/ProDerP3

The term 'transforming' is used herein to mean the introduction of foreign DNA into a host cell by transformation, transfection or infection with an appropriate plasmid or viral vector using e.g. conventional techniques as described in Genetic Engineering; Eds. S.M. Kingsman and A.J. Kingsman; Blackwell Scientific Publications; Oxford, England, 1988. The term 'transformed' or 'transformant' will hereafter apply to the resulting host cell containing and expressing the foreign gene of interest.

The expression vector is novel and also forms part of the invention. One particular aspect of the present invention provides an expression vector which comprises, and is capable of directing the expression of, a polynucleotide sequence encoding a cystein-mutated DerP1/ProDerP1 protein according to the invention. Another particular aspect of the invention provides an expression vector which comprises, and is capable of directing the expression of, a polynucleotide sequence encoding a cysteine-mutated DerP1/ProDerP1 protein wherein the codon usage pattern of the polynucleotide sequence is typical of highly expressed mammalian genes, preferably highly expressed human genes. The vector may be suitable for driving expression of heterologous DNA in bacterial, insect, yeast or mammalian cells, particularly human cells.

The replicable expression vector may be prepared in accordance with the invention, by cleaving a vector compatible with the host cell to provide a linear DNA segment having an intact replicon, and combining said linear segment with one or more DNA molecules which, together with said linear segment encode the desired product, such as the DNA polymer encoding the DerP1/ProDerP1 protein under ligating conditions.

The above vectors may also aply for mutated DerP3/ProDerP3 according to the present invention.

Thus, the DNA polymer may be preformed or formed during the construction of the vector, as desired.

The choice of vector will be determined in part by the host cell, which may be prokaryotic or eukaryotic. Suitable vectors include plasmids, bacteriophages, cosmids and recombinant viruses.

The preparation of the replicable expression vector may be carried out conventionally with appropriate enzymes for restriction, polymerisation and ligation of the DNA, by procedures described in, for example, Maniatis *et al* cited above.

The recombinant host cell is prepared, in accordance with the invention, by transforming a host cell with a replicable expression vector of the invention under transforming conditions. Suitable transforming conditions are conventional and are described in, for example, Maniatis et al cited above, or "DNA Cloning" Vol. II, D.M. Glover ed., IRL Press Ltd, 1985.

The choice of transforming conditions is determined by the host cell. Thus, a bacterial host such as *E. coli* may be treated with a solution of $CaCl_2$ (Cohen *et al*, Proc. Nat. Acad. Sci., 1973, 69, 2110) or with a solution comprising a mixture of RbCl, $MnCl_2$, potassium acetate and glycerol, and then with 3-[N-morpholino]-propane-sulphonic acid, RbCl and glycerol. Mammalian cells in culture may be transformed by calcium co-precipitation of the vector DNA onto the cells, by lipofection, or by electroporation. Yeast compatible vectors also carry markers that allow the selection of successful transformants by conferring prototrophy to auxotrophic mutants or resistance to heavy metals on wild-type strains. Control sequences for yeast vectors include promoters for glycolytic enzymes (Hess et al., J. Adv. Enzyme Reg. 1968, 7, 149), PHO5 gene encoding acid phosphatase, CUP1 gene, ARG3 gene, GAL genes promoters and synthetic promoter sequences. Other control elements useful in yeast expression are terminators and leader sequences. The leader sequence is particularly useful since it typically encodes a signal peptide comprised of hydrophobic amino acids, which direct the secretion of the protein from the cell. Suitable signal sequences can be encoded by genes for secreted yeast proteins such as the yeast invertase gene and the a-factor gene, acid phosphatase, killer toxin, the a-mating factor gene and recently the heterologous inulinase signal

sequence derived from INU1A gene of Kluyveromyces marxianus. Suitable vectors have been developed for expression in *Pichia pastoris* and *Saccharomyces cerevisiae*.

A variety of *P. pastoris* expression vectors are available based on various inducible or constitutive promoters (Cereghino and Cregg, FEMS Microbiol. Rev. 2000,24:45-66). For the production of cytosolic and secreted proteins,the most commonly used P. pastoris vectors contain the very strong and tightly regulated alcohol oxidase (AOX1) promoter. The vectors also contain the *P. pastoris* histidinol dehydrogenase (HIS4) gene for selection in his4 hosts. Secretion of foreign protein require the presence of a signal sequence and the *S. cerevisiae* prepro alpha mating factor leader sequence has been widly and successfully used in Pichia expression system. Expression vectors are integrated into the P. pastoris genome to maximize the stability of expression strains. As in *S.cerevisiae*, cleavage of a *P. pastoris* expression vector within a sequence shared by the host genome (AOX1 or HIS4) stimulates homologous recombination events that efficiently target integration of the vector to that genomic locus. In general, a recombinant strain that contains multiple integrated copies of an expression cassette can yield more heterologous protein than single-copy strain. The most effective way to obtain high copy number transformants requires the transformation of *Pichia* recipient strain by the sphaeroplast technique (Cregg et all 1985, Mol.Cell.Biol. 5: 3376-3385).

The invention also extends to a host cell transformed with a replicable expression vector of the invention.

Culturing the transformed host cell under conditions permitting expression of the DNA polymer is carried out conventionally, as described in, for example, Maniatis *et al* and "DNA Cloning" cited above. Thus, preferably the cell is supplied with nutrient and cultured at a temperature below 45°C.

The product is recovered by conventional methods according to the host cell. Thus, where the host cell is bacterial, such as *E. coli* it may be lysed physically, chemically or enzymatically and the protein product isolated from the resulting lysate. Where the host cell is mammalian, the product may generally be isolated from the nutrient medium or from cell free extracts. Conventional protein isolation techniques include selective precipitation, absorption chromatography, and affinity chromatography including a monoclonal antibody affinity column.

Alternatively, the expression may be carried out either in insect cells using a suitable vector such as a baculovirus, in transformed drosophila cells, or mammalian CHO cells. The novel protein of the invention may also be expressed in yeast cells as described for the CS protein in EP-A-0 278 941.

Pharmaceutical, immunogenic and vaccine compositions comprising a hypoallergenic DerP1/ProDerP1 derivative according to the invention; or the polynucleotide sequences encoding said proteins, either codon-optimised or not, are also provided. Such compositions comprising hypoallergenic DerP3/ProDerP3 are also provided. In preferred embodiments the DNA composition comprises a plurality of particles, preferably gold particles, coated with DNA comprising a vector encoding a polynucleotide sequence which encodes a *D. pteronyssinus* amino acid sequence, wherein the codon usage pattern of the polynucleotide sequence is typical of highly expressed mammalian genes, particularly human genes.

The polynucleotides and encoded polypeptides according to the invention may find use as therapeutic or prophylactic agents. In particlular the polynucleotides of the invention (including a polynucleotide sequence of native ProDerP1 – preferably codon optimised) may be used in DNA vaccination (NAVAC), the DNA being administered to the mammal e.g. human to be vaccinated. The nucleic acid, such as RNA or DNA, preferably DNA, is provided in the form of a vector, such as those described above, which may be expressed in the cells of the mammal. The polynucleotides may be administered by any available technique. For example, the nucleic acid may be introduced by needle injection, preferably intradermally, subcutaneously or intramuscularly. Alternatively, the nucleic acid may be delivered directly into the skin using a nucleic acid delivery device such as particle-mediated DNA delivery (PMDD). In this method, inert particles (such as gold beads) are coated with a nucleic acid, and are accelerated at speeds sufficient to enable them to penetrate a surface of a recipient (e.g. skin), for example by means of discharge under high pressure from a projecting device. (Particles coated with a nucleic acid molecule of the present invention are within the scope of the present invention, as are delivery devices loaded with such particles).

Suitable techniques for introducing the naked polynucleotide or vector into a patient include topical application with an appropriate vehicle. The nucleic acid may be administered topically to the skin, or to mucosal surfaces for example by intranasal, oral,

intravaginal or intrarectal administration. The naked polynucleotide or vector may be present together with a pharmaceutically acceptable excipient, such as phosphate buffered saline (PBS). DNA uptake may be further facilitated by use of facilitating agents such as bupivacaine, either separately or included in the DNA formulation. Other methods of administering the nucleic acid directly to a recipient include ultrasound, electrical stimulation, electroporation and microseeding which is described in US-5,697,901. Typically the nucleic acid is administered in an amount in the range of 1pg to 1mg, preferably 1pg to 10μg nucleic acid for particle mediated gene delivery and 10μg to 1mg for other routes.

A nucleic acid sequence of the present invention may also be administered by means of specialised delivery vectors useful in gene therapy. Gene therapy approaches are discussed for example by Verme *et al*, Nature 1997, **389**:239-242. Both viral and non-viral vector systems can be used. Viral based systems include retroviral, lentiviral, adenoviral, adeno-associated viral, herpes viral, Canarypox and vaccinia-viral based systems. Non-viral based systems include direct administration of nucleic acids, microsphere encapsulation technology (poly(lactide-co-glycolide) and, liposome-based systems. Viral and non-viral delivery systems may be combined where it is desirable to provide booster injections after an initial vaccination, for example an initial "prime" DNA vaccination using a non-viral vector such as a plasmid followed by one or more "boost" vaccinations using a viral vector or non-viral based system.

In this way, the inventors have found that vaccination with DNA encoding ProDerP1 (preferably codon optimised for mammals) induces a Th1 response in mice models (high titres of specific IgG2a antibodies and low titres of specific IgG1) and, remarkably, the absence of anti-ProDerP1 IgE.

The pharmaceutical compositions of the present invention may include adjuvant compounds, or other substances which may serve to increase the immune response induced by the protein.

The vaccine composition of the invention comprises an immunoprotective amount of the mutated version of the DerP1/ProDerP1 hypoallergenic protein or the mutated version of the DerP3/ProDerP3 hypoallergenic protein. The term "immunoprotective" refers to the amount necessary to elicit an immune response against a subsequent challenge such that allergic disease is averted or mitigated. In the vaccine of the

invention, an aqueous solution of the protein can be used directly. Alternatively, the protein, with or without prior lyophilization, can be mixed, adsorbed, or covalently linked with any of the various known adjuvants.

Suitable adjuvants are commercially available such as, for example, Freund's Incomplete Adjuvant and Complete Adjuvant (Difco Laboratories, Detroit, MI); Merck Adjuvant 65 (Merck and Company, Inc., Rahway, NJ); AS-2 (SmithKline Beecham, Philadelphia, PA); aluminum salts such as aluminum hydroxide gel (alum) or aluminum phosphate; salts of calcium, iron or zinc; an insoluble suspension of acylated tyrosine; acylated sugars; cationically or anionically derivatized polysaccharides; polyphosphazenes; biodegradable microspheres; monophosphoryl lipid A and quil A. Cytokines, such as GM-CSF or interleukin-2, -7, or -12, and chemokines may also be used as adjuvants.

In the formulations of the invention it is preferred that the adjuvant composition induces an immune response predominantly of the Th1 type. High levels of Th1-type cytokines (*e.g.*, IFN-γ, TNFα, IL-2 and IL-12) tend to favour the induction of cell mediated immune responses to an administered antigen. Within a preferred embodiment, in which a response is predominantly Th1-type, the level of Th1-type cytokines will increase to a greater extent than the level of Th2-type cytokines. The levels of these cytokines may be readily assessed using standard assays. For a review of the families of cytokines, see Mosmann and Coffman, *Ann. Rev. Immunol.* 7:145-173, 1989.

Accordingly, suitable adjuvants for use in eliciting a predominantly Th1-type response include, for example a combination of monophosphoryl lipid A, preferably 3-de-O-acylated monophosphoryl lipid A (3D-MPL) together with an aluminium salt. Other known adjuvants, which preferentially induce a TH1 type immune response, include CpG containing oligonucleotides. The oligonucleotides are characterised in that the CpG dinucleotide is unmethylated. Such oligonucleotides are well known and are described in, for example WO 96/02555. Immunostimulatory DNA sequences are also described, for example, by Sato et al., *Science 273*:352, 1996. CpG-containing oligonucleotides may also be used alone or in combination with other adjuvants. For example, an enhanced system involves the combination of a CpG-containing oligonucleotide and a saponin derivative particularly the combination of CpG and QS21 as disclosed in WO 00/09159

and WO 00/62800. Preferably the formulation additionally comprises an oil in water emulsion and/or tocopherol.

Another preferred adjuvant is a saponin, preferably QS21 (Aquila Biopharmaceuticals Inc., Framingham, MA), that may be used alone or in combination with other adjuvants. For example, an enhanced system involves the combination of a monophosphoryl lipid A and saponin derivative, such as the combination of QS21 and 3D-MPL as described in WO 94/00153, or a less reactogenic composition where the QS21 is quenched with cholesterol, as described in WO 96/33739. Other preferred formulations comprise an oil-in-water emulsion and tocopherol. A particularly potent adjuvant formulation involving QS21, 3D-MPL and tocopherol in an oil-in-water emulsion is described in WO 95/17210.

A particularly potent adjuvant formulation involving QS21 3D-MPL & tocopherol in an oil in water emulsion is described in WO 95/17210 and is a preferred formulation.

Other preferred adjuvants include Montanide ISA 720 (Seppic, France), SAF (Chiron, California, United States), ISCOMS (CSL), MF-59 (Chiron), Detox (Ribi, Hamilton, MT), RC-529 (Corixa, Hamilton, MT) and other aminoalkyl glucosaminide 4-phosphates (AGPs).

Accordingly there is provided an immunogenic composition comprising a DerP1/ProDerP1 hypoallergenic derivative as disclosed herein and an adjuvant, wherein the adjuvant comprises one or more of 3D-MPL, QS21, a CpG oligonucleotide, a polyethylene ether or ester or a combination of two or more of these adjuvants. The DerP1/ProDerP1 hypoallergenic derivative within the immunogenic composition is preferably presented in an oil in water or a water in oil emulsion vehicle.

There is further provided an immunogenic composition comprising a DerP3/ProDerP3 hypoallergenic derivative as disclosed herein and an adjuvant, wherein the adjuvant comprises one or more of 3D-MPL, QS21, a CpG oligonucleotide, a polyethylene ether or ester or a combination of two or more of these adjuvants. The DerP3/ProDerP3 hypoallergenic derivative within the immunogenic composition is preferably presented in an oil in water or a water in oil emulsion vehicle.

In a further aspect, the present invention provides a method of making a pharmaceutical composition including the step of mutating one or more cysteine residues of DerP1/ProDerP1 involved in disulphide bridge formation, such as Cys4, Cys31,

Cys65, Cys71, Cys103 or Cys117. In an alternative aspect, the invention provides a method of making a pharmaceutical composition including the step of deleting the amino-acid residues 227-240 of ProDerP1 (147-160 of DerP1).

The method further comprises the step of altering the codon usage pattern of a wild-type DerP1/ProDerP1 nucleotide sequence, or creating a polynucleotide sequence synthetically, to produce a sequence having a codon usage pattern typical of highly-expressed mammalian genes and encoding a codon-optimised cysteine-mutated ProDerP1/DerP1 amino acid sequence or a ProDerP1/DerP1 amino-acid sequence in which selected residues have been deleted according to the invention. Vaccine preparation is generally described in Vaccine Design ("The subunit and adjuvant approach" (eds. Powell M.F. & Newman M.J). (1995) Plenum Press New York). Encapsulation within liposomes is described by Fullerton, US Patent 4,235,877. Conjugation of proteins to macromolecules is disclosed, for example, by Likhite, US Patent 4,372,945 and Armor *et al.*, US Patent 4,474,757.

The amount of the protein of the present invention present in each vaccine dose is selected as an amount which induces an immunoprotective response without significant, adverse side effects in typical vaccines. Such amount will vary depending upon which specific immunogen is employed and whether or not the vaccine is adjuvanted. Generally, it is expected that each dose will comprise 1-1000 μg of protein, preferably 1-200 μg. An optimal amount for a particular vaccine can be ascertained by standard studies involving observation of antibody titres and other responses in subjects. The vaccines of the present invention may be administered to adults or infants, however, it is preferable to vaccinate individuals soon after birth before the establishment of substantial Th2-type memory responses. Following an initial vaccination, subjects will preferably receive a boost in about 4 weeks, followed by repeated boosts every six months for as long as a risk of allergic responses exists.

Vaccines and pharmaceutical compositions may be presented in unit-dose or multi-dose containers, such as sealed ampoules or vials. Such containers are preferably hermetically sealed to preserve sterility of the formulation until use. In general, formulations may be stored as suspensions, solutions or emulsions in oily or aqueous vehicles. Alternatively, a vaccine or pharmaceutical composition may be stored in a

freeze-dried condition requiring only the addition of a sterile liquid carrier immediately prior to use.

The present invention also provides a process for the production of a vaccine, comprising the steps of purifying a DerP1/ProDerP1 derivative or ProDerP3/DerP3 derivative according to the invention or a derivative thereof, by the process disclosed herein and admixing the resulting protein with a suitable adjuvant, diluent or other pharmaceutically acceptable excipient.

The present invention also provides a method for producing a vaccine formulation comprising mixing a protein of the present invention together with a pharmaceutically acceptable excipient.

Another aspect of the invention is the use of a protein or polynucleotide as claimed herein for the manufacture of a vaccine for immunotherapeutically treating a patient susceptible to or suffering from allergy. A method of treating patients susceptible to or suffering from allergy comprising administering to said patients a pharmaceutically active amount of the immunogenic composition disclosed herein is also contemplated by the present invention.

A further aspect of the invention provides a method of preventing or mitigating an allergic disease in man (particularly house dust mite allergy), which method comprises administering to a subject in need thereof an immunogenically effective amount of a mutated allergen of the invention, or of a vaccine in accordance with the invention.

FIGURE LEGENDS

Figure 1: IgG and IgE-binding reactivity of denatured ProDerP1 expressed in CHO cells. Immunoplates were coated with 500ng/well of purified native or denatured ProDerP1 and incubated with sera (diluted 1:8) radioallergosorbent positive to *D. pteronyssinus*. Bound IgE or IgG were quantitated by incubation with mouse anti-human IgE or IgG and alkaline phosphatase-labelled anti-mouse IgG antibodies, followed by an enzymatic assay. Results are expressed as OD_{410nm} values.

Figure 2: Correlation between the IgE reactivity of MBP-ProDerP1 and natural DerP. Immunoplates were coated with 500 ng/well of purified DerP or MBP-ProDerP1 and inculated with 95 sera (diluted 1:8) radioallergosorbent positive to D. pteronyssinus. Bound IgE was quantitated by incubation with mouse anti-human IgE and alkaline phosphatase-labelled anti-mouse Ig antibodies, followed by an enzymatic assay. Results are expressed as OD_{410nm} values.

Figure 3: IgE-binding reactivities of MBP-ProDerP1 mutants, carrying the mutations C4R, C31R and C65R. Immunoplates were coated with 500ng/well of Wild-type or mutant MBP-ProDerP1 and incubated with a pool of 20 sera (diluted 1:8) radioallergosorbent positive to *D. pteronyssinus*. Bound IgE was quantitated by incubation with mouse anti-human IgE and alkaline phosphatase-labelled anti-mouse IgG antibodies, followed by an enzymatic assay. Results are expressed as OD_{410nm} values.

Figure 4: Histamine release activity of allergens. Basophils isolated from the peripheral blood of one allergic donor were stimulated with serial dilutions of diiferent allergens. The histamine released from cells was measured by ELISA. The total amount of histamine in basophils was quantified after cell disruption with the detergent IGEPAL CA-630. Results are shown as the ratio of released histamine by allergens to total histamine.

Figure 5: schematic representation of the animal model of house dust mite allergy.

Figure 6: expression of ProDerP1 Δ227-240 in *P. pastoris* after induction with methanol for 24 and 48 hours. The culture supernatants of the recombinant clones are analysed by SDS PAGE. The blot is revealed by means of a polyclonal mouse serum against ProDer p 1 expressed in CHO. Tracks 1,2 : irrelevant proteins, Track 3 : yeasts not induced, Track 4 : purified ProDer p 1, Track 5 : clone 1 after induction for 24 hours, Track 6 : clone 1 after induction for 48 hours, Track 7 : clone 2 after induction for 24 hours, Track 8 : clone 2 after induction for 48 hours.

Figure 7

Sequence comparison of wild-type (AcaNucSeq) and bacterial codon-optimized (EcoNucSeq) PreProDer p 3 cDNA. The deduced amino acid sequence shown below each codon is designated by the single-letter code. The leader peptide and the propeptide sequence are indicated in italics and underlined respectively.

Figure 8

Expression of ProDerP3

After induction with 0.5 or 1mM IPTG for 1, 2, 3 and 16h, the bacteria were crushed. The cytoplasmic fraction (S) and the insoluble fraction (C) are analysed by Western blot for the presence of ProDer p 3

Figure 9

Detection of ProDer p 3 in SDS-PAGE after staining with Coomassie blue.

Track 1 : cytoplasmic fraction

Track 2 : washing of the insoluble fraction

Track 3 : insoluble fraction.

The arrow indicates the position of ProDer p 3.

Figure 10

Purification of ProDer p 3 by Ni2+-NTA chromatograpy

Bound proteins were eluted by addition of increasing concentrations of imidazol in the starting buffer. Fractions were analyzed by SDS PAGE after coomassie blue staining (left panel) and western blot using an anti-His antibody (right panel).
FT: flow-through, 20, 40, 45, 60, 100: imidazol concentration (mM), R: resin Ni2+-NTA after purification

Figure 11
Correlation between the IgE reactivity of recombinant ProDerP3 and natural DerP3.
Immunoplates were coated with 500ng/well of purified natural Der p 3 or recombinant ProDer p 3 and incubated with sera (diluted 1:8) radioallergosorbent positive to *D.pteronyssinus*. Bound IgE were detected after incubation with a mouse biotinylated anti-human IgE and alkaline phosphatase-labelled streptavidin, followed by an enzymatic assay. Results are expressed as OD_{410nm} values.

The examples which follow are illustrative but not limiting of the invention. Restriction enzymes and other reagents were used substantially in accordance with the vendors' instructions.

EXAMPLE I

General procedures

1. - SDS PAGE and Western blot analysis

Proteins were analyzed by SDS-PAGE on 12.5% polyacrylamide gels. After electrophoresis, proteins were transferred onto nitrocellulose membranes using a semi-dry transblot system (Bio-Rad). Membranes were saturated for 30 min with 0.5% Instagel (PB Gelatins) in TBS-T (50mM Tris HCl pH 7.5, 150mM NaCl, 0.1% Tween 80) and incubated with mouse polyclonal serum raised against denatured or native ProDerP1 diluted in blocking solution (1: 5000). Immunoreactive materials were detected using alkaline phosphatase-conjugated goat anti-mouse antibodies (Promega, 1:7500) and 5-bromo,4-chloro,3-indolylphosphate (BCIP, Boehringer)/ nitroblue tetrazolium (NBT, Sigma) as substrates.

2. - Glycan analysis

Carbohydrate analysis was carried out with the Glycan Differenciation Kit (Boehringer) using the following lectins : *Galanthus nivalis* agglutinin (GNA), *Sambucus nigra* agglutinin (SNA), *Maackia amurensis* agglutinin (MAA), Peanut agglutinin (PNA) and *Datura stramonium* agglutinin (DSA). Briefly, purified proteins were transferred from SDS-PAGE onto nitrocellulose membranes. Membranes were incubated with the different lectins conjugated to digoxigenin. Complexes were detected with anti-digoxigenin antibodies conjugated to alkaline phosphatase.

3. - Enzymatic assays

Enzymatic assays were performed in 50 mM Tris-HCl pH 7, containing 1mM EDTA and 20mM L-cysteine at 25°C in a total volume of 1ml. Hydrolysis of Cbz-Phe-Arg-7-amino-4-methylcoumarin (Cbz-Phe-Arg-AMC) and Boc-Gln-Ala-Arg-7-amino-4-methylcoumarin (Boc-Gln-Ala-Arg-AMC) (Sigma) (both substrates at a final concentration of 100µM) was monitored using a SLM 8000 spectrofluorimeter with λ_{ex} = 380nm and λ_{em} = 460nm. Assays were started by addition of cysteine activated allergen to a final concentration of 100 nM. Before any assay, purified DerP1 or ProDerP1 was incubated with a mixture of aprotinin- and p-aminobenzamidine-agarose resins (Sigma) to remove any putative trace of serine protease activity.

4. - Protein determination

Total protein concentration was determined by the bicinchoninic acid procedure (MicroBCA, Pierce) with bovine serum albumin as standard.

5. - DerP1 ELISA

DerP1 or recProDerP1 was detected with an ELISA kit using DerP1 specific monoclonal antibodies 5H8 and 4C1 (Indoor Biotechnologies). The DerP1 standard (UVA 93/03) used in the assay was at a concentration of 2.5µg/ml.

6. - IgE-binding activity

Immunoplates were coated overnight with DerP1 or ProDerP1 (500ng/well) at 4°C. Plates were then washed 5 times with 100µl per well of TBS-Tween buffer (50mM Tris-HCl pH 7.5, 150mM NaCl, 0.1% Tween 80) and saturated for 1 hr at 37°C with 150µl of the same buffer supplemented with 1% BSA. Sera from allergic patients to *D. pteronyssinus* and diluted at 1/8 were then incubated for 1 hr at 37°C. Out of the 95 sera used in the experiments, 16 sera ranged in their specific anti-*D. pteronyssinus*-IgE values (RAST-assays) from 58.1kU/L to 99kU/L and 79 above the upper cut-off value of 100kU/L. Plates were washed 5 times with TBS-Tween buffer and the allergen-IgE complexes were detected after incubation with a mouse anti-human IgE antibody (Southern Biotechnology Associates) and a goat anti-mouse IgG antibody coupled to alkaline phosphatase (dilution 1/7500 in TBS-Tween buffer, Promega). The enzymatic activity was measured using the p-nitrophenylphosphate substrate (Sigma) dissolved in diethanolamine buffer (pH 9.8). OD_{410nm} was measured in a Biorad Novapath ELISA reader.

For IgE inhibition assays, plates were coated with DerP1 or ProDerP1 at the same concentration (0.12 µM). A pool of 20 human sera from allergic patients (RAST value > 100kU/L) was preincubated overnight at 4°C with various concentrations (3.6-0.002 µM) of DerP1 or recProDerP1 as inhibitors and added on ELISA plates. IgE-binding was detected as described above.

7. - Histamine release

The histamine release was assayed using leukocytes from the peripheral heparinized blood of an allergic donor and by the Histamine-ELISA kit (Immunotech). Basophils were incubated with serial dilutions of recProDerP1 or DerP1 for 30min at 37°C. The total amount of histamine in basophils was quantified after cell disruption with the detergent IGEPAL CA-630 (Sigma).

8. – ProDerP1 denaturation

Recombinant ProDerP1 was heat-denatured for 5 min at 100°C in presence of 50mM β-mercaptoethanol.

9. - Immunisations

Groups of ten CBA/J mice (six weeks old) were four weekly immunised with 5µg of different proteins or 100µg of different plasmidic DNA. The purified allergens were injected in presence of alum as adjuvant. As controls, groups of mice were immunised with alum or pJW4304 DNA vector. Mice were bled from the retro-orbital venous plexus on days 7, 14, 21, 28 and sera were collected.

10. - Bronchoprovocation

Within 72h after immunisations, all mice were placed in a Plexiglas chamber (13 x 19 x 37.5 cm) and exposed to aerosolised crude *D.pteronyssinus* extract over a 20-min period for 7 consecutive days. The concentration of crude mite extract was 300µg/ml. The aerosols were generated by an ultrasonic nebulizer (Syst' AM). The output of the nebulizer was 0.5ml/min and the mean particle size of the aerosol was between 1 and 5 µm. As control, mice were nebulized with PBS.

11. - Measurement of DerP1-specific IgG, IgG1 and IgG2a

Sera were assayed for anti-DerP1 IgG, IgG1 and IgG2a antibodies by ELISA. Immunoplates were coated with ProDerP1 (500ng/well), for 16 hrs at 4°C. Plates were washed 5 times with TBS-Tween (50mM Tris-HCl pH 7.5, 150mM NaCl, 0.1% Tween 80) and saturated for 1 hr at 37°C with 150µl of the same buffer supplemented with 1% BSA. Serial dilutions of sera in saturation buffer were incubated for 1 hr at 37°C. Plates were washed 5 times with TBS-Tween buffer and antigen-bound antibodies were detected with the second antibody (goat anti-mouse IgG, Promega, USA) coupled to alkaline phosphatase (dilution 1/7500 in TBS-Tween buffer). The enzymatic activity was measured using the p-nitrophenylphosphate substrate (Sigma) dissolved in diethanolamine buffer (pH 9.8). OD_{415nm} was measured in a Biorad Novapath ELISA reader.

Mouse antibody subclass was determined using immunoplates coated as described above and IgG1- or IgG2a-specific biotin-labelled monoclonal antibodies (rat anti-mouse, dilution 1/7000 in TBS-Tween buffer and 1% BSA, Biosource) as second antibodies. Phosphatase alkaline-conjugated streptavidin (1/1000 dilution, Amersham) was added to each well. Assay of the enzymatic activity proceeded as described above.

In all cases, ELISA titers were identified as the reciprocal of the dilution giving a signal corresponding to 50% of the maximal $O.D._{415}$ value.

12. - Measurement of DerP1-specific IgE

Immunoplates were coated with rat anti-mouse IgE (10ng/well), for 16 hrs at 4°C. Plates were washed 5 times with TBS-Tween (50mM Tris-HCl pH 7.5, 150mM NaCl, 0.1% Tween 80) and saturated for 1 hr at 37°C with 150µl of the same buffer supplemented with 1% BSA. Serial dilutions of sera in saturation buffer were incubated for 1 hr at 37°C. ProDerP1 was then added at 500ng/ml in saturation buffer. Bound ProDerP1 was detected by addition of biotinylated anti-DerP1 monoclonal antibody 4C1 (Indoor Biotechnologies) Plates were washed 5 times with TBS-Tween buffer and antibodies-bound antigen were detected with addition of streptavidin coupled to alkaline phosphatase (dilution 1/7500 in TBS-Tween buffer). The enzymatic activity was measured using the p-nitrophenylphosphate substrate (Sigma) dissolved in diethanolamine buffer (pH 9.8). OD_{415nm} was measured in a Biorad Novapath ELISA reader.

13. - Proliferation assays

To measure DerP1-specific T-cell proliferative response, immunised mice were sacrificed before and after bronchoprovocations. Lymphocytes were isolated from spleens. Cells (4 x 10^5/well in triplicate), cultured in RPMI 1640 with 10% FCS containing 15mM HEPES and 30µM β-mercaptoethanol, were stimulated with serial dilutions of crude mite extract or ProDerP1 in 96-well plates (10 base 2 dilutions of the antigen were tested, starting from a concentration of 25µg/ml). As control, cells were incubated with only RPMI medium. After 4 days, cells were pulsed with 1µCi/well [^{3}H] thymidine (Amersham) for 16 hours. Cells were harvested and ^{3}H-thymidine uptake was measured by scintillation counting. Proliferative responses were calculated as the means of quadruplicate wells and were expressed as stimulation index (SI). A stimulation index of > 2 was considered positive.

14. - Cytokines assay

The level of IFNγ and IL-5 in the lymphocyte culture supernatants were measured in ELISA assays. Plates were coated with 1µg/ml of anti-mouse IL-5 monoclonal

(PharMingen) or anti-mouse IFNγ (Biosource) polyclonal antibodies. Plates were washed 5 times with TBS-Tween and saturated for 1 hr at 37°C with 150µl of TBS-Tween-BSA. Serial dilutions of splenocyte culture supernatants were added and incubated for 90 min at 37°C. Biotinylated anti-mouse IL-5 (PharMingen, 1µg/ml) or anti-mouse IFNγ (Biosource, 0.2µg/ml) antibodies were applied to the plates for 1h at 37°C. The antigen-antibody complexes were detected by incubation with streptavidin coupled to horseradish peroxydase (dilution 1/10000, Amersham). The enzymatic activity was measured using tetramethylbenzidine (TMB) as substrate (Sigma). The absorbance at 460nm was measured in a Biorad Novapath ELISA reader. Cytokine concentrations were determined by interpolation from a standard curve performed with purified mouse IL-5 or IFNγ.

15. - Bronchoalveolar lavage

Three days after the final aerosol exposure, mice were bled and sacrificed. The lungs were immediately washed via the trachea cannula with 1ml Hank's balanced salt solution (HBSS) which was instilled and gently recovered by aspiration three times. The lavage fluid was centrifuged at 400g for 10min at 4°C. The cell pellet was resuspended in 300µl Hank's balanced salt solution (HBSS) and cells were counted in a Thoma hemocytometer. Cytospin preparations from 50µl-aliquots were stained with May-Grünwald Giemsa 's stain for differential cell counts.

EXAMPLE II

Expression of MBP-ProDerP1 in *E. coli*

1. - Construction of MBP-ProDerP1 expression vector

The complete synthetic cDNA encoding ProDerP1 (1-302 aa) (SEQ ID NO:1) was isolated from the eukaryotic expression plasmid pNIV 4846 (a pEE 14-derived expression plasmid carrying humanized ProDerP1 coding cassette, (M.Massaer *et al.*, International Archives of Allergy and Immunology, 2001, **125**:32-43) after digestions with *Eag* I and *Xba* I. DNA was blunted using large fragment DNA polymerase (Klenow) before *Xba* I restriction. The 921 bp fragment was inserted at the *Asp* 718 (blunted end)-*Xba* I site of pMAL-c2E (New England Biolabs) to give pNIV4854, downstream of the

MBP gene. The amino acid sequence of ProDerP1, encoded by the cDNA of SEQ ID NO:1, is represented in fugure 2 (SEQ ID NO:2).

2. – Site-directed mutagenesis

Mutagenesis of DerP1 cysteine residues at position 4, 31 or 65 (mature ProDerP1 numbering, corresponds to positions 84, 111 or 145 in ProDerP1) was performed in the plasmid pNIV4854, after the substitution of DNA fragments carrying one of the three cysteine codons by synthetic oligonucleotides containing the mutations. The following oligonucleotides were used:

5'TTAAGACCCAGTTTGATCTCAACGCGGAGACCAACGCC**CGT**ATCAACGGCA ATGCCCCCGCTGAGATTGATCTGCGCCAGATGAGGACCGTGACTCCCATCCG CATGC3' (forward) and 5'CGGATGGGAGTCACGGTCCTCATCTG GCGCAGATCAATCTCAGCGGGGGCATTGCCGTTGATACT**ACG**GGCGTTGGTC TCCGCGTTGAGATCGAAACTGGGTC3' (reverse) to generate a 110bp *Afl* II-*Sph* I fragment for the mutation of cysteine residue 4 to arginine (C4R), 5'CAAGGCGGC**CGT**GGGTCTTGTTGGGCCTTTTCAGGCGTGGCCGCGACAG AGTCGGCATACCTCGCGTATCGGAATCAGAGCCTGGACCTCGC3' (forward) and 5'TCAGCGAGGTCCAGG CTCTGATTCCGATACGCGAGGTATGCCGACT CTGTCGCGGCCACGCCTGAAAAGGCCCAACAAGACCC**ACG**GCCGCCTTGCAT G3' (reverse) to generate a 98bp *Sph* I-*Blp* I fragment for the mutation of cysteine residue 31 to arginine (C31R), 5'TGAGCAGGAGCTCGTTGAC**CGT**GCCTCC CAACACGGATGTCATGGGGATACGATTCCCAGAGGTATCGAATACATCCAGC ATA3' (forward) and 5'CTGGATGTATTCGATACCTCTGGGAATCGTAT CC CCCATGACATCCGTGTTGGGAGGC**ACG**GTCAACGCGCTCCTGC3' (reverse) to generate a 82bp *Afl* II-*Sph* I fragment for the mutation of cysteine residue 65 to arginine (C65R).

The resulting plasmids containing the ProDerP1 cassette downstream to the MBP gene and carrying respectively the mutations C4R, C31R and C65R were called pNIV4870, pNIV4871 and pNIV4872. All the three mutations were verified by DNA sequencing. Mutated ProDerP1 amino acid sequences respectively carrying C4R, C31R and C65R mutation are illustrated in SEQ ID NO:3, SEQ ID NO:5 and SEQ ID NO:7 respectively.

The corresponding encoding nucleic acid sequences are shown in SEQ ID NO:4 (C4R mutation), SEQ ID NO:6 (C31R mutation) and SEQ ID NO:8 (C65R mutation).

3. – Expression and purification of wild-type and mutant MBP-ProDerP1

E. coli containing the different recombinant expression vectors were grown overnight at 37°C in 869 medium (A.Jacquet *et al.*, Prot. Exp. Purif. 1999, **17**, 392-400) with 100 µg/ml ampicillin. Cells were then diluted 1:100 and allowed to grow at 37°C to an optical density between 0.4 and 0.6 at 600 nm. Isopropyl β-D-thiogalactoside (IPTG) was added to a final concentration of 0.3 mM. After a 2h period of induction, cells were harvested by centrifugation at 10000 rpm for 15min.

Bacterial cell pellets from 1 liter cultures were resuspended in 20mM Tris-HCl pH 7.5, containing 1mM aprotinin and AEBSF, and broken under a pressure of 1800 bars using a Cell disrupter (Constant Systems Ltd, Warwick, UK). The lysate was ultracentrifugated at 150,000g for 60 min. The pellet resulting from the ultracentrifugation was washed with 20mM Tris-HCl pH 7.5. Insoluble proteins were extracted overnight at 4°C with 20mM Tris-HCl pH 7.5 containing 6M urea. The suspension was ultracentrifugated at 150,000g for 60 min. The supernatant was directly dialysed overnight against 20mM Tris-HCl pH 7.5, 200mM NaCl, 1mM EDTA. The solution was centrifugated to remove any precipitated protein and directly applied onto an amylose resin (1 x 15 cm) equilibrated in the same buffer. The column was washed with the starting buffer until the A_{280nm} reached the baseline. Proteins were eluted by the addition of 10mM maltose in the column buffer. Fractions containing the fusion proteins were pooled and concentrated. Purified proteins were stored at –20°C.

EXAMPLE III

Expression of three different ProDerP1 mutants in CHO cells

1. – Site-directed mutagenesis

Mutations of DerP1 cysteine residues at position 4, 31 or 65 (mature DerP1 numbering, corresponds to positions 84, 111 or 145 in ProDerP1) were introduced into the plasmid pNIV4846. Plasmids pNIV4870, pNIV4871 and pNIV4872, containing the DerP1

cassette downstream to the MBP (see Example II) gene and carrying respectively the mutations C4R, C31R and C65R were each restricted with *Sfu*I-*Xho*I to isolate a 714bp fragment. The purified DNA fragments were inserted into plasmid p4846 previously cleaved with the same restriction enzymes. The resulting plasmids containing the DerP1 variants C4R, C31R and C65R were called pNIV4873, pNIV4875 and pNIV4874.

2. – Transient transfections and selection of ProDerP1-producing stable CHO-K1 lines.

To determine the production of DerP1 by plasmids pNIV4873, pNIV4875 and pNIV4874, COS cells were transiently transfected by lipofection. For stable DerP1 expression, CHO-K1 cells were transfected with the different plasmids by lipofection. After a 3-weeks 25μM methionylsulphoximin (MSX) selection, one round of gene amplification was carried out with 100μM MSX.

EXAMPLE IV

Denatured ProDerP1 displays IgG but not IgE-binding reactivity towards allergic sera.

To determine whether a denatured form of ProDerP1 could be used as a hypoallergenic vaccine, IgG- and IgE binding reactivities of denatured (5 min at 100°C in the presence of 50mM β-mercaptoethanol) ProDerP1 were assayed in ELISA tests. As shown in figure 1, denatured ProDerP1 conserved the main part of the IgG epitopes present on native ProDerP1. On the other hand, the denatured allergen highly lost its IgE-binding reactivity. Our data suggest that denatured ProDerP1 could represent a hypoallergenic variant of ProDerP1.

EXAMPLE V

IgE reactivities of MBP-ProDerP1.

The aim of the experiment was to compare the IgE reactivity of MBP-ProDerP1 and of natural DerP1. The reactivity of MBP-ProDerP1 with specific IgE from sera of allergic patients was assessed in a direct ELISA wherein immunoplates were directly coated with DerP1 or MBP-ProDerP1. Figure 2 shows a strong correlation between the IgE binding to DerP1 and MBP-ProDerP1.

EXAMPLE VI

IgE-binding reactivities of MBP-ProDerP1 mutants.

The IgE-binding capacity of MBP-ProDerP1 mutants was determined in direct ELISA assays for which immunoplates were directly coated with the different forms of MBP-ProDerP1. A serum pool, made from 20 individual *D. pteronyssinus*-allergic patient sera with RAST value >100 kU/L, were used in the assays. As shown in figure 3, the IgE binding reactivity of the variants C31R and C65R drastically decreased to 5% compared with that of wild-type MBP-ProDerP1. Strikingly, no reactivity (0% left) of IgE to MBP-ProDerP1 was observed when residue cysteine 4 was mutated to arginine. The IgE reactivities were specific of the ProDerP1 moiety as there were no IgE-mediated immune recognitions of MBP or MBP in fusion with an irrelevant protein. Similar results were obtained with another serum pool from 20 others patients.

EXAMPLE VII

Histamine release activity of various forms of ProDerP1.

To compare the allergenic activity of natural DerP1 with that of recombinant mutated derivatives of ProDerP1, basophils from one allergic patient were challenged *in vitro* with various concentrations of allergens and the released histamine was measured. As shown in figure 4, natural DerP1 was able to induce histamine release from basophils even at a concentration of 1ng/ml. By contrast, recombinant mutated forms of ProDerP1 could only release histamine at a 1000-10000-fold higher concentration, These results clearly

showed that ProDerP1 mutants display lower IgE binding reactivity than does the natural DerP1.

EXAMPLE VIII

Immunogenicity experiments with various forms of ProDerP1.

1. – Animal model of house dust mite allergy

An animal model of house dust mite allergy has been developed. CBA/J mice were injected with purified DerP1 adjuvanted with alum. After four injections at one week interval, animals were subjected to a series of bronchoprovocation with *D. pteronyssinus* extract (figure 5). This model was used to test different recombinant forms of DerP1 as well as different DNA as prophylactic vaccines against house dust mite allergy.

EXAMPLE IX

Expression of a deleted form of ProDerP1.

1) The deletion was done by PCR and using synthetic oligonucleotides comprising sequences downstream and upstream of the fragment to be deleted. A Snab I/Avr II fragment of the plasmid pNIV4878 (remember, pNIV4878 is a pPIC9K plasmid (Invitrogen) containing the cDNA of ProDer p 1 (humanised cDNA) and favourable for expression of the allergen in *P. pastoris*) was replaced by the amplified and deleted fragment. *P. pastoris* yeasts were transformed by this recombinant plasmid and after selection with geneticine (G418), clones resistant at 0.25mg/ml G418 were isolated. Given that the ProDer p 1 cassette is situated downstream of a signal sequence, we tested the expression of ProDer p 1 Δ227-240 secreted after induction with methanol for 24 or 48 hours.

2) Introduction of the deletion by PCR

Primer1 : 5'-GCTATTACCGATACGTAGCTAGGG-3'

This primer comprises the SnabI restriction site downstream of the zone to be deleted.

Primer2 : 5'-CCGTTGTCGCGATCCTTGATTCCGATGATGACAGCG-3'

This primer is therefore homologous to part of the ProDer p 1 sequence, that downstream and upstream of the zone to be deleted.

Primer3 :

5'-CGGAATCAAGGATCGCGACAACGGGTATCAGCCAAACTACC-3'

This primer is also homologous to part of the ProDer p 1 sequence and will also allow deletion of 42pb. In addition, it contains a point mutation which will make it possible to modify the EcoRV site.

Primer4 : 5'-TAGGGGAGCTCAGATCTGATCCACTGAC-3'



3' terminal



Final PCR



3. Deletion verified by sequencing.

The *Pichia pastoris* yeasts were transformed by the recombinant vector previously linearised by BglII, using the spheroplast method. Transformants were selected for histidinol deshydrogenase (His+) prototrophy. The screening of His+ transformants for geneticin (G418) resistance was performed by plating clones on agar containing increasing concentrations of G418.
(0.25-1-2 and 4 mg/ml). After incubation at 30°C for several days, we obtained several resistant strains but for only one concentration of 0.25mg/ml G418.

The expression is induced by adding 0.5% methanol to the culture medium every day. Every day, one millilitre of culture medium is taken in order to recover the supernatant. Expression of ProDer p 1 is displayed by blot.

EXAMPLE X

Expression of a triple mutant form of ProDerP1.

1) In this example, the cysteine 71, 103 and 117 residues of Der p 1 are mutated into alanine. The Cys → Ala mutation breaks the disulphide bridge but does not introduce any positive charge into the structure of Der p 1. This gentler destructuring might not affect the expression and secretion of ProDer p 1. These three mutations are introduced by PCR, thanks to an oligonucleotide comprising the three mutations.

EXAMPLE XI

Construction of a PreProDer p 3 mutant

1. Construction of a PreProDer p 3 synthetic cDNA

A PreProDer p 3 cDNA was synthesised using a set of 10 partially overlapping oligonucleotides. These primers were designed, based on the codon preference of highly expressed E. Coli bacterial genes, and produced by a 394 DNA/RNA Applied Biosystem synthetizer. The degenerately encoded amino acids were not encoded by the most prevalent codons but taking the frequencies of the individual codons into account. For example, AAG or AAA encodes the lysine residue with a respective frequency of 21.45%

and 78.55% in highly expressed E. Coli bacterial genes. Consequently, we attempted to follow the same codon frequency instead of selecting only the AAA codon for each lysine residue in the synthetic PreProDer p 3. The oligonucleotides were the following:

5'TCATGATCATCTACAACATTCTGATCGTACTCCTGCTGGCCATTAACACTTT GGCTAATCCGATCCTGCCGGCATCCCCGAACGCGACCATCGTTGGC 3' (oligo 1, coding)

5'CACCACAGAAGTGGCTACTAGACTGCAGGGAGATCTGATATGGGCACTCAC CAGCCAGTGCTTTTTCGCCGCCAACGATGGTCGCG 3' (oligo 2, noncoding)

5'GTAGCCACTTCTGTGGTGGTACTATTCTTGACGAATACTGGATCCTGACCGC GGCACACTGCGTGGCCGGCCAAACAGCGAGCAAACTCTCC 3' (oligo 3, coding)

5'GTCGATCTGGTAGCTATCATATTTTTCATGTGCGAAAATTTTAGCAACAGAG ATCTTTTCGCCACCCAGTGAGTGTTTCAGGCTGTTGTAACGAATGGAGAGTTT GCTCGCTG 3' (oligo 4, noncoding)

5'GATAGCTACCAGATCGACAATGACATTGCGCTGATCAAGCTGAAATCCCCT ATGAAGCTGAACCAGAAAAACGCCAAAGCTGTGGGCCTGC 3' (oligo 5, coding)

5'CAGACGGCAGGGAGTAGCTGCCCTCTTCCAGATAACCCCAGCCAGAGACAC GCACCTGGTCACCAACTTTTACATCCGAGCCTTTCGCCGGCAGGCCCACAGCT TTG 3' (oligo 6, noncoding)

5'CTACTCCCTGCCGTCTGAATTACGCCGTGTTGATATCGCTGTGGTATCTCGC AAAGAATGTAACGAGCTGTACTCGAAAGCGAACGCTGAAGTCAC 3' (oligo 7, coding)

5'CCACCAGAATCGCCTTGACAAGAGTCCTTACCGCCGTTCGCAACATCACCA CCGCAGATCATATTGTCGGTGACTTCAGCGTTCGC 3' (oligo 8, noncoding)

5'CAAGGCGATTCTGGTGGGCCGGTGGTCGACGTTAAAAACAACCAGGTTGTA
GGTATCGTTTCCTGGGGCTACGGTTGCGCACGTAAAGGC3' (oligo 9, coding)

5'AAGCTTTCAGTGGTGGTGGTGGTGGTGCTGGCTACGTTTAGATTCAATCCAA
TCGATAAAGTTACCAACGCGCGTGTACACACCCGGATAGCCTTTACGTGCGC
AAC 3' (oligo 10, noncoding).

The oligonucleotides were incubated together for the amplification of a synthetic recPreProDer p 3 cDNA in a PCR reaction. PCR was conducted using Expand High Fidelity PCR System (Roche Diagnostics) with the following conditions: 30 cycles, denaturation at 94°C for 30 s, annealing at 52°C for 30 s and elongation at 72°C for 30 s. The generated products were amplified using the 3' and 5' terminal primers (oligo 1 and 10) in the same conditions. The resulting 812 bp fragment was cloned into a pCRII-TOPO cloning vector (Invitrogen).

Digestion with BamHI showed that clones 1, 3 and 9 were correctly inserted.

Intra recPreProDer p 3 oligonucleotides were used to sequence the insert:

5'AAGCTGAAATCCCCTATGAAGC3' (coding)
5'CTCTTCCAGATAACCCCAGCC3' (noncoding).

Only clone 3 proved to be correct, but missing the first 6 bases on 5' coding end. The addition of the missing bases was achieved by the use of two new oligonucleotides:

5'TTTTATTCATGATCATCTACAACATTCTGATCC3' (oligo 11, coding)
5'GATGCATGCTCGAGCGGC3' (oligo 12, noncoding).

The oligonucleotides were incubated with clone 3 DNA carrying the incomplete PreProDer p 3 sequence. The amplification of the synthetic gene was obtained by a PCR reaction using Expand High Fidelity PCR System (25 cycles: denaturation at 94°C for 30 s, annealing at 53°C for 30 s and elongation at 72°C for 30 s). Resulting fragment was

cloned into a pCRII-TOPO. The PreProDer p 3 cDNA was isolated after the double *Rca* I-*Xho*I restriction and cloned into pET15b expression vector digested with *Nco*I and *Xho*I. Competent AD494(DE3)pLys E Coli cells were transformed by the resulting plasmid and 1mM final concentration isopropyl-thiogalactoside (IPTG) (Duchefa) was added to the culture medium to detect ProDerP3 expression.

The deletion of the putative Der p 3 signal peptide was performed by PCR and using two new primers: 5'CATATGAATCCGATCCTGCCGGCATCCCC3' (oligo 13, coding) and 5'GGATCCTCACTGGCTACGTTTAGATTCAATCC3' (oligo 14, non coding) Amplification of the ProDerp3 cDNA was done by PCR with Taq Polymerase (Roche Diagnostics), 15 cycles: denaturation at 97°C for 30 s, annealing at 65°C for 30 s and elongation at 72°C for 1 min. The resulting 750bp fragment was cloned into a pCRII-TOPO cloning vector (Invitrogen). Top 10 competent E Coli were transformed by the resulting plasmid. 9 clones appeared positively inserted; digestion with *Eco*RI proved clones 1,4,8 to be correctly inserted, while sequencing showed that only clone 4 had the right sequence. The ProDer p 3 cDNA was isolated after the digestions with *Nde*I and *Xho*I and cloned into pET15b digested by the same enzymes. The BL21 and BL21 Star E Coli (Invitrogen) strains were transformed by the resulting plasmid Addition of IPTG in the culture medium induced the expression of recombinant ProDerp3 carrying $(His)_6$ tag at its N-terminal end.

2. Expression of the recombinant allergen in E Coli

The best producing recombinant E. Coli BL21 STAR clone was cultured (37°/250rpm) in 2 liters liquid 869 medium containing 100µg/ml ampicillin (Pentrexyl). When the culture absorbance at 620nm reached 0.5, expression was induced for three hours by the addition of 1mM final concentration isopropyl-thiogalactoside (Duchefa). The culture was then harvested and centrifuged at 11000g and stored at –20°C. Bacterial pellet was recovered and resuspended in 40 ml Tris buffer 20mM pH 7.5, implemented with Aprotinin 1/1000 (Sigma) and AEBSF 1/500 (ICN). Followed the crush of bacteria at 1500 bars and the storage at –20°C.

3. Purification of recProDer p 3 from crushed E. Coli

Harvested *E. coli* cells, resuspended in 20 mM Tris pH 7.5, aprotinin 1 mM and AEBSF 1 mM , were lysed through a cell disrupter (Cell D) and under a pressure of 1800kbars. The lysate was ultracentrifuged at 149000g for 1h. The supernatant was removed and the pellet containing recombinant Proder p 3 was subsequently extracted overnight at 4°C with 40 ml of 50mM Tris-HCl buffer containing 6M Guanidine Hydrochloride 6M pH 7.5. After ultracentrifugation (45', 149000g), the supernatant of extraction was applied at 3ml/min on a Nickel-NTA Superflow column (1.6x5cm, Qiagen) equilibrated with the extraction buffer. The column was washed at 1.5 ml/min with PBS NaCl 0.5M pH 7.5 to renaturate boun proteins. RecProDer p 3 was eluted at 4ml/min by addition of 200mM imidazole in the conditioning buffer. Fractions containing recProDer p 3 were pooled, concentrated by ultrafiltration (Amicon-Millipore regenerated cellulose ultrafiltration membranes, NMWL 10kDa) . During this step, the buffer was exchanged by PBS pH 7.3. Purified protein was stored at –20°C.

4. Purification of natural Der p 3 from natural mite whole body extracts

D. pteronyssimus extracts were submitted to a 60% final saturation $(NH_4)_2SO_4$ precipitation. After ultra centrifugation (45', 149000g), the supernatant was applied at 2ml/min on a Benzamidine Sepharose 4 fast flow column (1.6x5cm, Pharmacia) equilibrated with Tris buffer 50mM NaCl 0.5M pH 7.4. Der p 3 was eluted from the column with 50mM Glycine-HCl buffer pH2.5 and each 1ml fraction was immediately neutralized by the addition of 75µl Tris 1M pH 9.5. Fractions containing Der p 3 were pooled, concentrated (Amicon-Millipore regenerated cellulose ultrafiltration membranes, NMWL 10kDa) and applied at 0.5 ml/min on a Superdex 75 gel filtration chromatography column (Pharmacia) equilibrated with PBS pH 7.3. Purified Der p 3 was concentrated and stored at –20°C.

5. SDS PAGE and Western blot analysis

Proteins were analysed by SDS-PAGE on 12.5% polyacrylamide gels. After electrophoresis, proteins were transferred onto nitrocellulose membranes using a semi-dry transblot system (Sigma-Aldrich). Membranes were saturated for 30 min with 0.5% Instagel (PB Gelatins) in TBS-T (50mM Tris HCl pH 7.5, 150mM NaCl, 0.1% Tween

80) and incubated with mouse polyclonal serum raised against ProDer p 3 diluted in blocking solution (1: 2500). Immunoreactive materials were detected using alkaline phosphatase-conjugated goat anti-mouse antibodies (Promega, 1:7500) and 5-bromo,4-chloro,3-indolylphosphate (BCIP, Boehringer)/ nitroblue tetrazolium (NBT, Sigma) as substrates.

6. Protein determination

Total protein concentration was determined by the bicinchoninic acid procedure (MicroBCA, Pierce) with bovine serum albumin as standard.

7. IgE-binding activity.

Immunoplates were coated overnight with Der p 3 or recProDer p 3 (500ng/well) at 4°C. Plates were then washed 5 times with 100µl per well of TBS-Tween buffer (50mM Tris-HCl pH 7.5, 150mM NaCl, 0.1% Tween 80) and saturated for 1 hr at 37°C with 150µl of the same buffer supplemented with 1% BSA (Sigma). Sera from allergic patients to *D. pteronyssinus* and diluted at 1/8 were then incubated for 1 hr at 37°C. Out of the 47 sera used in the experiments, 5 sera ranged in their specific anti-*D.pteronyssinus* IgE values (RAST assays) from 0.7kU/L to 28.9kU/L, 8 from 68.3kU/L to 94.1kU/L and 34 above the upper cut-off value of 100kU/L. Plates were washed 5 times with TBS-Tween buffer and the allergen-IgE complexes were detected after incubation with a biotinconiugate mouse anti-human IgE antibody (dilution 1/2000 in TBS-T buffer, Southern Biotechnology Associates) and streptavidin-horseradish peroxydase (dilution 1/1000 in TBS-Tween buffer, Amersham Life Science). The enzymatic activity was measured using the 3,3',5,5'-tetramethyl-benzidine (TMB) (Sigma). OD_{450nm} was measured in a Biorad Novapath ELISA reader.

8. Enzymatic Assays

Enzymatic assays were performed in 50mM Tris-HCl pH 8, at 25°C in a total volume of 200µl. Hydrolysis of N-α-benzoyl-L-argine-p-nitroanilide (Sigma) (final concentration 1mM) was measured by a Biorad Novapath ELISA reader at 405nm. Assays were started by the addition of the allergen at the final concentration of 6.25µg/ml.

9. Cloning and expression of Der p 3

Expression in *Escherichia coli*.

An immature form of Der p 3, ProDer p 3, was expressed in bacteria. The cDNA of PreProDer p 3 was synthesised completely, with the help of 12 synthetic oligonucleotides and with use of codons optimised for expression in bacteria (Fig.2). The cassette coding for ProDer p 3 was cloned in the expression vector pET-15b downstream of a sequence coding for a poly-histidine tail. This vector contains a T7 promoter inducible by adding IPTG to the culture medium. Firstly, we tried to optimise the expression conditions of ProDer p 3. To do this, cultures of recombinant bacteria were incubated at 30°C and 37°C, with two concentrations of inducing agent (IPTG 0.5 and 1 mM) for periods of 1, 2, 3 and 16 hours. Each bacterial pellet was lysed in the French press. The lysates were centrifuged at 20000 rpm for 20 min. The presence of ProDer p 3 in the supernatants (cytoplasm fractions) and/or the pellets (debris and insoluble products) was revealed by Western blot using a mouse antibody against the poly-histidine tail of the recombinant ProDer p 3 (Fig.3).

The expression test shows only a slight effect of temperature and IPTG concentration on the production of ProDer p 3. ProDer p 3 is essentially expressed in insoluble form, its expression is optimal for an induction period of 2 to 3 h. The absence of a soluble form of ProDer p 3 for a 16-hour induction should be noted. ProDer p 3 is expressed because it is detected after staining with Coomassie blue. In SDS-PAGE, the protein is in the form of a band of ± 32kDa (Fig.4).

10. Purification of ProDer p 3

A protocol for purification of recombinant ProDer p 3 has been developed.
Given that ProDer p 3 is expressed in insoluble form, the recombinant allergen is solubilised by extraction of the pellet in denaturing conditions (Tris-HCl 20 mM, guanidine chloride 6 M pH 7.5). The extraction yield is in the order of 80-90%. The extract is applied to about 10 ml of a column of Ni^{2+}-chelating sepharose resin (1.6 cm diameter, 5 cm high) packed in the extraction buffer. After washing the column with the extraction buffer, the attached proteins are renatured directly on the column by a linear renaturation gradient with the buffer PBS 0.5 M NaCl pH 7.5. The volume of the gradient is 200ml.

The elution is then carried out by application of increasing concentrations of imidazole in the renaturation buffer (20, 50, 100 et 200mM). Analysis by SDS-PAGE shows that the protein is not present in the effluate and that the contaminants elute at an imidazole concentration of 20 mM while ProDer p 3 elutes between 60 and 100mM imidazole. All the ProDer p 3 is detached from the chromatographic support (see Figure 10).

The analysis of the N-terminal sequence of ProDer p 3 was done by micro-sequencing. The sequence corresponds to that of the histidine tail. It should be noted that in the vector pET-15b, the cloning site of the ProDer p 3 is downstream of the sequence coding for the histidine tail. ProDer p 3 and the histidine tail are separated by a thrombin restriction site. In order to verify the authenticity of ProDer p 3, we treated the purified protein with thrombin in order to eliminate the histidine tail. A second microsequencing of the

digested ProDer p 3 revealed the N-terminal sequence of the propeptide of Der p 3 (N P I L P A S P N A T).

Enzymatic activity : ProDer p 3 is inactive against BAPNA, a substrate restrictable by natural Der p 3.

11. IgE reactivity

Direct coating of allergens.

This preliminary result seems to indicate a lower reactivity of ProDer p 3 compared with Der p 3 in relation to the IgE of patients allergic to mites. (Figure 11)

2. – Vaccine formulations

Table 1 : protein and DNA vaccine formulations tested in the house dust mite allergy animal model depicted in figure 5.

Protein	DNA	Adjuvant	Way of injection
Natural DerP1		Alum	IP
ProDerP1 native		Alum	IP
ProDerP1 native		—	IM
ProDerP1 denatured		Alum	IP
MBP-ProDerP1		Alum	IP
MBP-ProDerP1 C4R		Alum	IP
MBP-ProDerP1 C31R		Alum	IP
MBP-ProDerP1 C65R		Alum	IP

IP= intraperitoneal injection

IM=intramuscular injection

3. – Antibody response - Results

Mice immunized by four injections of natural DerP1 produced high titers of IgG and IgG1, low titers of IgG2a and large amounts of IgE antibodies, indicating that natural DerP1 induces strong Th2 immunes responses (Tables 2 and 4).

The anti-DerP1 IgG and IgG1 antibody responses were also strong in mice injected with native or denatured ProDerP1. After injections with native ProDerP1, the IgG2a titers were slightly higher than those obtained with DerP1, IgE titers being comparable or slightly lower than those obtained with DerP1. In contrast to the native ProDerP1-immunized mice, animals injected with denatured ProDerP1 produced high IgG2a titers and very low IgE antibodies. As expected, immunizations with ProDerP1 in the absence of Alum induced poor immune responses (Table 4).

MBP-ProDerP1 wild type (WT), C4R, C31R and C65R-sensitized mice showed similar productions of specific IgG and IgG1 antibodies (Table 3). Highest IgG2a titers were observed in groups immunized with MBP-ProDerP1 WT and C31R.

Specific IgE titers were low, whatever the MBP-ProDerP1 variants injected.

Similar results were obtained after mice immunizations with plasmid encoding ProDerP1.

Table 2 : Titers of specific anti-DerP1 antibodies from mice immunized with different antigens. For IgE titers, results are expressed as OD_{415nm} values for a 1/10 dilution of sera. Titers were also measured after bronchoprovocations with PBS or with *D. pteronyssinus* extracts (HDM).

Antigen	Bleeding	Challenge	IgG	IgG1	IgG2a	IgE
DerP1	1		< 50	< 50	< 50	0
	2		214	900	< 50	1.1
	3		700	6062	< 50	0.2
	4		2500	24390	100	0.6
	5	PBS	8670	16340	300	0.7
		HDM	8230	17440	300	0.6
ProDerP1 native	1		< 50	< 50	< 50	0
	2		301	1146	< 50	1.1
	3		800	6860	86	0.3
	4		2500	28545	203	0.5
	5	PBS	8266	25500	600	0.3
		HDM	11880	38310	600	0.6
denatured	1		< 50	< 50	< 50	0
	2		330	861	120	0.2
	3		966	3402	210	0.07
	4		3093	14830	970	0.1
	5	PBS	16380	54040	2700	0.1
		HDM	14200	32140	2700	0.05

Table 3 : Titers of specific anti-DerP1 antibodies from mice immunized with different antigens. For IgE titers, results are expressed as OD_{415nm} values for a 1/10 dilution of sera. Titers were also measured after bronchoprovocations with PBS or with *D. pteronyssinus* extracts (HDM).

Antigen	Bleeding	Challenge	IgG	IgG1	IgG2a	IgE
MBP-ProDerP1 WT	2		637	3351	144	0.046
	3		4444	24720	757	0.039
	4		2500	24390	100	0.6
	5	PBS	6151	29500	2899	0,13
		HDM	3437	22210	1496	0,27
MBP-ProDerP1 C4R	2		583	2212	95	0
	3		1123	6131	356	0.021
	4		2500	28545	203	0.5
	5	PBS	2064	9077	624	0,004
		HDM	2418	14390	635	0,029
MBP-ProDerP1 C31R	2		1221	4572	144	0.017
	3		6472	40405	1311	0.029
	4		3093	14830	970	0.1
	5	PBS	2897	10880	857	0,063
		HDM	5508	24300	1959	0,074
MBP-ProDerP1 C65R	2		202	887	< 50	0.022
	3		1252	5718	363	0.066
	4		3093	14830	970	0.1
	5	PBS	782	3958	87	0,108
		HDM	3109	16250	430	0,117

Table 4: Titers of specific anti-DerP1 antibodies from mice immunized with different antigens. For IgE titers, results are expressed as OD_{415nm} values for a 1/10 dilution of sera. Titers were also measured after bronchoprovocations with PBS or with *D. pteronyssinus* extracts (HDM).

Antigen	Bleeding	Challenge	IgG	IgG1	IgG2a	IgE
DerP1	2		201	1135	< 20	0.852
	3		3264	18002	< 50	0.34
	4		8271	43306	< 50	0.59
	5	PBS	10072	57670	< 100	0.44
		HDM	6058	72810	< 100	0.68
ProDerP1 Alum	2		929	7422	159	0.8
	3		5061	27244	586	0.37
	4		15110	68960	1016	0.46
	5	PBS	10900	57255	1190	0,421
		HDM	16770	79460	1125	0,485
ProDerP1 (no adjuvant)	2		136	774	< 20	0.58
	3		1389	8571	104	0.13
	4		4704	14126	120	0.17
	5	PBS	3587	16930	105	0.28
		HDM	3880	20737	100	0.25

4. - T-cell proliferative response - Results

Before (control) and after aerosol challenge, splenocytes isolated from immunized mice were examined for T-cell proliferative response by stimulation with ProDerP1 or *D. pteronyssinus* extract. Results are shown in Table 5 (stimulation index) and in Table 6 (cytokines).

Allergen-specific T cell responses were detected in immunized mice with the different recombinant ProDerP1 mutants. Strongest responses were observed when splenocytes were restimulated with ProDerP1. T-cell reactivities appeared to be independent from the challenge.

These results in Table 5 indicated that the different forms of ProDerP1 shared common T-cell epitopes with natural DerP1. Moreover, destructuration of ProDerP1 by thermal denaturation or site-directed mutagenesis did not alter ProDerP1 T-cell reactivity, confirming that these forms are hypoallergens with very low IgE-binding reactivity able to stimulated T-cell responses.

Table 5:

Vaccinated mice were challenged or not with PBS or *D. pteronyssinus* extracts. Spleen cells were isolated and restimulated in vitro with purified ProDerP1 or with *D. pteronyssinus* extracts. Stimulation index was measured by [^{3}H]-thymidine incorporation. -: not available. These results are obtained from different experiments, not from only one. Consequently, cytokine assays can not be compared between all groups.

Antigen	Concentration of stimulating antigen (µg/ml)	S.I. (stimul. With ProDerP1)			S.I. (stimul. with HDM ext.)		
		Aerosol			aerosol		
		None	PBS	HDM	None	PBS	HDM
MBP-ProDerP1 WT	50	7.3	14.97	20.8	-	-	-
MBP-ProDerP1 C4R	50	19.1	9.7	16.3	-	-	-
MBP-ProDerP1 C31R	50	5.4	10.0	14.7	-	-	-
MBP-ProDerP1 C65R	50	6.8	8.8	13.0	-	-	-
DerP1	40	-	1.6	17.5	-	1.6	7.5
ProDerP1	40	-	30.9	11.5	-	2.8	2.8
ProDerP1	40	-	24.0	15.9	-	1.7	1.4

denatured							
Alum	40	-	4.2	4.6	-	2.0	1.3

The presence of cytokines IL-5 and IFNγ in the culture supernatants of restimulated splenocytes was determined in ELISA (Table 6). If we compared the ratio [IFNγ]/[IL-5], we could conclude that vaccinations with natural DerP1 or ProDerP1 adjuvanted with alum induced a better production of IL-5 than IFNγ. The different forms of MBP-ProDerP1 (mutants and wild-type) as well as denatured ProDerP1 induced comparable levels of both cytokines.

Table 6: [IL-5] and [IFNγ] in supernatants from ProDerP1-restimulated splenocytes. These results are obtained from different experiments, not from only one. Consequently, cytokine assays can not be compared between all groups.

Antigen	[IL-5] (pg/ml)			[IFNγ] (pg/ml)		
	Aerosol			Aerosol		
	none	PBS	HDM	None	PBS	HDM
MBP-ProDerP1	420	165	929	987	1076	1282
MBP-ProDerP1C4R	330	51	308	551	1366	1177
MBP-ProDerP1C31R	430	202	1141	1348	1281	3392
MBP-ProDerP1C65R	0	0	953	0	0	1161
Alum	0	0	0	0	0	0
DerP1	75	45	495	0	0	190
ProDerP1	0	355	400	0	125	210
ProDerP1 denatured	-	850	736	-	822	1119

5. – Bronchoalveolar lavage - Results

Sensitisation with natural DerP1 and subsequent exposure to aerosolised house dust mite extracts induced significantly higher bronchoalveolar cell numbers (Table 7). Seven exposures to aerosolised house dust mite extracts were shown to induce airway eosinophilia in only the animals vaccinated with DerP1. In this group, airway eosinophilia was not observed when DerP1-sensitised animals were not nebulized or exposed to aerosolised PBS.

Vaccinations with the different recombinant forms of ProDerP1 prevented airway eosinophilia, even after exposure to aerosolised HDM extracts.

Table 7: Characterization of the bronchoalveolar lavage fluid of different antigen-immunized mice exposed to PBS or house dust mite extracts aerosols

Antigen	Aerosol	Lympho (%)	Eosino (%)	Neutro (%)	Macro (%)	Mono (%)	Total cells (10^5/ml)
DerP1	none	86	4	0	6	3	2.2
	HDM	13	68	7	6	6	167
	PBS	90	0	2	4	4	4.8
ProDerP1	none	90	0	0	7	3	3.2
	HDM	69	7	12	3	10	5.1
	PBS	76	5	4	7	8	7.6
ProDerP1 denatured	none	51	5	2	22	20	4
	HDM	52	4	26	10	7	6.9
	PBS	67	2	2	20	9	5.2
Alum	none	88	1	4	7	0	3.6
	HDM	80	0	4	14	1	1.5
	PBS	88	1	5	5	1	1.2
MBP-ProDerP1	none	85	2	4	7	0	1.5
	HDM	70	3	14	8	5	2.1
	PBS	88	1	6	5	0	0.6
MBP-ProDerP1 C4R	none	90	2	4	4	1	2.2
	HDM	71	2	14	11	1	2
	PBS	80	2	7	10	1	4.5
MBP-ProDerP1 C31R	none	79	1	14	7	0	1.3
	HDM	65	4	27	5	1	2
	PBS	87	2	7	5	1	3

MBP-ProDerP1 C65R	none	85	0	4	10	1	2.4
	HDM	84	1	7	7	1	2.4
	PBS	84	1	4	12	0	1.5

EXAMPLE XII

Expression plasmid for nucleic acid vaccination (NAVAC)

1. - Construction of ProDerP1 encoding plasmid for nucleic acid vaccination

The ProDerP1 coding cassette (1-302aa) was excised from plasmid pNIV4846 (see above), restricted with *Hind*III and *Bgl*II, and inserted into plasmid pJW4304 previously cleaved with *Hind*III and *Bgl*II. The resulting plasmid, named pNIV4868, was verified by DNA sequencing.

2. – Site-directed mutagenesis

Mutations of ProDerP1 cysteine residues at position 4, 31 or 65 (mature DerP1 numbering, corresponds to positions 84, 111 or 145 in ProDerP1) were introduced into the plasmid pNIV4868. Plasmids pNIV4870, pNIV4871 and pNIV4872, containing the ProDerP1 cassette downstream to the MBP gene and carrying respectively the mutations C4R, C31R and C65R were each restricted with *Afl*II-*Bam*HI to isolate a 699bp fragment. pNIV 4868 was digested with *Afl*II-*Hpa*I to isolate a 480bp fragment. The two purified DNA fragments were inserted into plasmid pJW4304 previously cleaved with *Hpa*I-*Bam*HI. The resulting plasmids containing the ProDerP1 variants C4R, C31R and C65R were called pNIV4879, pNIV4880 and pNIV4881.

EXAMPLE XIII

Expression of ProDerP1 in *Pichia pastoris*

1. - Construction of ProDerP1 expression vector

The ProDerP1 coding cassette from pNIV4846 (full-length 1-302aa ProDerP1 cDNA with optimised mammalian codon usage) was amplified by PCR using the following primers: 5'ACTGAC**AGGCCT**CGGCCGAGCTCCATTAA3' (*Stu*I restriction site in bold, forward) and 5'CAGTCA**CCTAGG**TCTAGACTC GAGGGGAT3' (*Avr*II restriction site in bold, reverse). The amplified fragment was cloned into the pCR2.1 TOPO cloning vector. The correct ProDerP1 cassette was verified by DNA sequencing. Recombinant TOPO vector was digested with *Stu*I-*Avr*II to generate a 918bp fragment

which was introduced into the pPIC9K expression vector restricted with *Sna*BI-*Avr*II. The resulting plasmid, pNIV4878, contains the ProDerP1 cassette downstream to the S.cerevisae α factor

2. - Site-directed mutagenesis

Expression plasmid for the production of unglycosylated ProDerP1 (N52Q, mature DerP1 numbering) was derived from pNIV4878 by overlap extension PCR using a set of four primers. The following primers:

5'GGCTTTCGAACAC**CTTAAG**ACCCAG3' (primer 1, *Afl*II restriction site in bold, forward) and 5'GCTCCCTAGC**TACGTA** TCGGTAATAGC3' (primer 2, *Sna*BI restriction site in bold, reverse) were used to amplify a 317bp fragment encoding the ProDerP1 amino acid sequence 71-176.

The following primers 5'CCTCGCGTATCGG**CAA**CAGAGCCTGGACC3' (primer 3, mutation N52Q in bold, forward) and 5'GGTCCAGGCTCTG**TTG**CC GATACGCGAGG3' (primer 4, mutation N52Q in bold, reverse) were used to introduce mutation N52Q in the ProDerP1 sequence.

The mutated 317bp *Afl*II-*Sna*BI fragment was generated by a three-step process. In PCR n°1, primers 1 and 4 were mixed with pNIV4878 to produce a ~ 200 bp fragment. In PCR n°2, primers 2 and 3 were mixed with pNIV4878 to produce a ~ 140 bp. The two PCR products were purified onto agarose gel and used as templates for a third round of PCR to obtain a ~ 340 bp fragment. This purified fragment was cloned into the pCR2.1 TOPO cloning vector (Invitrogen). The mutation was verified by DNA sequencing. Recombinant TOPO vector was digested with *Afl*II-*Sna*BI to generate a 317bp fragment which was ligated into the similarly digested pNIV4878. The resulting plasmid, pNIV4883, contains the ProDerP1 N52Q downstream to the S.cerevisae α factor.

To obtain unglycosylated variants of ProDerP1 carrying mutations of DerP1 cysteine residues at position 4, 31 or 65 (mature DerP1 numbering), overlap extension PCR using the same set of primers were performed with plasmids pNIV4873, pNIV4875 and pNIV4874. The resulting plasmids pNIV4884, 4885 and 4886 encode respectively ProDerP1 N52Q C4R, N52Q C31R and N52Q C65R.

2. - Transformation of *P. pastoris*

Plasmid pNIV4878 was introduced *into P. pastoris* using the spheroplast transformation method. Transformants were selected for histidinol deshydrogenase (His+) prototrophy. The screening of His+ transformants for geneticin (G418) resistance was performed by plating clones on agar containing increasing concentrations of G418.

Transformation with plasmids encoding ProDerP1 N52Q, ProDerP1 N52Q C4R, N52Q C31R and N52Q C65R was performed using the same method.

3. - Production of ProDerP1 by recombinant yeast

G418 resistant clones were grown at 30°C in BMG medium to an OD_{600nm} of 2-6. Cells were collected by centrifugation and resuspended to an OD_{600nm} of 1 in 100ml of BMG medium. ProDerP1 expression was induced by daily addition of methanol 0.5% for 6 days. The supernatant was collected by centrifugation and stored at –20°C until purification.

4. - Purification of ProDerP1 from yeast culture supernatant

Supernatants were diluted 10 times with water and, after pH adjustment to 9, directly loaded onto a Q sepharose column equilibrated in in 20mM Tris-HCl pH 9. The column was washed with the starting buffer. Protein elutions proceeded by step-wise increasing NaCl concentration in the buffer. The ProDerP1-enriched fractions were pooled and concentrated by ultrafiltration onto a Filtron membrane (Omega serie, cut-off : 10kD). The ProDerP1 purification was achieved by a gel filtration chromatography onto a superdex-75 column (1 x 30 cm, Pharmacia) equilibrated in PBS pH 7,3. Purified ProDerP1 was concentrated and stored at –20°C.

SEQUENCE INFORMATION

SEQ ID NO:1

1 CGGCCGAGCTCCATTAAGACCTTCGAGGAATACAAGAAAGCCTTCAACAA
51 GAGCTATGCCACCTTCGAGGACGAGGAGGCCGCGCGCAAGAACTTCCTGG
101
AAAGCGTGAAATACGTGCAGAGCAACGGCGGGGCTATAAATCACCTGTCC
151
GACCTGTCTTTAGACGAGTTCAAGAACCGGTTCCTGATGAGCGCCGAGGC
201 TTTCGAACACCTTAAGACCCAGTTTGATCTCAACGCGGAGACCAACGCCT
251
GCAGTATCAACGGCAATGCCCCCGCTGAGATTGATCTGCGCCAGATGAGG
301 ACCGTGACTCCCATCCGCATGCAAGGCGGCTGCGGGTCTTGTTGGGCCTT
351
TTCAGGCGTGGCCGCGACAGAGTCGGCATACCTCGCGTATCGGAATCAGA
401
GCCTGGACCTCGCTGAGCAGGAGCTCGTTGACTGCGCCTCCCAACACGGA
451
TGTCATGGGGATACGATTCCCAGAGGTATCGAATACATCCAGCATAATGG
501
CGTCGTGCAGGAAAGCTATTACCGATACGTAGCTAGGGAGCAGTCCTGCC
551 GCCGTCCTAACGCACAGCGCTTCGGCATTTCCAATTATTGCCAGATCTAC
601
CCCCCTAATGCCAACAAGATCAGGGAGGCCCTGGCGCAGACGCACAGCGC
651 CATCGCTGTCATCATCGGAATCAAGGATCTGGACGCATTCCGGCACTATG
701
ACGGGCGCACAATCATCCAGCGCGACAACGGATATCAGCCAAACTACCAC
751
GCGGTCAACATCGTGGGTTACTCGAACGCCCAGGGGGTGGACTACTGGAT
801
CGTGAGAAACAGTTGGGACACTAACTGGGGCGACAACGGCTACGGCTACT

851
TCGCCGCCAACATCGACCTGATGATGATCGAGGAGTACCCGTACGTGGTG
901 ATCCTGTAA

SEQ ID NO:2

Arg Pro Ser Ser Ile Lys Thr Phe Glu Glu Tyr Lys Lys Ala Phe 15
Asn Lys Ser Tyr Ala Thr Phe Glu Asp Glu Glu Ala Ala Arg Lys 30
Asn Phe Leu Glu Ser Val Lys Tyr Val Gln Ser Asn Gly Gly Ala 45
Ile Asn His Leu Ser Asp Leu Ser Leu Asp Glu Phe Lys Asn Arg 60
Phe Leu Met Ser Ala Glu Ala Phe Glu His Leu Lys Thr Gln Phe 75
Asp Leu Asn Ala Glu Thr Asn Ala Cys Ser Ile Asn Gly Asn Ala 90
Pro Ala Glu Ile Asp Leu Arg Gln Met Arg Thr Val Thr Pro Ile 105
Arg Met Gln Gly Gly Cys Gly Ser Cys Trp Ala Phe Ser Gly Val 120
Ala Ala Thr Glu Ser Ala Tyr Leu Ala Tyr Arg Asn Gln Ser Leu 135
Asp Leu Ala Glu Gln Glu Leu Val Asp Cys Ala Ser Gln His Gly 150
Cys His Gly Asp Thr Ile Pro Arg Gly Ile Glu Tyr Ile Gln His 165
Asn Gly Val Val Gln Glu Ser Tyr Tyr Arg Tyr Val Ala Arg Glu 180
Gln Ser Cys Arg Arg Pro Asn Ala Gln Arg Phe Gly Ile Ser Asn 195
Tyr Cys Gln Ile Tyr Pro Pro Asn Val Asn Lys Ile Arg Glu Ala 210
Leu Ala Gln Thr His Ser Ala Ile Ala Val Ile Ile Gly Ile Lys 225
Asp Leu Asp Ala Phe Arg His Tyr Asp Gly Arg Thr Ile Ile Gln 240
Arg Asp Asn Gly Tyr Gln Pro Asn Tyr His Ala Val Asn Ile Val 255
Gly Tyr Ser Asn Ala Gln Gly Val Asp Tyr Trp Ile Val Arg Asn 270
Ser Trp Asp Thr Asn Trp Gly Asp Asn Gly Tyr Gly Tyr Phe Ala 285
Ala Asn Ile Asp Leu Met Met Ile Glu Glu Tyr Pro Tyr Val Val 300
Ile Leu 302

SEQ ID NO:3.

Arg Pro Ser Ser Ile Lys Thr Phe Glu Glu Tyr Lys Lys Ala Phe 15
Asn Lys Ser Tyr Ala Thr Phe Glu Asp Glu Glu Ala Ala Arg Lys 30
Asn Phe Leu Glu Ser Val Lys Tyr Val Gln Ser Asn Gly Gly Ala 45
Ile Asn His Leu Ser Asp Leu Ser Leu Asp Glu Phe Lys Asn Arg 60

Phe Leu Met Ser Ala Glu Ala Phe Glu His Leu Lys Thr Gln Phe 75
Asp Leu Asn Ala Glu Thr Asn Ala Arg Ser Ile Asn Gly Asn Ala 90
Pro Ala Glu Ile Asp Leu Arg Gln Met Arg Thr Val Thr Pro Ile 105
Arg Met Gln Gly Gly Cys Gly Ser Cys Trp Ala Phe Ser Gly Val 120
Ala Ala Thr Glu Ser Ala Tyr Leu Ala Tyr Arg Asn Gln Ser Leu 135
Asp Leu Ala Glu Gln Glu Leu Val Asp Cys Ala Ser Gln His Gly 150
Cys His Gly Asp Thr Ile Pro Arg Gly Ile Glu Tyr Ile Gln His 165
Asn Gly Val Val Gln Glu Ser Tyr Tyr Arg Tyr Val Ala Arg Glu 180
Gln Ser Cys Arg Arg Pro Asn Ala Gln Arg Phe Gly Ile Ser Asn 195
Tyr Cys Gln Ile Tyr Pro Pro Asn Val Asn Lys Ile Arg Glu Ala 210
Leu Ala Gln Thr His Ser Ala Ile Ala Val Ile Ile Gly Ile Lys 225
Asp Leu Asp Ala Phe Arg His Tyr Asp Gly Arg Thr Ile Ile Gln 240
Arg Asp Asn Gly Tyr Gln Pro Asn Tyr His Ala Val Asn Ile Val 255
Gly Tyr Ser Asn Ala Gln Gly Val Asp Tyr Trp Ile Val Arg Asn 270
Ser Trp Asp Thr Asn Trp Gly Asp Asn Gly Tyr Gly Tyr Phe Ala 285
Ala Asn Ile Asp Leu Met Met Ile Glu Glu Tyr Pro Tyr Val Val 300
Ile Leu 302

SEQ ID NO:4

1 CGGCCGAGCTCCATTAAGACCTTCGAGGAATACAAGAAAGCCTTCAACAA
51 GAGCTATGCCACCTTCGAGGACGAGGAGGCCGCGCGCAAGAACTTCCTGG
101
AAAGCGTGAAATACGTGCAGAGCAACGGCGGGGCTATAAATCACCTGTCC
151
GACCTGTCTTTAGACGAGTTCAAGAACCGGTTCCTGATGAGCGCCGAGGC
201
TTTCGAACACCTTAAGACCCAGTTTGATCTCAACGCGGAGACCAACGCCC
251
GTAGTATCAACGGCAATGCCCCCGCTGAGATTGATCTGCGCCAGATGAGG
301 ACCGTGACTCCCATCCGCATGCAAGGCGGCTGCGGGTCTTGTTGGGCCTT
351
TTCAGGCGTGGCCGCGACAGAGTCGGCATACCTCGCGTATCGGAATCAGA

401
GCCTGGACCTCGCTGAGCAGGAGCTCGTTGACTGCGCCTCCCAACACGGA
451
TGTCATGGGGATACGATTCCCAGAGGTATCGAATACATCCAGCATAATGG
501
CGTCGTGCAGGAAAGCTATTACCGATACGTAGCTAGGGAGCAGTCCTGCC
551 GCCGTCCTAACGCACAGCGCTTCGGCATTTCCAATTATTGCCAGATCTAC
601
CCCCCTAATGCCAACAAGATCAGGGAGGCCCTGGCGCAGACGCACAGCGC
651 CATCGCTGTCATCATCGGAATCAAGGATCTGGACGCATTCCGGCACTATG
701
ACGGGCGCACAATCATCCAGCGCGACAACGGATATCAGCCAAACTACCAC
751
GCGGTCAACATCGTGGGTTACTCGAACGCCCAGGGGGTGGACTACTGGAT
801
CGTGAGAAACAGTTGGGACACTAACTGGGGCGACAACGGCTACGGCTACT
851
TCGCCGCCAACATCGACCTGATGATGATCGAGGAGTACCCGTACGTGGTG
901 ATCCTGTAA

SEQ ID NO:5

Arg Pro Ser Ser Ile Lys Thr Phe Glu Glu Tyr Lys Lys Ala Phe 15
Asn Lys Ser Tyr Ala Thr Phe Glu Asp Glu Glu Ala Ala Arg Lys 30
Asn Phe Leu Glu Ser Val Lys Tyr Val Gln Ser Asn Gly Gly Ala 45
Ile Asn His Leu Ser Asp Leu Ser Leu Asp Glu Phe Lys Asn Arg 60
Phe Leu Met Ser Ala Glu Ala Phe Glu His Leu Lys Thr Gln Phe 75
Asp Leu Asn Ala Glu Thr Asn Ala Cys Ser Ile Asn Gly Asn Ala 90
Pro Ala Glu Ile Asp Leu Arg Gln Met Arg Thr Val Thr Pro Ile 105
Arg Met Gln Gly Gly Arg Gly Ser Cys Trp Ala Phe Ser Gly Val 120
Ala Ala Thr Glu Ser Ala Tyr Leu Ala Tyr Arg Asn Gln Ser Leu 135

Asp Leu Ala Glu Gln Glu Leu Val Asp Cys Ala Ser Gln His Gly 150

Cys His Gly Asp Thr Ile Pro Arg Gly Ile Glu Tyr Ile Gln His 165

Asn Gly Val Val Gln Glu Ser Tyr Tyr Arg Tyr Val Ala Arg Glu 180

Gln Ser Cys Arg Arg Pro Asn Ala Gln Arg Phe Gly Ile Ser Asn 195

Tyr Cys Gln Ile Tyr Pro Pro Asn Val Asn Lys Ile Arg Glu Ala 210

Leu Ala Gln Thr His Ser Ala Ile Ala Val Ile Ile Gly Ile Lys 225

Asp Leu Asp Ala Phe Arg His Tyr Asp Gly Arg Thr Ile Ile Gln 240

Arg Asp Asn Gly Tyr Gln Pro Asn Tyr His Ala Val Asn Ile Val 255

Gly Tyr Ser Asn Ala Gln Gly Val Asp Tyr Trp Ile Val Arg Asn 270

Ser Trp Asp Thr Asn Trp Gly Asp Asn Gly Tyr Gly Tyr Phe Ala 285

Ala Asn Ile Asp Leu Met Met Ile Glu Glu Tyr Pro Tyr Val Val 300

Ile Leu 302

SEQ ID NO:6

1 CGGCCGAGCTCCATTAAGACCTTCGAGGAATACAAGAAAGCCTTCAACAA

51

GAGCTATGCCACCTTCGAGGACGAGGAGGCCGCGCGCAAGAACTTCCTGG

101

AAAGCGTGAAATACGTGCAGAGCAACGGCGGGGCTATAAATCACCTGTCC

151

GACCTGTCTTTAGACGAGTTCAAGAACCGGTTCCTGATGAGCGCCGAGGC

201 TTTCGAACACCTTAAGACCCAGTTTGATCTCAACGCGGAGACCAACGCCT

251

GCAGTATCAACGGCAATGCCCCCGCTGAGATTGATCTGCGCCAGATGAGG

301 ACCGTGACTCCCATCCGCATGCAAGGCGGC**CGT**GGGTCTTGTTGGGCCTT

351

TTCAGGCGTGGCCGCGACAGAGTCGGCATACCTCGCGTATCGGAATCAGA

401

GCCTGGACCTCGCTGAGCAGGAGCTCGTTGACTGCGCCTCCCAACACGGA

451

TGTCATGGGGATACGATTCCCAGAGGTATCGAATACATCCAGCATAATGG

501

CGTCGTGCAGGAAAGCTATTACCGATACGTAGCTAGGGAGCAGTCCTGCC

551 GCCGTCCTAACGCACAGCGCTTCGGCATTTCCAATTATTGCCAGATCTAC

601

CCCCCTAATGCCAACAAGATCAGGGAGGCCCTGGCGCAGACGCACAGCGC

651 CATCGCTGTCATCATCGGAATCAAGGATCTGGACGCATTCCGGCACTATG

701

ACGGGCGCACAATCATCCAGCGCGACAACGGATATCAGCCAAACTACCAC

751

GCGGTCAACATCGTGGGTTACTCGAACGCCCAGGGGGTGGACTACTGGAT

801

CGTGAGAAACAGTTGGGACACTAACTGGGGCGACAACGGCTACGGCTACT

851

TCGCCGCCAACATCGACCTGATGATGATCGAGGAGTACCCGTACGTGGTG

901 ATCCTGTAA

SEQ ID NO:7

Arg Pro Ser Ser Ile Lys Thr Phe Glu Glu Tyr Lys Lys Ala Phe 15

Asn Lys Ser Tyr Ala Thr Phe Glu Asp Glu Glu Ala Ala Arg Lys 30

Asn Phe Leu Glu Ser Val Lys Tyr Val Gln Ser Asn Gly Gly Ala 45

Ile Asn His Leu Ser Asp Leu Ser Leu Asp Glu Phe Lys Asn Arg 60

Phe Leu Met Ser Ala Glu Ala Phe Glu His Leu Lys Thr Gln Phe 75

Asp Leu Asn Ala Glu Thr Asn Ala Cys Ser Ile Asn Gly Asn Ala 90

Pro Ala Glu Ile Asp Leu Arg Gln Met Arg Thr Val Thr Pro Ile 105

Arg Met Gln Gly Gly Cys Gly Ser Cys Trp Ala Phe Ser Gly Val 120

Ala Ala Thr Glu Ser Ala Tyr Leu Ala Tyr Arg Asn Gln Ser Leu 135

Asp Leu Ala Glu Gln Glu Leu Val Asp **Arg** Ala Ser Gln His Gly 150

Cys His Gly Asp Thr Ile Pro Arg Gly Ile Glu Tyr Ile Gln His 165

Asn Gly Val Val Gln Glu Ser Tyr Tyr Arg Tyr Val Ala Arg Glu 180

Gln Ser Cys Arg Arg Pro Asn Ala Gln Arg Phe Gly Ile Ser Asn 195

Tyr Cys Gln Ile Tyr Pro Pro Asn Val Asn Lys Ile Arg Glu Ala 210

Leu Ala Gln Thr His Ser Ala Ile Ala Val Ile Ile Gly Ile Lys 225

Asp Leu Asp Ala Phe Arg His Tyr Asp Gly Arg Thr Ile Ile Gln 240

Arg Asp Asn Gly Tyr Gln Pro Asn Tyr His Ala Val Asn Ile Val 255

Gly Tyr Ser Asn Ala Gln Gly Val Asp Tyr Trp Ile Val Arg Asn 270

Ser Trp Asp Thr Asn Trp Gly Asp Asn Gly Tyr Gly Tyr Phe Ala 285

Ala Asn Ile Asp Leu Met Met Ile Glu Glu Tyr Pro Tyr Val Val 301

Ile Leu 302

SEQ ID NO:8

1 CGGCCGAGCTCCATTAAGACCTTCGAGGAATACAAGAAAGCCTTCAACAA

51 GAGCTATGCCACCTTCGAGGACGAGGAGGCCGCGCGCAAGAACTTCCTGG

101

AAAGCGTGAAATACGTGCAGAGCAACGGCGGGGCTATAAATCACCTGTCC

151

GACCTGTCTTTAGACGAGTTCAAGAACCGGTTCCTGATGAGCGCCGAGGC

201 TTTCGAACACCTTAAGACCCAGTTTGATCTCAACGCGGAGACCAACGCCT
251
GCAGTATCAACGGCAATGCCCCCGCTGAGATTGATCTGCGCCAGATGAGG
301 ACCGTGACTCCCATCCGCATGCAAGGCGGCTGCGGGTCTTGTTGGGCCTT
351
TTCAGGCGTGGCCGCGACAGAGTCGGCATACCTCGCGTATCGGAATCAGA
401
GCCTGGACCTCGCTGAGCAGGAGCTCGTTGAC**CGT**GCCTCCCAACACGGA
451
TGTCATGGGGATACGATTCCCAGAGGTATCGAATACATCCAGCATAATGG
501
CGTCGTGCAGGAAAGCTATTACCGATACGTAGCTAGGGAGCAGTCCTGCC
551 GCCGTCCTAACGCACAGCGCTTCGGCATTTCCAATTATTGCCAGATCTAC
601
CCCCCTAATGCCAACAAGATCAGGGAGGCCCTGGCGCAGACGCACAGCGC
651 CATCGCTGTCATCATCGGAATCAAGGATCTGGACGCATTCCGGCACTATG
701
ACGGGCGCACAATCATCCAGCGCGACAACGGATATCAGCCAAACTACCAC
751
GCGGTCAACATCGTGGGTTACTCGAACGCCCAGGGGGTGGACTACTGGAT
801
CGTGAGAAACAGTTGGGACACTAACTGGGGCGACAACGGCTACGGCTACT
851
TCGCCGCCAACATCGACCTGATGATGATCGAGGAGTACCCGTACGTGGTG
901 ATCCTGTAA

SEQ ID NO:9.

Arg Pro Ser Ser Ile Lys Thr Phe Glu Glu Tyr Lys Lys Ala Phe 15
Asn Lys Ser Tyr Ala Thr Phe Glu Asp Glu Glu Ala Ala Arg Lys 30
Asn Phe Leu Glu Ser Val Lys Tyr Val Gln Ser Asn Gly Gly Ala 45
Ile Asn His Leu Ser Asp Leu Ser Leu Asp Glu Phe Lys Asn Arg 60
Phe Leu Met Ser Ala Glu Ala Phe Glu His Leu Lys Thr Gln Phe 75

Asp Leu Asn Ala Glu Thr Asn Ala Cys Ser Ile Asn Gly Asn Ala 90
Pro Ala Glu Ile Asp Leu Arg Gln Met Arg Thr Val Thr Pro Ile 105
Arg Met Gln Gly Gly Cys Gly Ser Cys Trp Ala Phe Ser Gly Val 120
Ala Ala Thr Glu Ser Ala Tyr Leu Ala Tyr Arg Asn Gln Ser Leu 135
Asp Leu Ala Glu Gln Glu Leu Val Asp Cys Ala Ser Gln His Gly 150
Arg His Gly Asp Thr Ile Pro Arg Gly Ile Glu Tyr Ile Gln His 165
Asn Gly Val Val Gln Glu Ser Tyr Tyr Arg Tyr Val Ala Arg Glu 180
Gln Ser Cys Arg Arg Pro Asn Ala Gln Arg Phe Gly Ile Ser Asn 195
Tyr Cys Gln Ile Tyr Pro Pro Asn Val Asn Lys Ile Arg Glu Ala 210
Leu Ala Gln Thr His Ser Ala Ile Ala Val Ile Ile Gly Ile Lys 225
Asp Leu Asp Ala Phe Arg His Tyr Asp Gly Arg Thr Ile Ile Gln 240
Arg Asp Asn Gly Tyr Gln Pro Asn Tyr His Ala Val Asn Ile Val 255
Gly Tyr Ser Asn Ala Gln Gly Val Asp Tyr Trp Ile Val Arg Asn 270
Ser Trp Asp Thr Asn Trp Gly Asp Asn Gly Tyr Gly Tyr Phe Ala 285
Ala Asn Ile Asp Leu Met Met Ile Glu Glu Tyr Pro Tyr Val Val 300
Ile Leu 302

SEQ ID NO:10

1 CGGCCGAGCTCCATTAAGACCTTCGAGGAATACAAGAAAGCCTTCAACAA
51
GAGCTATGCCACCTTCGAGGACGAGGAGGCCGCGCGCAAGAACTTCCTGG
101
AAAGCGTGAAATACGTGCAGAGCAACGGCGGGGCTATAAATCACCTGTCC
151
GACCTGTCTTTAGACGAGTTCAAGAACCGGTTCCTGATGAGCGCCGAGGC
201 TTTCGAACACCTTAAGACCCAGTTTGATCTCAACGCGGAGACCAACGCCT
251
GCAGTATCAACGGCAATGCCCCCGCTGAGATTGATCTGCGCCAGATGAGG
301 ACCGTGACTCCCATCCGCATGCAAGGCGGCTGCGGGTCTTGTTGGGCCTT
351
TTCAGGCGTGGCCGCGACAGAGTCGGCATACCTCGCGTATCGGAATCAGA

401
GCCTGGACCTCGCTGAGCAGGAGCTCGTTGACTGCGCCTCCCAACACGGA
451
CGTCATGGGGATACGATTCCCAGAGGTATCGAATACATCCAGCATAATGG
501
CGTCGTGCAGGAAAGCTATTACCGATACGTAGCTAGGGAGCAGTCCTGCC
551 GCCGTCCTAACGCACAGCGCTTCGGCATTTCCAATTATTGCCAGATCTAC
601
CCCCCTAATGCCAACAAGATCAGGGAGGCCCTGGCGCAGACGCACAGCGC
651 CATCGCTGTCATCATCGGAATCAAGGATCTGGACGCATTCCGGCACTATG
701
ACGGGCGCACAATCATCCAGCGCGACAACGGATATCAGCCAAACTACCAC
751
GCGGTCAACATCGTGGGTTACTCGAACGCCCAGGGGGTGGACTACTGGAT
801
CGTGAGAAACAGTTGGGACACTAACTGGGGCGACAACGGCTACGGCTACT
851
TCGCCGCCAACATCGACCTGATGATGATCGAGGAGTACCCGTACGTGGTG
901 ATCCTGTAA

SEQ ID NO:11

Arg Pro Ser Ser Ile Lys Thr Phe Glu Glu Tyr Lys Lys Ala Phe 15
Asn Lys Ser Tyr Ala Thr Phe Glu Asp Glu Glu Ala Ala Arg Lys 30
Asn Phe Leu Glu Ser Val Lys Tyr Val Gln Ser Asn Gly Gly Ala 45
Ile Asn His Leu Ser Asp Leu Ser Leu Asp Glu Phe Lys Asn Arg 60
Phe Leu Met Ser Ala Glu Ala Phe Glu His Leu Lys Thr Gln Phe 75
Asp Leu Asn Ala Glu Thr Asn Ala Cys Ser Ile Asn Gly Asn Ala 90
Pro Ala Glu Ile Asp Leu Arg Gln Met Arg Thr Val Thr Pro Ile 105
Arg Met Gln Gly Gly Cys Gly Ser Cys Trp Ala Phe Ser Gly Val 120
Ala Ala Thr Glu Ser Ala Tyr Leu Ala Tyr Arg Asn Gln Ser Leu 135

Asp Leu Ala Glu Gln Glu Leu Val Asp Cys Ala Ser Gln His Gly 150
Cys His Gly Asp Thr Ile Pro Arg Gly Ile Glu Tyr Ile Gln His 165
Asn Gly Val Val Gln Glu Ser Tyr Tyr Arg Tyr Val Ala Arg Glu 180
Gln Ser Arg Arg Arg Pro Asn Ala Gln Arg Phe Gly Ile Ser Asn 195
Tyr Cys Gln Ile Tyr Pro Pro Asn Val Asn Lys Ile Arg Glu Ala 210
Leu Ala Gln Thr His Ser Ala Ile Ala Val Ile Ile Gly Ile Lys 225
Asp Leu Asp Ala Phe Arg His Tyr Asp Gly Arg Thr Ile Ile Gln 240
Arg Asp Asn Gly Tyr Gln Pro Asn Tyr His Ala Val Asn Ile Val 255
Gly Tyr Ser Asn Ala Gln Gly Val Asp Tyr Trp Ile Val Arg Asn 270
Ser Trp Asp Thr Asn Trp Gly Asp Asn Gly Tyr Gly Tyr Phe Ala 285
Ala Asn Ile Asp Leu Met Met Ile Glu Glu Tyr Pro Tyr Val Val 300
Ile Leu 302

SEQ ID NO:12

1 CGGCCGAGCTCCATTAAGACCTTCGAGGAATACAAGAAAGCCTTCAACAA
51
GAGCTATGCCACCTTCGAGGACGAGGAGGCCGCGCGCAAGAACTTCCTGG
101
AAAGCGTGAAATACGTGCAGAGCAACGGCGGGGCTATAAATCACCTGTCC
151
GACCTGTCTTTAGACGAGTTCAAGAACCGGTTCCTGATGAGCGCCGAGGC
201 TTTCGAACACCTTAAGACCCAGTTTGATCTCAACGCGGAGACCAACGCCT
251
GCAGTATCAACGGCAATGCCCCCGCTGAGATTGATCTGCGCCAGATGAGG
301 ACCGTGACTCCCATCCGCATGCAAGGCGGCTGCGGGTCTTGTTGGGCCTT
351
TTCAGGCGTGGCCGCGACAGAGTCGGCATACCTCGCGTATCGGAATCAGA
401
GCCTGGACCTCGCTGAGCAGGAGCTCGTTGACTGCGCCTCCCAACACGGA
451
TGTCATGGGGATACGATTCCCAGAGGTATCGAATACATCCAGCATAATGG

501
CGTCGTGCAGGAAAGCTATTACCGATACGTAGCTAGGGAGCAGTCCCGTC
551 GCCGTCCTAACGCACAGCGCTTCGGCATTTCCAATTATTGCCAGATCTAC
601
CCCCCTAATGCCAACAAGATCAGGGAGGCCCTGGCGCAGACGCACAGCGC
651 CATCGCTGTCATCATCGGAATCAAGGATCTGGACGCATTCCGGCACTATG
701
ACGGGCGCACAATCATCCAGCGCGACAACGGATATCAGCCAAACTACCAC
751
GCGGTCAACATCGTGGGTTACTCGAACGCCCAGGGGGGTGGACTACTGGAT
801
CGTGAGAAACAGTTGGGACACTAACTGGGGCGACAACGGCTACGGCTACT
851
TCGCCGCCAACATCGACCTGATGATGATCGAGGAGTACCCGTACGTGGTG
901 ATCCTGTAA

SEQ ID NO:13

Arg Pro Ser Ser Ile Lys Thr Phe Glu Glu Tyr Lys Lys Ala Phe 15
Asn Lys Ser Tyr Ala Thr Phe Glu Asp Glu Glu Ala Ala Arg Lys 30
Asn Phe Leu Glu Ser Val Lys Tyr Val Gln Ser Asn Gly Gly Ala 45
Ile Asn His Leu Ser Asp Leu Ser Leu Asp Glu Phe Lys Asn Arg 60
Phe Leu Met Ser Ala Glu Ala Phe Glu His Leu Lys Thr Gln Phe 75
Asp Leu Asn Ala Glu Thr Asn Ala Cys Ser Ile Asn Gly Asn Ala 90
Pro Ala Glu Ile Asp Leu Arg Gln Met Arg Thr Val Thr Pro Ile 105
Arg Met Gln Gly Gly Cys Gly Ser Cys Trp Ala Phe Ser Gly Val 120
Ala Ala Thr Glu Ser Ala Tyr Leu Ala Tyr Arg Asn Gln Ser Leu 135
Asp Leu Ala Glu Gln Glu Leu Val Asp Cys Ala Ser Gln His Gly 150
Cys His Gly Asp Thr Ile Pro Arg Gly Ile Glu Tyr Ile Gln His 165
Asn Gly Val Val Gln Glu Ser Tyr Tyr Arg Tyr Val Ala Arg Glu 180
Gln Ser Cys Arg Arg Pro Asn Ala Gln Arg Phe Gly Ile Ser Asn 195
Tyr Arg Gln Ile Tyr Pro Pro Asn Val Asn Lys Ile Arg Glu Ala 210
Leu Ala Gln Thr His Ser Ala Ile Ala Val Ile Ile Gly Ile Lys 225

Asp Leu Asp Ala Phe Arg His Tyr Asp Gly Arg Thr Ile Ile Gln 240
Arg Asp Asn Gly Tyr Gln Pro Asn Tyr His Ala Val Asn Ile Val 255
Gly Tyr Ser Asn Ala Gln Gly Val Asp Tyr Trp Ile Val Arg Asn 270
Ser Trp Asp Thr Asn Trp Gly Asp Asn Gly Tyr Gly Tyr Phe Ala 285
Ala Asn Ile Asp Leu Met Met Ile Glu Glu Tyr Pro Tyr Val Val 300
Ile Leu 302

SEQ ID NO:14

1 CGGCCGAGCTCCATTAAGACCTTCGAGGAATACAAGAAAGCCTTCAACAA
51
GAGCTATGCCACCTTCGAGGACGAGGAGGCCGCGCGCAAGAACTTCCTGG
101
AAAGCGTGAAATACGTGCAGAGCAACGGCGGGGCTATAAATCACCTGTCC
151
GACCTGTCTTTAGACGAGTTCAAGAACCGGTTCCTGATGAGCGCCGAGGC
201 TTTCGAACACCTTAAGACCCAGTTTGATCTCAACGCGGAGACCAACGCCT
251
GCAGTATCAACGGCAATGCCCCCGCTGAGATTGATCTGCGCCAGATGAGG
301 ACCGTGACTCCCATCCGCATGCAAGGCGGCTGCGGGTCTTGTTGGGCCTT
351
TTCAGGCGTGGCCGCGACAGAGTCGGCATACCTCGCGTATCGGAATCAGA
401
GCCTGGACCTCGCTGAGCAGGAGCTCGTTGACTGCGCCTCCCAACACGGA
451
TGTCATGGGGATACGATTCCCAGAGGTATCGAATACATCCAGCATAATGG
501
CGTCGTGCAGGAAAGCTATTACCGATACGTAGCTAGGGAGCAGTCCTGCC
551 GCCGTCCTAACGCACAGCGCTTCGGCATTTCCAATTAT**CGT**CAGATCTAC
601
CCCCCTAATGCCAACAAGATCAGGGAGGCCCTGGCGCAGACGCACAGCGC
651 CATCGCTGTCATCATCGGAATCAAGGATCTGGACGCATTCCGGCACTATG

701
ACGGGCGCACAATCATCCAGCGCGACAACGGATATCAGCCAAACTACCAC
751
GCGGTCAACATCGTGGGTTACTCGAACGCCCAGGGGGTGGACTACTGGAT
801
CGTGAGAAACAGTTGGGACACTAACTGGGGCGACAACGGCTACGGCTACT
851
TCGCCGCCAACATCGACCTGATGATGATCGAGGAGTACCCGTACGTGGTG
901 ATCCTGTAA

SEQ ID NO:15 ProDer p 1 C71,103,117A (Der p 1 numbering)

Arg Pro Ser Ser Ile Lys Thr Phe Glu Glu Tyr Lys Lys Ala Phe 15
Asn Lys Ser Tyr Ala Thr Phe Glu Asp Glu Glu Ala Ala Arg Lys 30
Asn Phe Leu Glu Ser Val Lys Tyr Val Gln Ser Asn Gly Gly Ala 45
Ile Asn His Leu Ser Asp Leu Ser Leu Asp Glu Phe Lys Asn Arg 60
Phe Leu Met Ser Ala Glu Ala Phe Glu His Leu Lys Thr Gln Phe 75
Asp Leu Asn Ala Glu Thr Asn Ala Cys Ser Ile Asn Gly Asn Ala 90
Pro Ala Glu Ile Asp Leu Arg Gln Met Arg Thr Val Thr Pro Ile 105
Arg Met Gln Gly Gly Cys Gly Ser Cys Trp Ala Phe Ser Gly Val 120
Ala Ala Thr Glu Ser Ala Tyr Leu Ala Tyr Arg Asn Gln Ser Leu 135
Asp Leu Ala Glu Gln Glu Leu Val Asp Cys Ala Ser Gln His Gly 150
Ala His Gly Asp Thr Ile Pro Arg Gly Ile Glu Tyr Ile Gln His 165
Asn Gly Val Val Gln Glu Ser Tyr Tyr Arg Tyr Val Ala Arg Glu 180
Gln Ser **Ala** Arg Arg Pro Asn Ala Gln Arg Phe Gly Ile Ser Asn 195
Tyr **Ala** Gln Ile Tyr Pro Pro Asn Val Asn Lys Ile Arg Glu Ala 210
Leu Ala Gln Thr His Ser Ala Ile Ala Val Ile Ile Gly Ile Lys 225
Asp Leu Asp Ala Phe Arg His Tyr Asp Gly Arg Thr Ile Ile Gln 240
Arg Asp Asn Gly Tyr Gln Pro Asn Tyr His Ala Val Asn Ile Val 255
Gly Tyr Ser Asn Ala Gln Gly Val Asp Tyr Trp Ile Val Arg Asn 270

Ser Trp Asp Thr Asn Trp Gly Asp Asn Gly Tyr Gly Tyr Phe Ala 285
Ala Asn Ile Asp Leu Met Met Ile Glu Glu Tyr Pro Tyr Val Val 300
Ile Leu 302

SEQ ID NO:16 ProDer p 1 C71,103,117A (Der p 1 numbering)

1 CGGCCGAGCTCCATTAAGACCTTCGAGGAATACAAGAAAGCCTTCAACAA
51
GAGCTATGCCACCTTCGAGGACGAGGAGGCCGCGCGCAAGAACTTCCTGG
101
AAAGCGTGAAATACGTGCAGAGCAACGGCGGGGCTATAAATCACCTGTCC
151
GACCTGTCTTTAGACGAGTTCAAGAACCGGTTCCTGATGAGCGCCGAGGC
201 TTTCGAACACCTTAAGACCCAGTTTGATCTCAACGCGGAGACCAACGCCT
251
GCAGTATCAACGGCAATGCCCCCGCTGAGATTGATCTGCGCCAGATGAGG
301 ACCGTGACTCCCATCCGCATGCAAGGCGGCTGCGGGTCTTGTTGGGCCTT
351
TTCAGGCGTGGCCGCGACAGAGTCGGCATACCTCGCGTATCGGAATCAGA
401
GCCTGGACCTCGCTGAGCAGGAGCTCGTTGACTGCGCCTCCCAACACGGA
451
GCTCATGGGGATACGATTCCCAGAGGTATCGAATACATCCAGCATAATGG
501
CGTCGTGCAGGAAAGCTATTACCGATACGTAGCTAGGGAGCAGTCC**GCC**C
551 GCCGTCCTAACGCACAGCGCTTCGGCATTTCCAATTAT**GCC**CAGATCTAC
601
CCCCCTAATGCCAACAAGATCAGGGAGGCCCTGGCGCAGACGCACAGCGC
651 CATCGCTGTCATCATCGGAATCAAGGATCTGGACGCATTCCGGCACTATG
701
ACGGGCGCACAATCATCCAGCGCGACAACGGATATCAGCCAAACTACCAC
751
GCGGTCAACATCGTGGGTTACTCGAACGCCCAGGGGGTGGACTACTGGAT

801
CGTGAGAAACAGTTGGGACACTAACTGGGGCGACAACGGCTACGGCTACT
851
TCGCCGCCAACATCGACCTGATGATGATCGAGGAGTACCCGTACGTGGTG
901 ATCCTGTAA

SEQ ID NO:17 ProDer p 1 delta 147-160 (Der p 1 numbering)

Arg Pro Ser Ser Ile Lys Thr Phe Glu Glu Tyr Lys Lys Ala Phe 15
Asn Lys Ser Tyr Ala Thr Phe Glu Asp Glu Glu Ala Ala Arg Lys 30
Asn Phe Leu Glu Ser Val Lys Tyr Val Gln Ser Asn Gly Gly Ala 45
Ile Asn His Leu Ser Asp Leu Ser Leu Asp Glu Phe Lys Asn Arg 60
Phe Leu Met Ser Ala Glu Ala Phe Glu His Leu Lys Thr Gln Phe 75
Asp Leu Asn Ala Glu Thr Asn Ala Cys Ser Ile Asn Gly Asn Ala 90
Pro Ala Glu Ile Asp Leu Arg Gln Met Arg Thr Val Thr Pro Ile 105
Arg Met Gln Gly Gly Cys Gly Ser Cys Trp Ala Phe Ser Gly Val 120
Ala Ala Thr Glu Ser Ala Tyr Leu Ala Tyr Arg Asn Gln Ser Leu 135
Asp Leu Ala Glu Gln Glu Leu Val Asp Cys Ala Ser Gln His Gly 150
Cys His Gly Asp Thr Ile Pro Arg Gly Ile Glu Tyr Ile Gln His 165
Asn Gly Val Val Gln Glu Ser Tyr Tyr Arg Tyr Val Ala Arg Glu 180
Gln Ser Cys Arg Arg Pro Asn Ala Gln Arg Phe Gly Ile Ser Asn 195
Tyr Cys Gln Ile Tyr Pro Pro Asn Val Asn Lys Ile Arg Glu Ala 210
Leu Ala Gln Thr His Ser Ala Ile Ala Val Ile Ile Gly Ile Lys 225
Asp - - - - - - - - - - - - - - - - 240
Arg Asp Asn Gly Tyr Gln Pro Asn Tyr His Ala Val Asn Ile Val 255
Gly Tyr Ser Asn Ala Gln Gly Val Asp Tyr Trp Ile Val Arg Asn 270
Ser Trp Asp Thr Asn Trp Gly Asp Asn Gly Tyr Gly Tyr Phe Ala 285
Ala Asn Ile Asp Leu Met Met Ile Glu Glu Tyr Pro Tyr Val Val 300

Ile Leu 302

SEQ ID NO:18 ProDer p 1 delta 147-160 (Der p 1 numbering)

1 CGGCCGAGCTCCATTAAGACCTTCGAGGAATACAAGAAAGCCTTCAACAA

51

GAGCTATGCCACCTTCGAGGACGAGGAGGCCGCGGCGCAAGAACTTCCTGG

101

AAAGCGTGAAATACGTGCAGAGCAACGGCGGGGCTATAAATCACCTGTCC

151

GACCTGTCTTTAGACGAGTTCAAGAACCGGTTCCTGATGAGCGCCGAGGC

201 TTTCGAACACCTTAAGACCCAGTTTGATCTCAACGCGGAGACCAACGCCT

251

GCAGTATCAACGGCAATGCCCCCGCTGAGATTGATCTGCGCCAGATGAGG

301 ACCGTGACTCCCATCCGCATGCAAGGCGGCTGCGGGTCTTGTTGGGCCTT

351

TTCAGGCGTGGCCGCGACAGAGTCGGCATACCTCGCGTATCGGAATCAGA

401

GCCTGGACCTCGCTGAGCAGGAGCTCGTTGACTGCGCCTCCCAACACGGA

451

TGTCATGGGGATACGATTCCCAGAGGTATCGAATACATCCAGCATAATGG

501

CGTCGTGCAGGAAAGCTATTACCGATACGTAGCTAGGGAGCAGTCCTGCC

551 GCCGTCCTAACGCACAGCGCTTCGGCATTTCCAATTATTGCCAGATCTAC

601

CCCCCTAATGCCAACAAGATCAGGGAGGCCCTGGCGCAGACGCACAGCGC

651 CATCGCTGTCATCATCGGAATCAAGGAT----------

701 ----------CGCGACAACGGGTATCAGCCAAACTACCAC

751

GCGGTCAACATCGTGGGTTACTCGAACGCCCAGGGGGTGGACTACTGGAT

801

CGTGAGAAACAGTTGGGACACTAACTGGGGCGACAACGGCTACGGCTACT

851
TCGCCGCCAACATCGACCTGATGATGATCGAGGAGTACCCGTACGTGGTG
901 ATCCTGTAA

SEQ ID NO: 19

Amino acid sequence of PreProDer p 3

Full sequence of PreProDerP3 is amino-acids 1-261

Prosequence is amino-acids 19-261

Mature Der p 3 is amino-acids 30-261

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

1 Met Ile Ile Tyr Asn Ile Leu Ile Val Leu Leu Leu Ala Ile Asn 15
16 Thr Leu Ala Asn Pro Ile Leu Pro Ala Ser Pro Asn Ala Thr Ile 30
31 Val Gly Gly Glu Lys Ala Leu Ala Gly Glu Cys Pro Tyr Gln Ile 45
46 Ser Leu Gln Ser Ser Ser His Phe Cys Gly Gly Thr Ile Leu Asp 60
61 Glu Tyr Trp Ile Leu Thr Ala Ala His Cys Val Ala Gly Gln Thr 75
76 Ala Ser Lys Leu Ser Ile Arg Tyr Asn Ser Leu Lys His Ser Leu 90
91 Gly Gly Glu Lys Ile Ser Val Ala Lys Ile Phe Ala His Glu Lys 105
106 Tyr Asp Ser Tyr Gln Ile Asp Asn Asp Ile Ala Leu Ile Lys Leu 120
121 Lys Ser Pro Met Lys Leu Asn Gln Lys Asn Ala Lys Ala Val Gly 135
136 Leu Pro Ala Lys Gly Ser Asp Val Lys Val Gly Asp Gln Val Arg 150
151 Val Ser Gly Trp Gly Tyr Leu Glu Glu Gly Ser Tyr Ser Leu Pro 165
166 Ser Glu Leu Arg Arg Val Asp Ile Ala Val Val Ser Arg Lys Glu 180
181 Cys Asn Glu Leu Tyr Ser Lys Ala Asn Ala Glu Val Thr Asp Asn 195
196 Met Ile Cys Gly Gly Asp Val Ala Asn Gly Gly Lys Asp Ser Cys 210
211 Gln Gly Asp Ser Gly Gly Pro Val Val Asp Val Lys Asn Asn Gln 225
226 Val Val Gly Ile Val Ser Trp Gly Tyr Gly Cys Ala Arg Lys Gly 240
241 Tyr Pro Gly Val Tyr Thr Arg Val Gly Asn Phe Ile Asp Trp Ile 255
256 Glu Ser Lys Arg Ser Gln

SEQ ID NO: 20

Natural cDNA sequence of PreProDer p 3

cDNA of Leader peptide is 1-786

cDNA of Prosequence is 55-786

cDNA of Mature Der p 3 is 88-786

1 atgatcatct ataatatttt aattgtttta ttattggcca ttaatacatt ggctaatcca

61 attctaccag catcaccaaa tgcaactatt gttggtggtg aaaaagcatt agctggtgaa

121 tgtccatatc agatttcatt acaatcaagt agtcattttt gtggtggtac tattcttgat

181 gaatattgga ttttaacagc tgcacattgt gttgccggac aaacagcaag taaactttca

241 attcgttaca atagtttaaa acattcatta ggtggtgaaa aaatttctgt tgctaaaatt

301 tttgcacatg aaaaatatga tagttatcaa attgataatg atattgcatt gattaagctt

361 aaatcaccta tgaaattaaa tcagaaaaat gccaaagctg ttggattacc agcaaaagga

421 tcggatgtaa aagttggtga tcaagttcgt gtttctggtt ggggttatct tgaagaagga

481 agttattcat taccatctga attaagacgt gttgatattg ctgttgtatc acgtaaagaa

541 tgtaatgaat tatattcaaa agctaatgct gaagttactg ataatatgat ttgtggtggt

601 gatgttgcaa atggtggtaa agattcttgt caaggtgatt ctggtggacc ggttgttgat

661 gttaaaaata atcaagttgt tggtattgtt tcatggggtt atggttgtgc acgtaaaggt

721 tatccaggtg tttatacacg tgttggtaat tttatcgatt ggattgaatc aaaacgttca

781 cagtga

SEQ ID NO: 21

Synthetic cDNA sequence of PreProDer p 3

cDNA of Leader peptide is 1-786

cDNA of Prosequence is 55-786

cDNA of Mature Der p 3 is 88-786

The modified nucleotides are in bold and underlined

1 atgatcatct a**C**aa**C**att**C**t **G**at**C**gt**AC**t**C** **C**t**GC**tggcca ttaa**C**ac**T**tt ggctaatcc**G**

61 at**C**ct**G**cc**G**g catc**C**cc**G**aa **C**gc**G**ac**C**at**C** gttgg**C**gg**C**g aaaaagc**AC**t **G**gctggtga**G**

121 tg**C**ccatatc agat**C**tc**CC**t **G**ca**G**tc**T**agt ag**C**ca**C**tt**C**t gtggtggtac tattcttga**C**

181 gaataCtgga tCCtGacCgc GgcacaCtgC gtGgccggCc aaacagcGag CaaactCtcC
241 attcgttaca aCagCCtGaa acaCtcaCtG ggtggCgaaa aGatttctgt tgctaaaatt
301 ttCgcacatg aaaaatatga tagCtaCcaG atCgaCaatg aCattgcGCt gatCaagctG
361 aaatcCccta tgaaGCtGaa CcagaaaaaC gccaaagctg tGggCCtGcc GgcGaaaggC
421 tcggatgtaa aagttggtga CcaGgtGcgt gtCtctggCt ggggttatct GgaagaGggC
481 agCtaCtcCC tGccGtctga attaCgCcgt gttgatatCg ctgtGgtatc TcgCaaagaa
541 tgtaaCgaGc tGtaCtcGaa agcGaaCgct gaagtCacCg aCaatatgat CtgCggtggt
601 gatgttgcGa aCggCggtaa GgaCtcttgt caaggCgatt ctggtggGcc ggtGgtCgaC
661 gttaaaaaCa aCcaGgttgt AggtatCgtt tcAtggggCt aCggttgCgc acgtaaaggC
721 tatccGggtg tGtaCacGcg CgttggtaaC tttatcgatt ggattgaatc TaaacgtAGC
781 cagtga

CLAIMS

1. A recombinant *Dermatophagoides pteronyssinus* DerP1 or ProDerP1 (DerP1/ProDerP1) protein allergen derivative wherein said allergen derivative has a significantly reduced allergenic activity compared to that the wild-type allergen.
2. A recombinant DerP1/ProDerP1 derivative as claimed in claim 1, wherein said derivative has been thermally treated.
3. A recombinant DerP1/ProDerP1 derivative as claimed in claim 1, wherein said derivative has been genetically mutated.
4. A recombinant DerP1/ProDerP1 mutant as claimed in claim 3, wherein said mutant comprises one or more of the DerP1 following mutation: a mutation of the cysteine 4 residue, a mutation of the cysteine 31 residue, a mutation of the cysteine 65 residue, a mutation of the cysteine 71 residue, a mutation of the cysteine 103 residue and a mutation of the cysteine 117 residue.
5. A recombinant DerP1/ProDerP1 mutant as claimed in claim 4, wherein said mutant comprises the three following mutations: a mutation of the cysteine 71 residue, a mutation of the cysteine 103 residue and a mutation of the cysteine 117 residue.
6. A recombinant DerP1/ProDerP1 mutant as claimed in claim 3, wherein said mutant comprises a deletion of amino acid residues 147 to 160 of DerP1 or residues 227-140 of ProDerP1.
7. A recombinant mutant allergen having any of the sequences selected from the group consisting of: SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17.
8. An isolated nucleic acid molecule encoding a mutated version of an allergen as claimed in any previous claim.
9. A nucleic acid sequence according to claim 8 wherein the codon usage pattern resembles that of highly expressed mammalian genes.
10. An expression vector containing a nucleic acid of claim 8 or 9.
11. A host cell transformed with a nucleic acid sequence of claim 8 or 9 or with a vector as claimed in claim 10.

12. An immunogenic composition comprising a recombinant protein or mutant allergen as claimed in any one of claims 1 to 7, or an encoding polynucleotide as claimed in claim 8 to 10, and, optionally, an adjuvant.
13. An immunogenic composition as claimed in claim 12, wherein the adjuvant is a preferential stimulator of Th1-type immune responses.
14. An immunogenic composition as claimed in claim 12 or 13 wherein the adjuvant comprises one or more of 3D-MPL, QS21, a CpG oligonucleotide, a polyethylene ether or ester or a combination of two or more of these adjuvants.
15. An immunogenic composition as claimed in any of claims 12 to 14 wherein the allergen is presented in an oil in water or a water in oil emulsion vehicle.
16. A immunogenic composition as claimed herein for use in medicine.
17. Use of a recombinant protein or mutant allergen as claimed in any one of claims 1 to 7 in the manufacture of a medicament for the treatment of allergy.
18. A method of treating a patient suffering from or preventing a patient susceptible to allergic responses, comprising administering to said individual an immunogenic composition as claimed in claims 12 to 15.
19. A recombinant *Dermatophagoides pteronyssinus* DerP3 or ProDerP3 (DerP3/ProDerP3) protein allergen derivative wherein said allergen derivative has a significantly reduced allergenic activity compared to that the wild-type allergen.
20. 20. A recombinant DerP3/ProDerP3 derivative as claimed in claim 1, wherein said derivative has been thermally treated.
21. A recombinant DerP3/ProDerP3 derivative as claimed in claim 1, wherein said derivative has been genetically mutated.
22. A recombinant DerP3/ProDerP3 mutant as claimed in claim 3, wherein said mutant comprises a mutation of a cysteine residue.
23. A recombinant allergen having the sequence of: SEQ ID NO:19.
24. An isolated nucleic acid molecule encoding a mutated version of an allergen as claimed in any previous claim
25. An isolated nucleic acid molecule having the sequence of any of SEQ ID NOs.20 or 21.
26. An expression vector containing a nucleic acid of claim 24 or 25.

27. A host cell transformed with a nucleic acid sequence of claim 24 or 25 or with a vector as claimed in claim 26.

28. An immunogenic composition comprising a recombinant protein or mutant allergen as claimed in any one of claims 19 to 23, or an encoding polynucleotide as claimed in claim 24 to 25, and, optionally, an adjuvant.

29. An immunogenic composition as claimed in claim 28, wherein the adjuvant is a preferential stimulator of Th1-type immune responses.

30. An immunogenic composition as claimed in claim 28 or 29 wherein the adjuvant comprises one or more of 3D-MPL, QS21, a CpG oligonucleotide, a polyethylene ether or ester or a combination of two or more of these adjuvants.

31. An immunogenic composition as claimed in any of claims 28 to 30 wherein the allergen is presented in an oil in water or a water in oil emulsion vehicle.

32. A immunogenic composition as claimed herein for use in medicine.

33. Use of a recombinant protein or mutant allergen as claimed in any one of claims 19 to 23 in the manufacture of a medicament for the treatment of allergy.

34. A method of treating a patient suffering from or preventing a patient susceptible to allergic responses, comprising administering to said individual an immunogenic composition as claimed in claims 28 to 31.

Abstract

The present invention provides a novel treatment for allergy comprising the provision of a recombinant DerP1/ProDerP1 allergen derivative or a recombinant DerP3/ProDerP3 allergen derivative with hypoallergenic activity. Pharmaceutical compositions comprising said mutant allergens which stimulate a Th1-type immune response in allergic or naïve individuals thereby reducing the potential for an allergic response upon contact with the wild-type allergen, are also provided.

SEQUENCE LISTING

<110> GlaxoSmithKline Biologicals s.a.

<120> Novel Compounds

<130> B45282

<160> 26

<170> FastSEQ for Windows Version 4.0

<210> 1
<211> 909
<212> DNA
<213> Dermatophagoides pteronyssinus

<220>
<221> CDS
<222> (1)...(906)

<400> 1
cgg ccg agc tcc att aag acc ttc gag gaa tac aag aaa gcc ttc aac 48
Arg Pro Ser Ser Ile Lys Thr Phe Glu Glu Tyr Lys Lys Ala Phe Asn
1 5 10 15

aag agc tat gcc acc ttc gag gac gag gag gcc gcg cgc aag aac ttc 96
Lys Ser Tyr Ala Thr Phe Glu Asp Glu Glu Ala Ala Arg Lys Asn Phe
20 25 30

ctg gaa agc gtg aaa tac gtg cag agc aac ggc ggg gct ata aat cac 144
Leu Glu Ser Val Lys Tyr Val Gln Ser Asn Gly Gly Ala Ile Asn His

35 40 45

ctg tcc gac ctg tct tta gac gag ttc aag aac cgg ttc ctg atg agc 192
Leu Ser Asp Leu Ser Leu Asp Glu Phe Lys Asn Arg Phe Leu Met Ser
50 55 60

gcc gag gct ttc gaa cac ctt aag acc cag ttt gat ctc aac gcg gag 240
Ala Glu Ala Phe Glu His Leu Lys Thr Gln Phe Asp Leu Asn Ala Glu
65 70 75 80

acc aac gcc tgc agt atc aac ggc aat gcc ccc gct gag att gat ctg 288
Thr Asn Ala Cys Ser Ile Asn Gly Asn Ala Pro Ala Glu Ile Asp Leu
85 90 95

cgc cag atg agg acc gtg act ccc atc cgc atg caa ggc ggc tgc ggg 336
Arg Gln Met Arg Thr Val Thr Pro Ile Arg Met Gln Gly Gly Cys Gly
100 105 110

tct tgt tgg gcc ttt tca ggc gtg gcc gcg aca gag tcg gca tac ctc 384
Ser Cys Trp Ala Phe Ser Gly Val Ala Ala Thr Glu Ser Ala Tyr Leu
115 120 125

gcg tat cgg aat cag agc ctg gac ctc gct gag cag gag ctc gtt gac 432
Ala Tyr Arg Asn Gln Ser Leu Asp Leu Ala Glu Gln Glu Leu Val Asp
130 135 140

tgc gcc tcc caa cac gga tgt cat ggg gat acg att ccc aga ggt atc 480
Cys Ala Ser Gln His Gly Cys His Gly Asp Thr Ile Pro Arg Gly Ile
145 150 155 160

gaa tac atc cag cat aat ggc gtc gtg cag gaa agc tat tac cga tac 528
Glu Tyr Ile Gln His Asn Gly Val Val Gln Glu Ser Tyr Tyr Arg Tyr
165 170 175

gta gct agg gag cag tcc tgc cgc cgt cct aac gca cag cgc ttc ggc 576
Val Ala Arg Glu Gln Ser Cys Arg Arg Pro Asn Ala Gln Arg Phe Gly
180 185 190

att tcc aat tat tgc cag atc tac ccc cct aat gcc aac aag atc agg 624
Ile Ser Asn Tyr Cys Gln Ile Tyr Pro Pro Asn Ala Asn Lys Ile Arg
195 200 205

gag gcc ctg gcg cag acg cac agc gcc atc gct gtc atc atc gga atc 672
Glu Ala Leu Ala Gln Thr His Ser Ala Ile Ala Val Ile Ile Gly Ile
210 215 220

aag gat ctg gac gca ttc cgg cac tat gac ggg cgc aca atc atc cag 720
Lys Asp Leu Asp Ala Phe Arg His Tyr Asp Gly Arg Thr Ile Ile Gln
225 230 235 240

cgc gac aac gga tat cag cca aac tac cac gcg gtc aac atc gtg ggt 768
Arg Asp Asn Gly Tyr Gln Pro Asn Tyr His Ala Val Asn Ile Val Gly
245 250 255

tac tcg aac gcc cag ggg gtg gac tac tgg atc gtg aga aac agt tgg 816
Tyr Ser Asn Ala Gln Gly Val Asp Tyr Trp Ile Val Arg Asn Ser Trp
260 265 270

gac act aac tgg ggc gac aac ggc tac ggc tac ttc gcc gcc aac atc 864
Asp Thr Asn Trp Gly Asp Asn Gly Tyr Gly Tyr Phe Ala Ala Asn Ile
275 280 285

gac ctg atg atg atc gag gag tac ccg tac gtg gtg atc ctg 906
Asp Leu Met Met Ile Glu Glu Tyr Pro Tyr Val Val Ile Leu
290 295 300

taa 909

<210> 2

<211> 302

<212> PRT

<213> Dermatophagoides pteronyssinus

<400> 2

Arg Pro Ser Ser Ile Lys Thr Phe Glu Glu Tyr Lys Lys Ala Phe Asn
1 5 10 15

Lys Ser Tyr Ala Thr Phe Glu Asp Glu Glu Ala Ala Arg Lys Asn Phe
20 25 30

Leu Glu Ser Val Lys Tyr Val Gln Ser Asn Gly Gly Ala Ile Asn His
35 40 45

Leu Ser Asp Leu Ser Leu Asp Glu Phe Lys Asn Arg Phe Leu Met Ser
50 55 60

Ala Glu Ala Phe Glu His Leu Lys Thr Gln Phe Asp Leu Asn Ala Glu
65 70 75 80

Thr Asn Ala Cys Ser Ile Asn Gly Asn Ala Pro Ala Glu Ile Asp Leu
85 90 95

Arg Gln Met Arg Thr Val Thr Pro Ile Arg Met Gln Gly Gly Cys Gly
100 105 110

Ser Cys Trp Ala Phe Ser Gly Val Ala Ala Thr Glu Ser Ala Tyr Leu
115 120 125

Ala Tyr Arg Asn Gln Ser Leu Asp Leu Ala Glu Gln Glu Leu Val Asp
130 135 140

Cys Ala Ser Gln His Gly Cys His Gly Asp Thr Ile Pro Arg Gly Ile
145 150 155 160

Glu Tyr Ile Gln His Asn Gly Val Val Gln Glu Ser Tyr Tyr Arg Tyr
165 170 175

Val Ala Arg Glu Gln Ser Cys Arg Arg Pro Asn Ala Gln Arg Phe Gly
180 185 190

Ile Ser Asn Tyr Cys Gln Ile Tyr Pro Pro Asn Val Asn Lys Ile Arg
195 200 205

Glu Ala Leu Ala Gln Thr His Ser Ala Ile Ala Val Ile Ile Gly Ile
210 215 220

Lys Asp Leu Asp Ala Phe Arg His Tyr Asp Gly Arg Thr Ile Ile Gln
225 230 235 240
Arg Asp Asn Gly Tyr Gln Pro Asn Tyr His Ala Val Asn Ile Val Gly
245 250 255
Tyr Ser Asn Ala Gln Gly Val Asp Tyr Trp Ile Val Arg Asn Ser Trp
260 265 270
Asp Thr Asn Trp Gly Asp Asn Gly Tyr Gly Tyr Phe Ala Ala Asn Ile
275 280 285
Asp Leu Met Met Ile Glu Glu Tyr Pro Tyr Val Val Ile Leu
290 295 300

<210> 3
<211> 302
<212> PRT
<213> Artificial Sequence

<220>
<223> C4R mutant of ProDerP1

<400> 3
Arg Pro Ser Ser Ile Lys Thr Phe Glu Glu Tyr Lys Lys Ala Phe Asn
1 5 10 15
Lys Ser Tyr Ala Thr Phe Glu Asp Glu Glu Ala Ala Arg Lys Asn Phe
20 25 30
Leu Glu Ser Val Lys Tyr Val Gln Ser Asn Gly Gly Ala Ile Asn His
35 40 45
Leu Ser Asp Leu Ser Leu Asp Glu Phe Lys Asn Arg Phe Leu Met Ser
50 55 60
Ala Glu Ala Phe Glu His Leu Lys Thr Gln Phe Asp Leu Asn Ala Glu
65 70 75 80
Thr Asn Ala Arg Ser Ile Asn Gly Asn Ala Pro Ala Glu Ile Asp Leu
85 90 95
Arg Gln Met Arg Thr Val Thr Pro Ile Arg Met Gln Gly Gly Cys Gly

100 105 110

Ser Cys Trp Ala Phe Ser Gly Val Ala Ala Thr Glu Ser Ala Tyr Leu

115 120 125

Ala Tyr Arg Asn Gln Ser Leu Asp Leu Ala Glu Gln Glu Leu Val Asp

130 135 140

Cys Ala Ser Gln His Gly Cys His Gly Asp Thr Ile Pro Arg Gly Ile

145 150 155 160

Glu Tyr Ile Gln His Asn Gly Val Val Gln Glu Ser Tyr Tyr Arg Tyr

165 170 175

Val Ala Arg Glu Gln Ser Cys Arg Arg Pro Asn Ala Gln Arg Phe Gly

180 185 190

Ile Ser Asn Tyr Cys Gln Ile Tyr Pro Pro Asn Val Asn Lys Ile Arg

195 200 205

Glu Ala Leu Ala Gln Thr His Ser Ala Ile Ala Val Ile Ile Gly Ile

210 215 220

Lys Asp Leu Asp Ala Phe Arg His Tyr Asp Gly Arg Thr Ile Ile Gln

225 230 235 240

Arg Asp Asn Gly Tyr Gln Pro Asn Tyr His Ala Val Asn Ile Val Gly

245 250 255

Tyr Ser Asn Ala Gln Gly Val Asp Tyr Trp Ile Val Arg Asn Ser Trp

260 265 270

Asp Thr Asn Trp Gly Asp Asn Gly Tyr Gly Tyr Phe Ala Ala Asn Ile

275 280 285

Asp Leu Met Met Ile Glu Glu Tyr Pro Tyr Val Val Ile Leu

290 295 300

<210> 4

<211> 909

<212> DNA

<213> Artificial Sequence

<220>

<221> CDS

<222> (1)...(906)

<223> C4R mutant of ProDerP1

<400> 4

cgg ccg agc tcc att aag acc ttc gag gaa tac aag aaa gcc ttc aac 48
Arg Pro Ser Ser Ile Lys Thr Phe Glu Glu Tyr Lys Lys Ala Phe Asn
1 5 10 15

aag agc tat gcc acc ttc gag gac gag gag gcc gcg cgc aag aac ttc 96
Lys Ser Tyr Ala Thr Phe Glu Asp Glu Glu Ala Ala Arg Lys Asn Phe
20 25 30

ctg gaa agc gtg aaa tac gtg cag agc aac ggc ggg gct ata aat cac 144
Leu Glu Ser Val Lys Tyr Val Gln Ser Asn Gly Gly Ala Ile Asn His
35 40 45

ctg tcc gac ctg tct tta gac gag ttc aag aac cgg ttc ctg atg agc 192
Leu Ser Asp Leu Ser Leu Asp Glu Phe Lys Asn Arg Phe Leu Met Ser
50 55 60

gcc gag gct ttc gaa cac ctt aag acc cag ttt gat ctc aac gcg gag 240
Ala Glu Ala Phe Glu His Leu Lys Thr Gln Phe Asp Leu Asn Ala Glu
65 70 75 80

acc aac gcc cgt agt atc aac ggc aat gcc ccc gct gag att gat ctg 288
Thr Asn Ala Arg Ser Ile Asn Gly Asn Ala Pro Ala Glu Ile Asp Leu
85 90 95

cgc cag atg agg acc gtg act ccc atc cgc atg caa ggc ggc tgc ggg 336
Arg Gln Met Arg Thr Val Thr Pro Ile Arg Met Gln Gly Gly Cys Gly
100 105 110

tct tgt tgg gcc ttt tca ggc gtg gcc gcg aca gag tcg gca tac ctc 384

Ser Cys Trp Ala Phe Ser Gly Val Ala Ala Thr Glu Ser Ala Tyr Leu
115 120 125

gcg tat cgg aat cag agc ctg gac ctc gct gag cag gag ctc gtt gac 432
Ala Tyr Arg Asn Gln Ser Leu Asp Leu Ala Glu Gln Glu Leu Val Asp
130 135 140

tgc gcc tcc caa cac gga tgt cat ggg gat acg att ccc aga ggt atc 480
Cys Ala Ser Gln His Gly Cys His Gly Asp Thr Ile Pro Arg Gly Ile
145 150 155 160

gaa tac atc cag cat aat ggc gtc gtg cag gaa agc tat tac cga tac 528
Glu Tyr Ile Gln His Asn Gly Val Val Gln Glu Ser Tyr Tyr Arg Tyr
165 170 175

gta gct agg gag cag tcc tgc cgc cgt cct aac gca cag cgc ttc ggc 576
Val Ala Arg Glu Gln Ser Cys Arg Arg Pro Asn Ala Gln Arg Phe Gly
180 185 190

att tcc aat tat tgc cag atc tac ccc cct aat gcc aac aag atc agg 624
Ile Ser Asn Tyr Cys Gln Ile Tyr Pro Pro Asn Ala Asn Lys Ile Arg
195 200 205

gag gcc ctg gcg cag acg cac agc gcc atc gct gtc atc atc gga atc 672
Glu Ala Leu Ala Gln Thr His Ser Ala Ile Ala Val Ile Ile Gly Ile
210 215 220

aag gat ctg gac gca ttc cgg cac tat gac ggg cgc aca atc atc cag 720
Lys Asp Leu Asp Ala Phe Arg His Tyr Asp Gly Arg Thr Ile Ile Gln
225 230 235 240

cgc gac aac gga tat cag cca aac tac cac gcg gtc aac atc gtg ggt 768
Arg Asp Asn Gly Tyr Gln Pro Asn Tyr His Ala Val Asn Ile Val Gly
245 250 255

tac tcg aac gcc cag ggg gtg gac tac tgg atc gtg aga aac agt tgg 816
Tyr Ser Asn Ala Gln Gly Val Asp Tyr Trp Ile Val Arg Asn Ser Trp
260 265 270

gac act aac tgg ggc gac aac ggc tac ggc tac ttc gcc gcc aac atc 864
Asp Thr Asn Trp Gly Asp Asn Gly Tyr Gly Tyr Phe Ala Ala Asn Ile
275 280 285

gac ctg atg atg atc gag gag tac ccg tac gtg gtg atc ctg 906
Asp Leu Met Met Ile Glu Glu Tyr Pro Tyr Val Val Ile Leu
290 295 300

taa 909

<210> 5
<211> 302
<212> PRT
<213> Artificial Sequence

<220>
<223> C31R mutant of ProDerP1

<400> 5
Arg Pro Ser Ser Ile Lys Thr Phe Glu Glu Tyr Lys Lys Ala Phe Asn
1 5 10 15
Lys Ser Tyr Ala Thr Phe Glu Asp Glu Glu Ala Ala Arg Lys Asn Phe
20 25 30
Leu Glu Ser Val Lys Tyr Val Gln Ser Asn Gly Gly Ala Ile Asn His
35 40 45
Leu Ser Asp Leu Ser Leu Asp Glu Phe Lys Asn Arg Phe Leu Met Ser
50 55 60
Ala Glu Ala Phe Glu His Leu Lys Thr Gln Phe Asp Leu Asn Ala Glu
65 70 75 80

Thr Asn Ala Cys Ser Ile Asn Gly Asn Ala Pro Ala Glu Ile Asp Leu
85 90 95

Arg Gln Met Arg Thr Val Thr Pro Ile Arg Met Gln Gly Gly Arg Gly
100 105 110

Ser Cys Trp Ala Phe Ser Gly Val Ala Ala Thr Glu Ser Ala Tyr Leu
115 120 125

Ala Tyr Arg Asn Gln Ser Leu Asp Leu Ala Glu Gln Glu Leu Val Asp
130 135 140

Cys Ala Ser Gln His Gly Cys His Gly Asp Thr Ile Pro Arg Gly Ile
145 150 155 160

Glu Tyr Ile Gln His Asn Gly Val Val Gln Glu Ser Tyr Tyr Arg Tyr
165 170 175

Val Ala Arg Glu Gln Ser Cys Arg Arg Pro Asn Ala Gln Arg Phe Gly
180 185 190

Ile Ser Asn Tyr Cys Gln Ile Tyr Pro Pro Asn Val Asn Lys Ile Arg
195 200 205

Glu Ala Leu Ala Gln Thr His Ser Ala Ile Ala Val Ile Ile Gly Ile
210 215 220

Lys Asp Leu Asp Ala Phe Arg His Tyr Asp Gly Arg Thr Ile Ile Gln
225 230 235 240

Arg Asp Asn Gly Tyr Gln Pro Asn Tyr His Ala Val Asn Ile Val Gly
245 250 255

Tyr Ser Asn Ala Gln Gly Val Asp Tyr Trp Ile Val Arg Asn Ser Trp
260 265 270

Asp Thr Asn Trp Gly Asp Asn Gly Tyr Gly Tyr Phe Ala Ala Asn Ile
275 280 285

Asp Leu Met Met Ile Glu Glu Tyr Pro Tyr Val Val Ile Leu
290 295 300

<210> 6

<211> 909

<212> DNA

<213> Artificial Sequence

<220>

<221> CDS

<222> (1)...(906)

<223> C31R mutant of ProDerP1

<400> 6

cgg ccg agc tcc att aag acc ttc gag gaa tac aag aaa gcc ttc aac 48
Arg Pro Ser Ser Ile Lys Thr Phe Glu Glu Tyr Lys Lys Ala Phe Asn
1 5 10 15

aag agc tat gcc acc ttc gag gac gag gag gcc gcg cgc aag aac ttc 96
Lys Ser Tyr Ala Thr Phe Glu Asp Glu Glu Ala Ala Arg Lys Asn Phe
20 25 30

ctg gaa agc gtg aaa tac gtg cag agc aac ggc ggg gct ata aat cac 144
Leu Glu Ser Val Lys Tyr Val Gln Ser Asn Gly Gly Ala Ile Asn His
35 40 45

ctg tcc gac ctg tct tta gac gag ttc aag aac cgg ttc ctg atg agc 192
Leu Ser Asp Leu Ser Leu Asp Glu Phe Lys Asn Arg Phe Leu Met Ser
50 55 60

gcc gag gct ttc gaa cac ctt aag acc cag ttt gat ctc aac gcg gag 240
Ala Glu Ala Phe Glu His Leu Lys Thr Gln Phe Asp Leu Asn Ala Glu
65 70 75 80

acc aac gcc tgc agt atc aac ggc aat gcc ccc gct gag att gat ctg 288
Thr Asn Ala Cys Ser Ile Asn Gly Asn Ala Pro Ala Glu Ile Asp Leu
85 90 95

cgc cag atg agg acc gtg act ccc atc cgc atg caa ggc ggc cgt ggg 336
Arg Gln Met Arg Thr Val Thr Pro Ile Arg Met Gln Gly Gly Arg Gly

100 105 110

tct tgt tgg gcc ttt tca ggc gtg gcc gcg aca gag tcg gca tac ctc 384
Ser Cys Trp Ala Phe Ser Gly Val Ala Ala Thr Glu Ser Ala Tyr Leu
115 120 125

gcg tat cgg aat cag agc ctg gac ctc gct gag cag gag ctc gtt gac 432
Ala Tyr Arg Asn Gln Ser Leu Asp Leu Ala Glu Gln Glu Leu Val Asp
130 135 140

tgc gcc tcc caa cac gga tgt cat ggg gat acg att ccc aga ggt atc 480
Cys Ala Ser Gln His Gly Cys His Gly Asp Thr Ile Pro Arg Gly Ile
145 150 155 160

gaa tac atc cag cat aat ggc gtc gtg cag gaa agc tat tac cga tac 528
Glu Tyr Ile Gln His Asn Gly Val Val Gln Glu Ser Tyr Tyr Arg Tyr
165 170 175

gta gct agg gag cag tcc tgc cgc cgt cct aac gca cag cgc ttc ggc 576
Val Ala Arg Glu Gln Ser Cys Arg Arg Pro Asn Ala Gln Arg Phe Gly
180 185 190

att tcc aat tat tgc cag atc tac ccc cct aat gcc aac aag atc agg 624
Ile Ser Asn Tyr Cys Gln Ile Tyr Pro Pro Asn Ala Asn Lys Ile Arg
195 200 205

gag gcc ctg gcg cag acg cac agc gcc atc gct gtc atc atc gga atc 672
Glu Ala Leu Ala Gln Thr His Ser Ala Ile Ala Val Ile Ile Gly Ile
210 215 220

aag gat ctg gac gca ttc cgg cac tat gac ggg cgc aca atc atc cag 720
Lys Asp Leu Asp Ala Phe Arg His Tyr Asp Gly Arg Thr Ile Ile Gln
225 230 235 240

cgc gac aac gga tat cag cca aac tac cac gcg gtc aac atc gtg ggt 768
Arg Asp Asn Gly Tyr Gln Pro Asn Tyr His Ala Val Asn Ile Val Gly
245 250 255

tac tcg aac gcc cag ggg gtg gac tac tgg atc gtg aga aac agt tgg 816
Tyr Ser Asn Ala Gln Gly Val Asp Tyr Trp Ile Val Arg Asn Ser Trp
260 265 270

gac act aac tgg ggc gac aac ggc tac ggc tac ttc gcc gcc aac atc 864
Asp Thr Asn Trp Gly Asp Asn Gly Tyr Gly Tyr Phe Ala Ala Asn Ile
275 280 285

gac ctg atg atg atc gag gag tac ccg tac gtg gtg atc ctg 906
Asp Leu Met Met Ile Glu Glu Tyr Pro Tyr Val Val Ile Leu
290 295 300

taa 909

<210> 7
<211> 302
<212> PRT
<213> Artificial Sequence

<220>
<223> C65R mutant of ProDerP1

<400> 7
Arg Pro Ser Ser Ile Lys Thr Phe Glu Glu Tyr Lys Lys Ala Phe Asn
1 5 10 15
Lys Ser Tyr Ala Thr Phe Glu Asp Glu Glu Ala Ala Arg Lys Asn Phe
20 25 30
Leu Glu Ser Val Lys Tyr Val Gln Ser Asn Gly Gly Ala Ile Asn His
35 40 45
Leu Ser Asp Leu Ser Leu Asp Glu Phe Lys Asn Arg Phe Leu Met Ser

50 55 60

Ala Glu Ala Phe Glu His Leu Lys Thr Gln Phe Asp Leu Asn Ala Glu

65 70 75 80

Thr Asn Ala Cys Ser Ile Asn Gly Asn Ala Pro Ala Glu Ile Asp Leu

85 90 95

Arg Gln Met Arg Thr Val Thr Pro Ile Arg Met Gln Gly Gly Cys Gly

100 105 110

Ser Cys Trp Ala Phe Ser Gly Val Ala Ala Thr Glu Ser Ala Tyr Leu

115 120 125

Ala Tyr Arg Asn Gln Ser Leu Asp Leu Ala Glu Gln Glu Leu Val Asp

130 135 140

Arg Ala Ser Gln His Gly Cys His Gly Asp Thr Ile Pro Arg Gly Ile

145 150 155 160

Glu Tyr Ile Gln His Asn Gly Val Val Gln Glu Ser Tyr Tyr Arg Tyr

165 170 175

Val Ala Arg Glu Gln Ser Cys Arg Arg Pro Asn Ala Gln Arg Phe Gly

180 185 190

Ile Ser Asn Tyr Cys Gln Ile Tyr Pro Pro Asn Val Asn Lys Ile Arg

195 200 205

Glu Ala Leu Ala Gln Thr His Ser Ala Ile Ala Val Ile Ile Gly Ile

210 215 220

Lys Asp Leu Asp Ala Phe Arg His Tyr Asp Gly Arg Thr Ile Ile Gln

225 230 235 240

Arg Asp Asn Gly Tyr Gln Pro Asn Tyr His Ala Val Asn Ile Val Gly

245 250 255

Tyr Ser Asn Ala Gln Gly Val Asp Tyr Trp Ile Val Arg Asn Ser Trp

260 265 270

Asp Thr Asn Trp Gly Asp Asn Gly Tyr Gly Tyr Phe Ala Ala Asn Ile

275 280 285

Asp Leu Met Met Ile Glu Glu Tyr Pro Tyr Val Val Ile Leu

290 295 300

<210> 8

<211> 909

<212> DNA

<213> Artificial Sequence

<220>

<221> CDS

<222> (1)...(906)

<223> C65R mutant of ProDerP1

<400> 8

cgg ccg agc tcc att aag acc ttc gag gaa tac aag aaa gcc ttc aac 48
Arg Pro Ser Ser Ile Lys Thr Phe Glu Glu Tyr Lys Lys Ala Phe Asn
1 5 10 15

aag agc tat gcc acc ttc gag gac gag gag gcc gcg cgc aag aac ttc 96
Lys Ser Tyr Ala Thr Phe Glu Asp Glu Glu Ala Ala Arg Lys Asn Phe
20 25 30

ctg gaa agc gtg aaa tac gtg cag agc aac ggc ggg gct ata aat cac 144
Leu Glu Ser Val Lys Tyr Val Gln Ser Asn Gly Gly Ala Ile Asn His
35 40 45

ctg tcc gac ctg tct tta gac gag ttc aag aac cgg ttc ctg atg agc 192
Leu Ser Asp Leu Ser Leu Asp Glu Phe Lys Asn Arg Phe Leu Met Ser
50 55 60

gcc gag gct ttc gaa cac ctt aag acc cag ttt gat ctc aac gcg gag 240
Ala Glu Ala Phe Glu His Leu Lys Thr Gln Phe Asp Leu Asn Ala Glu
65 70 75 80

acc aac gcc tgc agt atc aac ggc aat gcc ccc gct gag att gat ctg 288
Thr Asn Ala Cys Ser Ile Asn Gly Asn Ala Pro Ala Glu Ile Asp Leu
85 90 95

cgc cag atg agg acc gtg act ccc atc cgc atg caa ggc ggc tgc ggg 336
Arg Gln Met Arg Thr Val Thr Pro Ile Arg Met Gln Gly Gly Cys Gly
100 105 110

tct tgt tgg gcc ttt tca ggc gtg gcc gcg aca gag tcg gca tac ctc 384
Ser Cys Trp Ala Phe Ser Gly Val Ala Ala Thr Glu Ser Ala Tyr Leu
115 120 125

gcg tat cgg aat cag agc ctg gac ctc gct gag cag gag ctc gtt gac 432
Ala Tyr Arg Asn Gln Ser Leu Asp Leu Ala Glu Gln Glu Leu Val Asp
130 135 140

cgt gcc tcc caa cac gga tgt cat ggg gat acg att ccc aga ggt atc 480
Arg Ala Ser Gln His Gly Cys His Gly Asp Thr Ile Pro Arg Gly Ile
145 150 155 160

gaa tac atc cag cat aat ggc gtc gtg cag gaa agc tat tac cga tac 528
Glu Tyr Ile Gln His Asn Gly Val Val Gln Glu Ser Tyr Tyr Arg Tyr
165 170 175

gta gct agg gag cag tcc tgc cgc cgt cct aac gca cag cgc ttc ggc 576
Val Ala Arg Glu Gln Ser Cys Arg Arg Pro Asn Ala Gln Arg Phe Gly
180 185 190

att tcc aat tat tgc cag atc tac ccc cct aat gcc aac aag atc agg 624
Ile Ser Asn Tyr Cys Gln Ile Tyr Pro Pro Asn Ala Asn Lys Ile Arg
195 200 205

gag gcc ctg gcg cag acg cac agc gcc atc gct gtc atc atc gga atc 672
Glu Ala Leu Ala Gln Thr His Ser Ala Ile Ala Val Ile Ile Gly Ile
210 215 220

aag gat ctg gac gca ttc cgg cac tat gac ggg cgc aca atc atc cag 720

Lys Asp Leu Asp Ala Phe Arg His Tyr Asp Gly Arg Thr Ile Ile Gln
225 230 235 240

cgc gac aac gga tat cag cca aac tac cac gcg gtc aac atc gtg ggt 768
Arg Asp Asn Gly Tyr Gln Pro Asn Tyr His Ala Val Asn Ile Val Gly
245 250 255

tac tcg aac gcc cag ggg gtg gac tac tgg atc gtg aga aac agt tgg 816
Tyr Ser Asn Ala Gln Gly Val Asp Tyr Trp Ile Val Arg Asn Ser Trp
260 265 270

gac act aac tgg ggc gac aac ggc tac ggc tac ttc gcc gcc aac atc 864
Asp Thr Asn Trp Gly Asp Asn Gly Tyr Gly Tyr Phe Ala Ala Asn Ile
275 280 285

gac ctg atg atg atc gag gag tac ccg tac gtg gtg atc ctg 906
Asp Leu Met Met Ile Glu Glu Tyr Pro Tyr Val Val Ile Leu
290 295 300

taa 909

<210> 9
<211> 302
<212> PRT
<213> Artificial Sequence

<220>
<223> C71R mutant of ProDerP1

<400> 9
Arg Pro Ser Ser Ile Lys Thr Phe Glu Glu Tyr Lys Lys Ala Phe Asn
1 5 10 15
Lys Ser Tyr Ala Thr Phe Glu Asp Glu Glu Ala Ala Arg Lys Asn Phe
20 25 30

Leu Glu Ser Val Lys Tyr Val Gln Ser Asn Gly Gly Ala Ile Asn His
35 40 45
Leu Ser Asp Leu Ser Leu Asp Glu Phe Lys Asn Arg Phe Leu Met Ser
50 55 60
Ala Glu Ala Phe Glu His Leu Lys Thr Gln Phe Asp Leu Asn Ala Glu
65 70 75 80
Thr Asn Ala Cys Ser Ile Asn Gly Asn Ala Pro Ala Glu Ile Asp Leu
85 90 95
Arg Gln Met Arg Thr Val Thr Pro Ile Arg Met Gln Gly Gly Cys Gly
100 105 110
Ser Cys Trp Ala Phe Ser Gly Val Ala Ala Thr Glu Ser Ala Tyr Leu
115 120 125
Ala Tyr Arg Asn Gln Ser Leu Asp Leu Ala Glu Gln Glu Leu Val Asp
130 135 140
Cys Ala Ser Gln His Gly Arg His Gly Asp Thr Ile Pro Arg Gly Ile
145 150 155 160
Glu Tyr Ile Gln His Asn Gly Val Val Gln Glu Ser Tyr Tyr Arg Tyr
165 170 175
Val Ala Arg Glu Gln Ser Cys Arg Arg Pro Asn Ala Gln Arg Phe Gly
180 185 190
Ile Ser Asn Tyr Cys Gln Ile Tyr Pro Pro Asn Val Asn Lys Ile Arg
195 200 205
Glu Ala Leu Ala Gln Thr His Ser Ala Ile Ala Val Ile Ile Gly Ile
210 215 220
Lys Asp Leu Asp Ala Phe Arg His Tyr Asp Gly Arg Thr Ile Ile Gln
225 230 235 240
Arg Asp Asn Gly Tyr Gln Pro Asn Tyr His Ala Val Asn Ile Val Gly
245 250 255
Tyr Ser Asn Ala Gln Gly Val Asp Tyr Trp Ile Val Arg Asn Ser Trp
260 265 270
Asp Thr Asn Trp Gly Asp Asn Gly Tyr Gly Tyr Phe Ala Ala Asn Ile
275 280 285
Asp Leu Met Met Ile Glu Glu Tyr Pro Tyr Val Val Ile Leu
290 295 300

<210> 10

<211> 909

<212> DNA

<213> Artificial Sequence

<220>

<221> CDS

<222> (1)...(906)

<223> C71R mutant of ProDerP1

<400> 10

cgg ccg agc tcc att aag acc ttc gag gaa tac aag aaa gcc ttc aac 48
Arg Pro Ser Ser Ile Lys Thr Phe Glu Glu Tyr Lys Lys Ala Phe Asn
1 5 10 15

aag agc tat gcc acc ttc gag gac gag gag gcc gcg cgc aag aac ttc 96
Lys Ser Tyr Ala Thr Phe Glu Asp Glu Glu Ala Ala Arg Lys Asn Phe
20 25 30

ctg gaa agc gtg aaa tac gtg cag agc aac ggc ggg gct ata aat cac 144
Leu Glu Ser Val Lys Tyr Val Gln Ser Asn Gly Gly Ala Ile Asn His
35 40 45

ctg tcc gac ctg tct tta gac gag ttc aag aac cgg ttc ctg atg agc 192
Leu Ser Asp Leu Ser Leu Asp Glu Phe Lys Asn Arg Phe Leu Met Ser
50 55 60

gcc gag gct ttc gaa cac ctt aag acc cag ttt gat ctc aac gcg gag 240
Ala Glu Ala Phe Glu His Leu Lys Thr Gln Phe Asp Leu Asn Ala Glu
65 70 75 80

acc aac gcc tgc agt atc aac ggc aat gcc ccc gct gag att gat ctg 288
Thr Asn Ala Cys Ser Ile Asn Gly Asn Ala Pro Ala Glu Ile Asp Leu
85 90 95

cgc cag atg agg acc gtg act ccc atc cgc atg caa ggc ggc tgc ggg 336
Arg Gln Met Arg Thr Val Thr Pro Ile Arg Met Gln Gly Gly Cys Gly
100 105 110

tct tgt tgg gcc ttt tca ggc gtg gcc gcg aca gag tcg gca tac ctc 384
Ser Cys Trp Ala Phe Ser Gly Val Ala Ala Thr Glu Ser Ala Tyr Leu
115 120 125

gcg tat cgg aat cag agc ctg gac ctc gct gag cag gag ctc gtt gac 432
Ala Tyr Arg Asn Gln Ser Leu Asp Leu Ala Glu Gln Glu Leu Val Asp
130 135 140

tgc gcc tcc caa cac gga cgt cat ggg gat acg att ccc aga ggt atc 480
Cys Ala Ser Gln His Gly Arg His Gly Asp Thr Ile Pro Arg Gly Ile
145 150 155 160

gaa tac atc cag cat aat ggc gtc gtg cag gaa agc tat tac cga tac 528
Glu Tyr Ile Gln His Asn Gly Val Val Gln Glu Ser Tyr Tyr Arg Tyr
165 170 175

gta gct agg gag cag tcc tgc cgc cgt cct aac gca cag cgc ttc ggc 576
Val Ala Arg Glu Gln Ser Cys Arg Arg Pro Asn Ala Gln Arg Phe Gly
180 185 190

att tcc aat tat tgc cag atc tac ccc cct aat gcc aac aag atc agg 624
Ile Ser Asn Tyr Cys Gln Ile Tyr Pro Pro Asn Ala Asn Lys Ile Arg
195 200 205

gag gcc ctg gcg cag acg cac agc gcc atc gct gtc atc atc gga atc 672
Glu Ala Leu Ala Gln Thr His Ser Ala Ile Ala Val Ile Ile Gly Ile

210 215 220

aag gat ctg gac gca ttc cgg cac tat gac ggg cgc aca atc atc cag 720
Lys Asp Leu Asp Ala Phe Arg His Tyr Asp Gly Arg Thr Ile Ile Gln
225 230 235 240

cgc gac aac gga tat cag cca aac tac cac gcg gtc aac atc gtg ggt 768
Arg Asp Asn Gly Tyr Gln Pro Asn Tyr His Ala Val Asn Ile Val Gly
245 250 255

tac tcg aac gcc cag ggg gtg gac tac tgg atc gtg aga aac agt tgg 816
Tyr Ser Asn Ala Gln Gly Val Asp Tyr Trp Ile Val Arg Asn Ser Trp
260 265 270

gac act aac tgg ggc gac aac ggc tac ggc tac ttc gcc gcc aac atc 864
Asp Thr Asn Trp Gly Asp Asn Gly Tyr Gly Tyr Phe Ala Ala Asn Ile
275 280 285

gac ctg atg atg atc gag gag tac ccg tac gtg gtg atc ctg 906
Asp Leu Met Met Ile Glu Glu Tyr Pro Tyr Val Val Ile Leu
290 295 300

taa 909

<210> 11
<211> 302
<212> PRT
<213> Artificial Sequence

<220>
<223> C103R mutant of ProDerP1

<400> 11
Arg Pro Ser Ser Ile Lys Thr Phe Glu Glu Tyr Lys Lys Ala Phe Asn

1 5 10 15

Lys Ser Tyr Ala Thr Phe Glu Asp Glu Glu Ala Ala Arg Lys Asn Phe
20 25 30

Leu Glu Ser Val Lys Tyr Val Gln Ser Asn Gly Gly Ala Ile Asn His
35 40 45

Leu Ser Asp Leu Ser Leu Asp Glu Phe Lys Asn Arg Phe Leu Met Ser
50 55 60

Ala Glu Ala Phe Glu His Leu Lys Thr Gln Phe Asp Leu Asn Ala Glu
65 70 75 80

Thr Asn Ala Cys Ser Ile Asn Gly Asn Ala Pro Ala Glu Ile Asp Leu
85 90 95

Arg Gln Met Arg Thr Val Thr Pro Ile Arg Met Gln Gly Gly Cys Gly
100 105 110

Ser Cys Trp Ala Phe Ser Gly Val Ala Ala Thr Glu Ser Ala Tyr Leu
115 120 125

Ala Tyr Arg Asn Gln Ser Leu Asp Leu Ala Glu Gln Glu Leu Val Asp
130 135 140

Cys Ala Ser Gln His Gly Cys His Gly Asp Thr Ile Pro Arg Gly Ile
145 150 155 160

Glu Tyr Ile Gln His Asn Gly Val Val Gln Glu Ser Tyr Tyr Arg Tyr
165 170 175

Val Ala Arg Glu Gln Ser Arg Arg Arg Pro Asn Ala Gln Arg Phe Gly
180 185 190

Ile Ser Asn Tyr Cys Gln Ile Tyr Pro Pro Asn Val Asn Lys Ile Arg
195 200 205

Glu Ala Leu Ala Gln Thr His Ser Ala Ile Ala Val Ile Ile Gly Ile
210 215 220

Lys Asp Leu Asp Ala Phe Arg His Tyr Asp Gly Arg Thr Ile Ile Gln
225 230 235 240

Arg Asp Asn Gly Tyr Gln Pro Asn Tyr His Ala Val Asn Ile Val Gly
245 250 255

Tyr Ser Asn Ala Gln Gly Val Asp Tyr Trp Ile Val Arg Asn Ser Trp
260 265 270

Asp Thr Asn Trp Gly Asp Asn Gly Tyr Gly Tyr Phe Ala Ala Asn Ile

275 280 285

Asp Leu Met Met Ile Glu Glu Tyr Pro Tyr Val Val Ile Leu

290 295 300

<210> 12

<211> 909

<212> DNA

<213> Artificial Sequence

<220>

<221> CDS

<222> (1)...(906)

<223> C103R mutant of ProDerP1

<400> 12

cgg ccg agc tcc att aag acc ttc gag gaa tac aag aaa gcc ttc aac 48

Arg Pro Ser Ser Ile Lys Thr Phe Glu Glu Tyr Lys Lys Ala Phe Asn

1 5 10 15

aag agc tat gcc acc ttc gag gac gag gag gcc gcg cgc aag aac ttc 96

Lys Ser Tyr Ala Thr Phe Glu Asp Glu Glu Ala Ala Arg Lys Asn Phe

20 25 30

ctg gaa agc gtg aaa tac gtg cag agc aac ggc ggg gct ata aat cac 144

Leu Glu Ser Val Lys Tyr Val Gln Ser Asn Gly Gly Ala Ile Asn His

35 40 45

ctg tcc gac ctg tct tta gac gag ttc aag aac cgg ttc ctg atg agc 192

Leu Ser Asp Leu Ser Leu Asp Glu Phe Lys Asn Arg Phe Leu Met Ser

50 55 60

gcc gag gct ttc gaa cac ctt aag acc cag ttt gat ctc aac gcg gag 240

Ala Glu Ala Phe Glu His Leu Lys Thr Gln Phe Asp Leu Asn Ala Glu
65 70 75 80

acc aac gcc tgc agt atc aac ggc aat gcc ccc gct gag att gat ctg 288
Thr Asn Ala Cys Ser Ile Asn Gly Asn Ala Pro Ala Glu Ile Asp Leu
85 90 95

cgc cag atg agg acc gtg act ccc atc cgc atg caa ggc ggc tgc ggg 336
Arg Gln Met Arg Thr Val Thr Pro Ile Arg Met Gln Gly Gly Cys Gly
100 105 110

tct tgt tgg gcc ttt tca ggc gtg gcc gcg aca gag tcg gca tac ctc 384
Ser Cys Trp Ala Phe Ser Gly Val Ala Ala Thr Glu Ser Ala Tyr Leu
115 120 125

gcg tat cgg aat cag agc ctg gac ctc gct gag cag gag ctc gtt gac 432
Ala Tyr Arg Asn Gln Ser Leu Asp Leu Ala Glu Gln Glu Leu Val Asp
130 135 140

tgc gcc tcc caa cac gga tgt cat ggg gat acg att ccc aga ggt atc 480
Cys Ala Ser Gln His Gly Cys His Gly Asp Thr Ile Pro Arg Gly Ile
145 150 155 160

gaa tac atc cag cat aat ggc gtc gtg cag gaa agc tat tac cga tac 528
Glu Tyr Ile Gln His Asn Gly Val Val Gln Glu Ser Tyr Tyr Arg Tyr
165 170 175

gta gct agg gag cag tcc cgt cgc cgt cct aac gca cag cgc ttc ggc 576
Val Ala Arg Glu Gln Ser Arg Arg Arg Pro Asn Ala Gln Arg Phe Gly
180 185 190

att tcc aat tat tgc cag atc tac ccc cct aat gcc aac aag atc agg 624
Ile Ser Asn Tyr Cys Gln Ile Tyr Pro Pro Asn Ala Asn Lys Ile Arg
195 200 205

gag gcc ctg gcg cag acg cac agc gcc atc gct gtc atc atc gga atc 672
Glu Ala Leu Ala Gln Thr His Ser Ala Ile Ala Val Ile Ile Gly Ile
210 215 220

aag gat ctg gac gca ttc cgg cac tat gac ggg cgc aca atc atc cag 720
Lys Asp Leu Asp Ala Phe Arg His Tyr Asp Gly Arg Thr Ile Ile Gln
225 230 235 240

cgc gac aac gga tat cag cca aac tac cac gcg gtc aac atc gtg ggt 768
Arg Asp Asn Gly Tyr Gln Pro Asn Tyr His Ala Val Asn Ile Val Gly
245 250 255

tac tcg aac gcc cag ggg gtg gac tac tgg atc gtg aga aac agt tgg 816
Tyr Ser Asn Ala Gln Gly Val Asp Tyr Trp Ile Val Arg Asn Ser Trp
260 265 270

gac act aac tgg ggc gac aac ggc tac ggc tac ttc gcc gcc aac atc 864
Asp Thr Asn Trp Gly Asp Asn Gly Tyr Gly Tyr Phe Ala Ala Asn Ile
275 280 285

gac ctg atg atg atc gag gag tac ccg tac gtg gtg atc ctg 906
Asp Leu Met Met Ile Glu Glu Tyr Pro Tyr Val Val Ile Leu
290 295 300

taa 909

<210> 13
<211> 302
<212> PRT
<213> Artificial Sequence

<220>
<223> C117R mutant of ProDerP1

<400> 13

Arg Pro Ser Ser Ile Lys Thr Phe Glu Glu Tyr Lys Lys Ala Phe Asn
1 5 10 15

Lys Ser Tyr Ala Thr Phe Glu Asp Glu Glu Ala Ala Arg Lys Asn Phe
20 25 30

Leu Glu Ser Val Lys Tyr Val Gln Ser Asn Gly Gly Ala Ile Asn His
35 40 45

Leu Ser Asp Leu Ser Leu Asp Glu Phe Lys Asn Arg Phe Leu Met Ser
50 55 60

Ala Glu Ala Phe Glu His Leu Lys Thr Gln Phe Asp Leu Asn Ala Glu
65 70 75 80

Thr Asn Ala Cys Ser Ile Asn Gly Asn Ala Pro Ala Glu Ile Asp Leu
85 90 95

Arg Gln Met Arg Thr Val Thr Pro Ile Arg Met Gln Gly Gly Cys Gly
100 105 110

Ser Cys Trp Ala Phe Ser Gly Val Ala Ala Thr Glu Ser Ala Tyr Leu
115 120 125

Ala Tyr Arg Asn Gln Ser Leu Asp Leu Ala Glu Gln Glu Leu Val Asp
130 135 140

Cys Ala Ser Gln His Gly Cys His Gly Asp Thr Ile Pro Arg Gly Ile
145 150 155 160

Glu Tyr Ile Gln His Asn Gly Val Val Gln Glu Ser Tyr Tyr Arg Tyr
165 170 175

Val Ala Arg Glu Gln Ser Cys Arg Arg Pro Asn Ala Gln Arg Phe Gly
180 185 190

Ile Ser Asn Tyr Arg Gln Ile Tyr Pro Pro Asn Val Asn Lys Ile Arg
195 200 205

Glu Ala Leu Ala Gln Thr His Ser Ala Ile Ala Val Ile Ile Gly Ile
210 215 220

Lys Asp Leu Asp Ala Phe Arg His Tyr Asp Gly Arg Thr Ile Ile Gln
225 230 235 240

Arg Asp Asn Gly Tyr Gln Pro Asn Tyr His Ala Val Asn Ile Val Gly
245 250 255

Tyr Ser Asn Ala Gln Gly Val Asp Tyr Trp Ile Val Arg Asn Ser Trp
260 265 270
Asp Thr Asn Trp Gly Asp Asn Gly Tyr Gly Tyr Phe Ala Ala Asn Ile
275 280 285
Asp Leu Met Met Ile Glu Glu Tyr Pro Tyr Val Val Ile Leu
290 295 300

<210> 14
<211> 909
<212> DNA
<213> Artificial Sequence

<220>
<221> CDS
<222> (1)...(906)

<223> C117R mutant of ProDerP1

<400> 14
cgg ccg agc tcc att aag acc ttc gag gaa tac aag aaa gcc ttc aac 48
Arg Pro Ser Ser Ile Lys Thr Phe Glu Glu Tyr Lys Lys Ala Phe Asn
1 5 10 15

aag agc tat gcc acc ttc gag gac gag gag gcc gcg cgc aag aac ttc 96
Lys Ser Tyr Ala Thr Phe Glu Asp Glu Glu Ala Ala Arg Lys Asn Phe
20 25 30

ctg gaa agc gtg aaa tac gtg cag agc aac ggc ggg gct ata aat cac 144
Leu Glu Ser Val Lys Tyr Val Gln Ser Asn Gly Gly Ala Ile Asn His
35 40 45

ctg tcc gac ctg tct tta gac gag ttc aag aac cgg ttc ctg atg agc 192
Leu Ser Asp Leu Ser Leu Asp Glu Phe Lys Asn Arg Phe Leu Met Ser

50 55 60

gcc gag gct ttc gaa cac ctt aag acc cag ttt gat ctc aac gcg gag 240
Ala Glu Ala Phe Glu His Leu Lys Thr Gln Phe Asp Leu Asn Ala Glu
65 70 75 80

acc aac gcc tgc agt atc aac ggc aat gcc ccc gct gag att gat ctg 288
Thr Asn Ala Cys Ser Ile Asn Gly Asn Ala Pro Ala Glu Ile Asp Leu
85 90 95

cgc cag atg agg acc gtg act ccc atc cgc atg caa ggc ggc tgc ggg 336
Arg Gln Met Arg Thr Val Thr Pro Ile Arg Met Gln Gly Gly Cys Gly
100 105 110

tct tgt tgg gcc ttt tca ggc gtg gcc gcg aca gag tcg gca tac ctc 384
Ser Cys Trp Ala Phe Ser Gly Val Ala Ala Thr Glu Ser Ala Tyr Leu
115 120 125

gcg tat cgg aat cag agc ctg gac ctc gct gag cag gag ctc gtt gac 432
Ala Tyr Arg Asn Gln Ser Leu Asp Leu Ala Glu Gln Glu Leu Val Asp
130 135 140

tgc gcc tcc caa cac gga tgt cat ggg gat acg att ccc aga ggt atc 480
Cys Ala Ser Gln His Gly Cys His Gly Asp Thr Ile Pro Arg Gly Ile
145 150 155 160

gaa tac atc cag cat aat ggc gtc gtg cag gaa agc tat tac cga tac 528
Glu Tyr Ile Gln His Asn Gly Val Val Gln Glu Ser Tyr Tyr Arg Tyr
165 170 175

gta gct agg gag cag tcc tgc cgc cgt cct aac gca cag cgc ttc ggc 576
Val Ala Arg Glu Gln Ser Cys Arg Arg Pro Asn Ala Gln Arg Phe Gly
180 185 190

att tcc aat tat cgt cag atc tac ccc cct aat gcc aac aag atc agg 624
Ile Ser Asn Tyr Arg Gln Ile Tyr Pro Pro Asn Ala Asn Lys Ile Arg
195 200 205

gag gcc ctg gcg cag acg cac agc gcc atc gct gtc atc atc gga atc 672
Glu Ala Leu Ala Gln Thr His Ser Ala Ile Ala Val Ile Ile Gly Ile
210 215 220

aag gat ctg gac gca ttc cgg cac tat gac ggg cgc aca atc atc cag 720
Lys Asp Leu Asp Ala Phe Arg His Tyr Asp Gly Arg Thr Ile Ile Gln
225 230 235 240

cgc gac aac gga tat cag cca aac tac cac gcg gtc aac atc gtg ggt 768
Arg Asp Asn Gly Tyr Gln Pro Asn Tyr His Ala Val Asn Ile Val Gly
245 250 255

tac tcg aac gcc cag ggg gtg gac tac tgg atc gtg aga aac agt tgg 816
Tyr Ser Asn Ala Gln Gly Val Asp Tyr Trp Ile Val Arg Asn Ser Trp
260 265 270

gac act aac tgg ggc gac aac ggc tac ggc tac ttc gcc gcc aac atc 864
Asp Thr Asn Trp Gly Asp Asn Gly Tyr Gly Tyr Phe Ala Ala Asn Ile
275 280 285

gac ctg atg atg atc gag gag tac ccg tac gtg gtg atc ctg 906
Asp Leu Met Met Ile Glu Glu Tyr Pro Tyr Val Val Ile Leu
290 295 300

taa 909

<210> 15
<211> 108
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer

<400> 15
ttaagaccca gtttgatctc aacgcggaga ccaacgcccg tatcaacggc aatgcccccg 60
ctgagattga tctgcgccag atgaggaccg tgactcccat ccgcatgc 108

<210> 16
<211> 103
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer

<400> 16
cggatgggag tcacggtcct catctggcgc agatcaatct cagcgggggc attgccgttg 60
atactacggg cgttggtctc cgcgttgaga tcgaaactgg gtc 103

<210> 17
<211> 92
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer

<400> 17
caaggcggcc gtgggtcttg ttgggccttt tcaggcgtgg ccgcgacaga gtcggcatac 60
ctcgcgtatc ggaatcagag cctggacctc gc 92

<210> 18
<211> 99

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 18

tcagcgaggt ccaggctctg attccgatac gcgaggtatg ccgactctgt cgcggccacg 60

cctgaaaagg cccaacaaga cccacggccg ccttgcatg 99

<210> 19

<211> 83

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 19

tgagcaggag ctcgttgacc gtgcctccca acacggatgt catggggata cgattcccag 60

aggtatcgaa tacatccagc ata 83

<210> 20

<211> 77

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 20

ctggatgtat tcgatacctc tgggaatcgt atcccccatg acatccgtgt tgggaggcac 60

ggtcaacgcg ctcctgc 77

<210> 21
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer

<400> 21
actgacaggc ctcggccgag ctccattaa 29

<210> 22
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer

<400> 22
cagtcaccta ggtctagact cgaggggat 29

<210> 23
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer

<400> 23
ggctttcgaa caccttaaga cccag 25

<210> 24

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 24

gctccctagc tacgtatcgg taatagc 27

<210> 25

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 25

cctcgcgtat cggcaacaga gcctggacc 29

<210> 26

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer

<400> 26

ggtccaggct ctgttgccga tacgcgagg 29

FIG. 1: IgG and IgE-binding reactivity of denatured ProDerP1 expressed in CHO cells.



IgG



FIG. 2: Correlation between the IgE reactivity of MBP-ProDerP1 and natural DerP1.



FIG. 3: IgE-binding reactivities of MBP-ProDerP1 mutants, carrying the mutations C4R, C31R and C65R.



FIG. 4: Histamine release activity of allergens.



Fig. 5: Schematic representation of the animal model of house dust mite allergy.



FIG 6

Expression of ProDer p 1 delta 227-240



FIG. 7


AcaNucSéq: 51 ACAACCAGAA AGATGATCAT CTATAATATT TTAATTGTTT TATTATTGGC
EcoNucSéq: 51 acaaccagaa agatgatcat ctaCaaCatt CtGatCgtAC tCCtGCtggc
PeptidSéq: M I I Y N I L I V L L L A
AcaNucSéq: 101 CATTAATACA TTGGCTAATC CAATTCTACC AGCATCACCA AATGCAACTA
EcoNucSéq: 101 cattaaCacT ttggctaatc cGatCctGcc GgcatcCccG aaCgcGacCa
PeptidSéq: I N T L A N P I L P A S P N A T
AcaNucSéq: 151 TTGTTGGTGG TGAAAAAGCA TTAGCTGGTG AATGTCCATA TCAGATTTCA
EcoNucSéq: 151 tCgttggCgg CgaaaaagcA CtGgctggtg aGtgCccata tcagatCtcC
PeptidSéq: I V G G E K A L A G E C P Y Q I S
AcaNucSéq: 201 TTACAATCAA GTAGTCATTT TTGTGGTGGT ACTATTCTTG ATGAATATTG
EcoNucSéq: 201 CtGcaGtcTa gtagCcaCtt CtgtggtggT actattcttg aCgaataCtg
PeptidSéq: L Q S S S H F C G G T I L D E Y W
AcaNucSéq: 251 GATTTTAACA GCTGCACATT GTGTTGCCGG ACAAACAGCA AGTAAACTTT
EcoNucSéq: 251 gatCCtGacC gcGgcacaCt gCgtGgccgg CcaaacagcG agCaaactCt
PeptidSéq: I L T A A H C V A G Q T A S K L
AcaNucSéq: 301 CAATTCGTTA CAATAGTTTA AAACATTCAT TAGGTGGTGA AAAAATTTCT
EcoNucSéq: 301 cCattcgtta caaCagCCtG aaacaCtcaC tGggtggCga aaaGatttct
PeptidSéq: S I R Y N S L K H S L G G E K I S
AcaNucSéq: 351 GTTGCTAAAA TTTTTGCACA TGAAAAATAT GATAGTTATC AAATTGATAA
EcoNucSéq: 351 gttgctaaaa ttttCgcaca tgaaaaatat gatagCtaCc aGatCgaCaa
PeptidSéq: V A K I F A H E K Y D S Y Q I D N
AcaNucSéq: 401 TGATATTGCA TTGATTAAGC TTAAATCACC TATGAAATTA AATCAGAAAA
EcoNucSéq: 401 tgaCattgcG CtgatCaagc tGaaatcCcc tatgaaGCtG aaCcagaaaa
PeptidSéq: D I A L I K L K S P M K L N Q K
AcaNucSéq: 451 ATGCCAAAGC TGTTGGATTA CCAGCAAAAG GATCGGATGT AAAAGTTGGT
EcoNucSéq: 451 aCgccaaagc tgtGggCCtG ccGgcGaaag gCtcggatgt aaaagttggt
PeptidSéq: N A K A V G L P A K G S D V K V G
AcaNucSéq: 501 GATCAAGTTC GTGTTTCTGG TTGGGGTTAT CTTGAAGAAG GAAGTTATTC
EcoNucSéq: 501 gaCcaGgtGc gtgtCtctgg CtggggttAt ctGgaagaGg gCagCtaCtc
PeptidSéq: D Q V R V S G W G Y L E E G S Y S
AcaNucSéq: 551 ATTACCATCT GAATTAAGAC GTGTTGATAT TGCTGTTGTA TCACGTAAAG
EcoNucSéq: 551 CCtGccGtct gaattaCgCc gtgttgatat CgctgtGgta tcTcgCaaag
PeptidSéq: L P S E L R R V D I A V V S R K
AcaNucSéq: 601 AATGTAATGA ATTATATTCA AAAGCTAATG CTGAAGTTAC TGATAATATG
EcoNucSéq: 601 aatgtaaCga GctGtaCtcG aaagcGaaCg ctgaagtCac CgaCaatatg
PeptidSéq: R C N E L Y S K A N A E V T D N M
AcaNucSéq: 651 ATTTGTGGTG GTGATGTTGC AAATGGTGGT AAAGATTCTT GTCAAGGTGA
EcoNucSéq: 651 atCtgCggtg gtgatgttgc GaaCggCggt aaGgaCtctt gtcaaggCga
PeptidSéq: I C G G D V A N G G K D S C Q G D
AcaNucSéq: 701 TTCTGGTGGA CCGGTTGTTG ATGTTAAAAA TAATCAAGTT GTTGGTATTG
EcoNucSéq: 701 ttctggtggG ccggtGgtCg aCgttaaaaa CaaCcaGgtt gtAggtatCg
PeptidSéq: S G G P V V D V K N N Q V V G I
AcaNucSéq: 751 TTTCATGGGG TTATGGTTGT GCACGTAAAG GTTATCCAGG TGTTTATACA
EcoNucSéq: 751 tttcAtgggg CtaCggttgC gcacgtaaag gCtatccGgg tgtGtaCacG
PeptidSéq: V S W G Y G C A R K G Y P G V Y T
AcaNucSéq: 801 CGTGTTGGTA ATTTTATCGA TTGGATTGAA TCAAAACGTT CACAGTGATT
EcoNucSéq: 801 cgCgttggta aCtttatcga ttggattgaa tcTaaacgtA GCcagtgatt
PeptidSéq: R V G N F I D W I E S K R S Q

FIG 8


t = 1 hour
68 kDa
43 kDa
29 kDa
M C C S C S C S C S
t0 0.5 mM 30°C 0.5 mM 37°C 1 mM 30°C 1 mM 37°C
t = 2 hours
68 kDa
43 kDa
29 kDa
M C S C S C S C S
0.5 mM 30°C 0.5 mM 37°C 1 mM 30°C 1 mM 37°C
t = 3 hours
68 kDa
43 kDa
29 kDa
M C S C S C S C S
0.5 mM 30°C 0.5 mM 37°C 1 mM 30°C 1 mM 37°C
t = 16 hours
68 kDa
43 kDa
29 kDa
S C S M C S C S C S
t0 0.5 mM 30°C 0.5 mM 37°C 1 mM 30°C 1 mM 37°

FIG 9



FIG 10


97 kDa
68 kDa
43 kDa
29 kDa
M FT 20 40 45 60 60 100 100 R
97 kDa
68 kDa
43 kDa
29 kDa
M FT 20 40 45 60 60 100 100 R

FIG. 11


y = 0.3208x
R2 = 0.5662
OD410nm ProDer p 3
OD410nm Der p 3
1.2
1
0.8
0.6
0.4
0.2
0
0
0.5
1
1.5
2
2.5
3

PCT Application
PCT/EP2004/001850